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Abstract 
 
Migraine pathophysiology is thought to involve activation of the trigeminal fibres which 
innervate dural structures. The nociceptive inflow from the meninges is relayed to the 
trigeminocervical complex (TCC), before ascending to higher brain areas, including the 
thalamus. Glutamate is implicated in the transmission of the nociceptive information 
and thus an increased understanding of the nature and effects of glutamate receptors 
activation has major implications in migraine pathophysiology and treatment. Here the 
role of kainate receptors, a member of the ionotropic glutamate receptors subfamily, 
was investigated in relaying sensory information upon activation of the 
trigeminovascular system. 
In order to study the role of kainate receptors on the periphery, we used the 
neurogenic dural vasodilation (NDV) model, in which electrical stimulation of the dura 
mater causes reproducible vasodilation, due to calcitonic gene-related peptide (CGRP) 
release. In this set of experiments kainate receptor activation but not blockade was 
effective in inhibiting NDV. Vasodilation induced by systemic administration of CGRP 
was not changed by administration of a kainate receptor agonist. 
In the TCC, local application by microiontophoresis of a selective kainate 
receptor antagonist on second order neurons which were excited by meningeal electrical 
stimulation, caused dual effects; 50% of the neurons tested were inhibited, whereas in a 
second subpopulation, activation in response to meningeal stimulation was facilitated. 
However, in all neurons tested, post-synaptic activation in response to kainate receptor 
agonists application was selectively inhibited. 
Microiontophoretic ejection of a kainate receptor antagonist in the 
ventroposteromedial thalamus (VPM) was able to inhibit cell firing in response to dural 
stimulation, as well as post-synaptic firing in response to kainate receptor activation. 
Both effects were reversed when the kainate receptor antagonist was co-ejected with a 
5-HT1B receptor antagonist.  
We also carried electrophysiology studies in both the TCC and the VPM nucleus 
in order to compare the effects of the clinically active kainate receptor antagonist 
LY466195. Systemic and local application of LY466195 was able to inhibit cell firing 
in response to dura mater stimulation in both the TCC and VPM nucleus. Moreover, 
further to the kainate binding, a significant action of the compound on N-methyl-D-
aspartate receptors was observed.  
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Glossary 
 
3V,  third ventricle 
5-HT,        5-hytroxytryptamine 
ACC,  antireor cingular cortex 
AChE,  acetylcholinesterase 
AMPA,   α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid
ASICs,  acid-sensing ion channels 
ATPA,   (RS)-2-alpha-amino-3-(3-hydroxy-5-tert-butylisoxazol-
4-yl) propanoic acid 
B2,  Bradykinin 2 receptor 
BDNF,  brain-derived neurotrophic factor 
CB1,  cannabinoid receptor 1 
CCL3,  Chemokine (c-c motif) ligand 3 
CGRP,   calcitonin gene-related peptide 
CNQX,  6-cyano-7-nitroquinoxaline-2,3-dione  
CNS,  central nervous system 
CSD,  cortical spreading depression 
CSF,  cerebrospinal fluid 
DHE,  dihydroergotamine 
DOR,  delta opioid receptor 
DRG,  dorsal root ganglia 
DRN,  dorsal raphe nucleus 
EAA,  excitatory amino acids 
EAAC,  excitatory amino acid carrier 
EAAT,  excitatory amino acid transporter 
EP,  E series of prostaglandin receptors 
EP,  Entopeduncular nucleus  
EPSC,  excitatory post-synaptic current 
ES,  electrical stimulation 
FHM,  familial hemiplegic migraine 
Fos,  Fos proteine-like immunoreactivity 
GABA,  γ-aminobutyric acid 
GDH,  glutamate dehydrogenase 
GLAST,  glutamate/aspartate transporter 
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GLT,  glutamate transporter 
GlyR,  glycine receptors 
GPCRs,  G-protein-coupled receptors  
GR127935,    N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-
methy-l-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-1,1'-
biphenyl-4-carboxamide hydrochloride 
GS,  glutamine synthetase 
GTP,  guanosine 5′-triphosphate 
GYKI 52466,  4-(8-Methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-
y l)-benzenamine hydrochloride 
IACUC,  Institutional Animal Care and Use Committee 
iGluR,  ionotropic glutamate receptor 
IHS,  international headache society 
kainate,  2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine  
LTM,  low threshold mechanosensitive 
LY293558,   (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-
yl)ethyl]decahydroisoquinoline-3-carboxylic acid 
monohydrate 
LY382884,  3S, 4aR,6S, 8aR)-6-((4-carboxyphenyl)methyl-
1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic 
acid  
LY466195,   (3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoro-1-
pyrrolidinyl]-methyl]decahydro-3-isoquinolinecarboxylic 
acid   
MDH,  medullary horn 
mGluR,  metabotropic glutamate receptor 
MK 801,  dizocipline maleate 
MMA,  middle meningeal artery 
MOR,  mu-opioid receptor 
MRI,  magnetic resonance image 
NA,  noradrenaline 
NAS-181,   (2R)-2-[[[3-(4-Morpholinylmethyl)-2H-1-benzopyran-8-
yl] oxy]methyl]morpholine dimethanesulfonate 
Nav,   voltage-gated sodium channel 
NBQX,  2,3-Dioxo-6-nitro-1,2,3,4-
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tetrahydrobenzo[f]quinoxaline-7-sulfonamide  
NK,  neurokinin 
NMDA,  N-methyl-D-aspartic acid 
NO,  nitric oxide 
NOS,  nitric oxide synthase 
NPY,  neuropeptide Y 
NRM,  nucleus raphe magnus 
NS,  nociceptive specific  
NS-102,  5-nitro-6,7,8,9-tetrahydrobenzo[g]indole-2,3-dione-3-
oxime  
NSAID,  non-stereoidal anti-inflammatory drugs 
P2,  purinergic receptors 
PACAP,  pituitary adenylate cyclase-activating peptide 
PAG,  periaqueductal gray 
PET,  positron emission tomography 
PHI,  peptide histidine 
POm,  posterior medial thalamus 
PPE,  plasma protein extravasation 
PVP,  Paraventricular nucleus 
RE,  Reunions nucleus 
RT,  reticular nucleus 
SP,  substance P 
SSS,  superior sagittal sinus  
SYM 2081,   (2S,4R)-4-Methylglutamic acid  
TAC's,  trigeminal autonomic cephalalgias 
TASK,  two-pore domain weak inward rectifying K+ channels – 
related arachidonic acid-stimulated K+ channel  
TBOA,  DL-threo-β-Benzyloxyaspartic acid 
TCC,  trigeminocervical complex 
TM,  transmembrane domain 
TNC,  trigeminal nucleus caudalis 
TREK,  two-pore domain weak inward rectifying K+ channels-
related K+ channel  
TRPA,  transient receptor potential ankyrin  
TRPM,  transient receptor potential melastatin  
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TRPV,  transient receptor potential vanilloid 
VB,  ventrobasal complex 
Vc,  subnucleus caudalis 
VGCC,  voltage-gated calcium channels 
VGLUT,  vesicular transporter 
VIP,  vasoactive intestinal peptide 
VL,  ventrolateral nucleus 
vlPAG,  ventrolateral column of the PAG 
VM,  Ventromedial nucleus 
Vp,  principal trigeminal nuclei 
VPI,  ventral posterior inferior nucleus 
VPL,  ventral posterior lateral nucleus  
VPM,  ventroposteromedial thalamic nucleus 
VPMpc,  ventral posterior medial parvicellular nucleus  
Vsp,  spinal trigeminal nucleus 
WAY 100135,   (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-
yl)-2-phenylpropanamide dihydrochloride 
WDR,  wide dynamic range 
ZI,  zona incerta 
α-KG,  α-Ketoglutarate  
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Chapter 1: Introduction  
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1.1 Headache classification  
 
Headache disorders are very common among the population and include disorders with 
head pain characteristics. In 1988 the International Headache Society (IHS) developed 
the widely used headache classification system, which was subsequently revised in 
2004 (Headache Classification Committee of the International Headache Society, 2004), 
with the aim to provide an accurate headache diagnostic tool to facilitate the 
management of patients with headache disorders. 
 
The IHS classification divides headache in three groups: 
A. Primary headaches; classification is based on headache symptoms and the 
headache itself is the primary problem, with no identifiable underlying cause.  
 
B. Secondary headaches; classification is based on their cause and headache 
symptoms are due to an underlying condition. 
 
C. Cranial neuralgias, facial pain and other headaches which are more uncommon 
than the other two categories.  
 
Headaches are classified in 14 major categories (table 1) and each one is divided in 
different subcategories depending on the specific symptoms. Migraine is the most 
common and well studied type of primary headache. 
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Table 1: Headache classification  
 IHS code 
Classification 
 
1. 
 
Migraine 
 
2. Tension-type headache  
 
3. Cluster headache and other trigeminal autonomic 
cephalalgias 
 
Primary headaches 
4. Other primary headaches 
 
 
5. 
 
Headache attributed to head and/or neck trauma 
 
6. Headache attributed to cranial or cervical vascular 
disorder 
 
7. Headache attributed to non-vascular intracranial 
disorder 
 
 
8. Headache attributed to a substance or its 
withdrawal 
 
9. Headache attributed to infection 
 
10. Headache attributed to disorder of homoeostasis 
 
11. Headache or facial pain attributed to disorder of 
cranium, neck, eyes, ears, nose, sinuses, teeth, 
mouth or other facial or cranial structures 
 
Secondary 
headaches 
12. Headache attributed to psychiatric disorder 
 
  13.  Cranial neuralgias and central causes of facial pain 
 
Central neuralgias, 
central and primary 
facial pains, and 
other headaches 
  14. Other headache, cranial neuralgia, central or 
primary facial pain 
 
Adapted from (Headache Classification Committee of the International Headache 
Society, 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20
1.2 Migraine classification 
 
Migraine is one of the most disabling chronic disorders (Menken et al., 2000). It is 
defined as a chronic disorder that results in severe, normally unilateral, pulsating 
headaches which can involve aura that results in neurological symptoms (Headache 
Classification Committee of the International Headache Society, 2004).  The IHS 
classification of migraine is divided in six sub-categories (table 2) and each one is 
divided into a variety of subtypes including familial hemiplegic migraine (FHM) and 
chronic migraine. Migraine without aura is the most common form which accounts for 
70-90% of attacks (Rasmussen and Olesen, 1992) and it is defined as: 
 
• An idiopathic, recurring headache disorder manifesting in attacks lasting 4-72 
hours. Typical characteristics of headache are unilateral location, pulsating 
quality, moderate or severe intensity, aggravation by routine physical activity, 
and association with nausea, photo- and phonophobia. 
 
Migraine with aura symptoms are typically seen in about 15-20% of patients 
(Rasmussen and Olesen, 1992) and it is defined as: 
 
• An idiopathic, recurring disorder manifesting with attacks of neurological 
symptoms unequivocally localisable to cerebral cortex or brain stem, usually 
gradually developed over 15-20 minutes and usually lasting less than 60 
minutes. Headache, nausea and/or photophobia usually follow the neurological 
aura symptoms directly or after a free interval of less than an hour. The 
headache usually lasts 4-72 hours. 
 
According to the IHS diagnostic criteria for primary headaches, a migraine diagnosis 
requires that certain clinical features must be present for attacks to qualify as migraine 
(table 3).  
 
 
 
 
 
 
 
 
 21
Table 2: International Headache Society classification of Migraine  
 
IHS 
code 
Migraine type 
1.1 Migraine without aura 
1.2 Migraine with aura  
1.2.1    Typical aura with migraine headache 
1.2.2    Typical aura with non-migraine headache 
1.2.3    Typical aura without headache 
1.2.4    Familial hemiplegic migraine (FHM) 
1.2.5    Sporadic hemiplegic migraine 
                   1.2.6    Basilar-type migraine 
1.3 Childhood periodic syndromes that are commonly precursors  
of migraine 
1.3.1     Cyclical vomiting 
1.3.2     Abdominal migraine 
1.3.3     Benign paroxysmal vertigo of childhood 
1.4 Retinal migraine 
1.5 Complications of migraine 
1.5.1    Chronic migraine 
1.5.2    Status migrainous 
1.5.3    Persistent aura without infarction 
1.5.4    Migrainous infarction 
1.5.5    Migraine-triggered seizure 
1.6 Probable migraine  
1.6.1    Probable migraine without aura 
1.6.2    Probable migraine with aura 
1.6.3    Probable chronic migraine 
Adapted from (Headache Classification Committee of the International Headache 
Society, 2004) 
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Table 3: Diagnostic criteria for migraine  
migraine without aura migraine with aura 
A. At least 5 attacks fulfilling criteria          
     B–D          
B. Headache attacks lasting 4–72   
     hours 
C. Headache has at least two of the     
     following characteristics: 
     1. unilateral location 
     2. pulsating quality 
     3. moderate or severe pain    
       intensity 
     4. aggravation by or causing         
       avoidance of routine physical   
       activity 
D. During headache at least one of the  
     following: 
     1. nausea and/or vomiting 
     2. photophobia and phonophobia 
E.  Not attributed to another disorder 
A. At least 2 attacks fulfilling B 
 
B. At least three of the following 
characteristics: 
1. one or more fully reversible aura  
      symptoms indicating focal cerebral   
      cortical and/or brainstem        
      dysfunction 
     2.  at least one aura symptom 
     develops gradually over more than 4  
     minutes or two or more symptoms   
     occur in succession. 
     3. aura symptoms last no more than   
     60  minutes  
     4. headache follow aura with a free 
     interval of less than 60 minutes, but  
     may begin before or      
     simultaneously with the aura 
Adapted from (Headache Classification Committee of the International Headache 
Society, 2004) 
 
 
 
 
 
 
1.3 Migraine prevalence 
 
Headache disorders are the most prevalent neurological conditions (Rasmussen et al., 
1991; Leonardi et al., 1998) and migraine is a very common condition worldwide. 
Estimates of its prevalence have varied widely, ranging from 3% to 23% (figure 1) and 
these differences can, in the main, be accounted for the differing definitions and 
methodologies employed. Population based-studies carried out using the IHS 
classification (Headache Classification Committee of the International Headache 
Society, 2004) in United States and European countries, suggest a lifetime prevalence of 
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16% with a female to male ratio of approximately 3:1 and the one year overall 
prevalence to be 6% in males and 15% to 18% among females (Launer et al., 1999; 
Lipton et al., 2002; Steiner et al., 2003; Lipton and Bigal, 2005b; Rasmussen, 2006). 
Onset of migraine is most common in the 2nd and 3rd decade of life (Breslau et al., 1991; 
Russell et al., 1995). 
 
 
 
 
 
 
 
Figure 1: Estimates of migraine prevalence in studies using the diagnostic criteria 
of the International Headache Society 
1 lifetime prevalence; 2 one-year prevalence; 3 not available period for prevalence 
Adapted from (Peres, 2005) 
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Migraine prevalence is age and gender dependent (Russell et al., 1995). Before puberty, 
migraine is slightly more common in boys, with the highest incidence between 6-10 
years of age, but this is reversed (Russell et al., 1995) with the onset of female’s cyclic 
hormonal changes (Epstein et al., 1975; Stewart et al., 2000). In general, women are 
more commonly affected than men with a lifetime prevalence of 12-17% and 4-6%, 
respectively (Russell et al., 1995; Peres, 2005). The male to female ratio in Europe is 
similar to that in America and Africa although the exact percentages differ.  America 
has a prevalence of 5.9% and 17.6% respectively (Lipton et al., 2001; Lipton et al., 
2002; Lipton and Bigal, 2005a), while Africa has a much lower prevalence of 1.7% in 
males and 4.2% in females (Tekle Haimanot et al., 1995).  A more recent survey carried 
out over five countries across Europe and America found an overall prevalence of 
between 5% and 12% in agreement with previous epidemiologic studies (MacGregor et 
al., 2003). 
 
 
 
 
 
 
1.4 The clinical picture of migraine 
 
The clinical picture of  a migraine attack can be divided into three or four distinct stages 
depending on the presence of aura (figure  2) (Blau, 1992) and each phase may occur 
alone or in combination with any other phase. 
 
1.4.1 Premonitory symptoms 
 
Premonitory symptoms are neurological, behavioral or physiological symptoms that in 
some patients can precede a migraine attack. Preceding symptoms can be forewarning 
of a migraine attack by 2-48 hours before the aura in migraine with aura and before the 
onset of pain in migraine without aura (Giffin et al., 2003). 
 
Until recently accurate data on premonitory symptom prevalence was lacking (Rossi et 
al., 2005). Recent studies using patients who fulfill the IHS criteria, described 
premonitory symptoms in 87% of subjects and the presence of premonitory symptoms 
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in 84% of migraine attacks. The symptoms were more frequent in patients experiencing 
migraine with aura (Quintela et al., 2006; Schoonman et al., 2006). Premonitory 
symptoms vary between individuals and in general neuropsychiatric were the most 
frequent (82%), followed by sensory (65%) and other general symptoms (58-63%) 
(Quintela et al., 2006). In an electronic diary-based study the most common 
premonitory symptoms reported were tiredness (72%), poor concentration (51%) and 
stiff neck (50%) (Giffin et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Stages of a migraine attack and possible symptoms during the different 
phases  
The clinical picture of a migraine attack can be divided into distinct phases and each 
phase may occur alone or in combination with any other, while characteristic symptoms 
occur during each phase. Adapted from (Blau, 1992).  
 
 
 
 
 
Headache 
Premonitory 
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The diverse nature of symptoms associated with the premonitory phase, suggests that 
central disturbances occur at both cortical and subcortical levels. Changes in water 
metabolism or appetite would implicate hypothalamic involvement (Zurak, 1997), as 
the hypothalamus is the main centre for the integration of endocrine functions, 
autonomic responses and behaviour, and governs the rythmicity of many physical 
functions such as body temperature, feeding behaviour and sleep-wake regulation 
(Saper, 1990; Swaab, 1997). A recent study using positron emission tomography (PET) 
scanning of spontaneous migraine attacks revealed hypothalamic activation during the 
attack (Denuelle et al., 2007). The presence of cognitive slowing during the premonitory 
phase suggests cortical level disruption (Reeves, 1976; Farmer et al., 2003). However, 
the pathophysiology of the premonitory phase is largely speculative due to the lack of 
direct studies specifically investigating this phenomenon and demonstrating the actual 
activation of any brain area during this phase. Dopamine upregulation is likely to be 
involved in the development of these symptoms in brainstem pathways (De Marinis et 
al., 2003), as dopamine antagonists have been shown to eliminate the premonitory 
symptoms of migraine (Peroutka, 1997).  
 
1.4.2 The Aura 
 
The aura symptoms consist of reversible visual, sensory, language or less frequently 
motor symptoms that precede or accompany the migraine-like headache (table 4). 
Typically aura develops over 5-20 minutes and last for less than 1 hour. Headache 
follows aura about 80% of the time and usually commences while cerebral blood flow 
remains diminished (Olesen et al., 1990).  
 
Visual symptoms are the most common, and are usually described as zigzag or 
scintillating figures (fortification spectrum), scotomata, flashing lights, distortions in 
shape and size and they mostly affect one hemifield of both eyes, although subjectively 
they often appear to affect only one eye. The most frequent visual auras start as a small 
uncolored but bright flickering spot in the visual field, which becomes more apparent as 
it begins to expand into a 'C' or inverted 'C' shape zigzag-shaped line. This continues to 
travel across the visual field, eventually breaking up and disappearing. Occasionally in 
some patients, sensory symptoms affecting the hand and gradually spreading to the 
whole arm and the perioral region occur in conjunction with visual aura. These 
symptoms are frequently described as a sensation of pins and needles, usually affecting 
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one arm, which travels up from the hand over several minutes to affect the face and 
tongue (Russell and Olesen, 1996). Motor aura is less frequent and not well recognized 
by patients and is usually described as motor weakness (Silberstein et al., 2001). 
 
The pathology of aura is now believed to be due to a wave of cortical spreading 
depression (CSD; paragraph 1.7) which spreads out from the occipital lobe across the 
cortex, resulting in an initial hyperaemic phase followed by a oligaemic phase (Olesen 
et al., 1990; Lauritzen, 1994; Olesen, 1998).   
 
1.4.3 The Headache phase 
 
The headache phase lasts between 4-72 hours if untreated. The pain can be severe and in 
about 80% of the patient the head pain is described as throbbing, as compared to 
pressing or bursting-like. The head pain of a migraine is more often unilateral than 
bilateral and may be accompanied by sensitivity to light and sound and difficulties in 
concentrating and focusing. Movement usually aggravates the pain and nausea, 
especially in patients suffering from migraine without aura (Zagami and Bahra, 2006).  
Many migraine patients develop cutaneous allodynia- a painful response to a stimulus 
that is ordinarily not painful- during a migraine headache, characterised by increased 
skin sensitivity, mostly within the referred area of pain of the ipsilateral head, which 
could spread to the other side of the head or the forearm (Burstein et al., 2000).  The 
appearance and spread of cutaneous allodynia is a due to the development and spread of 
neuronal sensitization from first order trigeminal peripheral neurons to second and third 
order central neurons in the brainstem and thalamus (Dodick and Silberstein, 2006).  
 
1.4.4 The Resolution phase 
                                                                                                                                                                
The resolution phase or the postdrome is the phase following the severe headache, 
before full recovery of migraine symptoms (Blau, 1982).  In a recent study, Quintela et 
al. (2006) found resolution symptoms after a migraine attack in 80% of patients and the 
most common resolution symptoms reported were asthenia, tiredness, somnolence and 
concentration difficulties. In the same study the severity of the headache was 
significantly associated with a higher frequency of resolution symptoms.  
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Table 4: Summary of different types of aura 
Adapted from (Silberstein et al., 2001). 
 
 
 
 
1.5 Migraine Triggers 
 
A wide range of events and conditions have been proposed to alter conditions in the 
brain that may trigger migraines. Any single trigger may not be enough to enhance the 
probability of a migraine attack on its own and migraine triggers vary greatly from one 
person to another. Triggers often appear to be cumulative, reaching a threshold above 
which migraine is initiated. Triggers can be both external and internal stimuli including 
hormonal changes, dietary factors, environmental changes, sensory stimuli and stress 
(figure 3). 
 
In a recent study Kelman (2007) found that 76% of the patients could recognise the 
presence of one or more triggers that could initiate their migraine attacks. The most 
frequent triggers reported are (figure 3): hormonal changes in women (33.3%), stress 
(25.5%), missing a meal (12%), weather changes (11.3%), perfume smells (10.7%), 
neck pain (10.6%), alcohol (9.5%) and sleep disturbance (8.6%).  
 
Hormonal change as seen in menstrual migraine is a reliable trigger of attacks in women 
and this additional hormonal trigger may account for the increased prevalence of 
migraine in women compared with men in the reproductive years (Silberstein and 
Merriam, 1991). Migraine in women usually declines after the onset of menopause 
(Neri et al., 1993; Fettes, 1999), indicating the influence of hormonal changes on 
migraine occurrence. 
Aura Characteristics 
Visual Scotoma, photopsia or phosphenes, rotation, 
oscillation, shimmering of objects, excessive 
brightness 
Visual hallucinations or 
distortions 
Metamorphosia, macropsia, zoom or mosaic vision 
Sensory Paresthesias, often migrating, and can become 
bilateral olfactory hallucinations 
Motor Weakness or ataxia 
Language Dysarthria or aphasia 
Delusions and disturbed 
consciousness 
Déjà vu, multiple conscious trance-like states 
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Figure 3: Common migraine triggers identified by migraineurs 
Percentage frequency of individual migraine triggers occurring at least occasionally 
(>33% of headaches). Hormone trigger refers only to women. Adapted from (Kelman, 
2007). 
 
 
 
 
Nitroglycerin, which is a nitric oxide (NO) donor is now used in human experimental 
models for headache induction (Iversen et al., 1989; van der Kuy and Lohman, 2003; 
Afridi et al., 2004; Afridi et al., 2005a). Red wine is also believed to act via a similar 
mechanism, as it can cause significant increases in NO release (Leikert et al., 2002), 
though other studies suggest ethanol causes vasodilation of meningeal vessels by 
transient vanilloid 1 receptor  (TRPV1) activation (Nicoletti et al., 2007). It is important 
to note that certain migraine triggers may not be a contributory factor, but a result of the 
migraine premonitory symptoms, giving the impression of a triggering function 
(Headache Classification Committee of the International Headache Society, 2004).  
 
How different triggers act to initiate a migraine attack is not known.  A rather complex 
hypothesis has been suggested implying that different triggers can activate 
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hypothalamic, limbic and cortical areas that can impinge on parasympathetic neurons 
innervating the meninges resulting in vasodilation and local release of molecules that 
activate meningeal nociceptors (Burstein and Jakubowski, 2005). Recently in a series of 
experiments Lambert et al. (2008) suggested that cortical activation can indirectly 
through inhibition of the nucleus raphe magnus (NRM) induce pain responses. In this 
study it was shown that stimulation of the NRM can suppress trigeminovascular 
activation in the brainstem. This NRM-mediated inhibition of trigeminovascular activity 
was antagonised by cortical activation (CSD and light were used as triggers of cortical 
neuronal activation), through inhibition of neurons in the NRM. Thus migraine triggers 
could cause cortical activation, which disinhibits trigeminovascular sensation through 
the NRM (Lambert et al., 2008).  As this area consists of both descending inhibitory 
systems and facilitatory descending pathways to the spinal cord and trigeminocervical 
complex, it is likely that stimulation of the NRM induces inhibition of 
trigeminovascular activity through activation of the inhibitory descending pathway in 
the NRM. Cortical activation could in turn utilise the facilitatory descending pathway in 
the NRM, which is hypothesised to facilitate trigeminovascular nociceptive 
transmission, or suppress the inhibitory descending pathway. A more detailed 
discussion on the descending inhibitory and facilitatory descending pathways of the 
NRM and the interrelated region of the ventromedial medulla follows in section 1.8.7. 
 
 
 
 
1.6 Genetics of migraine 
 
Migraine is a multifactorial disorder and genetic factors play an important role in the 
development of the disorder. Studies examining the genetic basis of migraine are 
complicated by the heterogeneous nature of the condition and the lack of objective 
clinical or diagnostic tests. Family and twin studies showed evidence for an increase 
risk in the family members of migraineurs (Noble-Topham et al., 2003) and a higher 
concordance rate in monozygotic twins for migraine (Ziegler et al., 1998), indicating 
that genetic factors are a major contribution to the pathogenesis of both migraine with 
or without aura.   
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Familial Hemiplegic Migraine (FHM) is a rare subtype of migraine with prominent aura 
symptoms which is inherited in an autosomal dominant manner. The molecular linkage 
of FHM involves three mutations which form the only establish molecular knowledge 
of migraine so far (van den Maagdenberg et al., 2007): 
 
A) FHM 1 locus affecting the CACNA1A calcium channel gene (mapped to 
chromosome 19p13) (Ophoff et al., 1996). The CACNA1A gene encodes the 
pore-forming A1 subunit of Cav2.1 (P/Q-type) voltage-gated neuronal calcium 
channels that modulate release of neurotransmitters at peripheral and central 
synapses. Over 50 CACNA1A mutations have been associated with a wide range 
of clinical phenotypes including FHM, and also sometimes associated with 
ataxia or even fatal coma, episodic ataxia type 2 and spinocerebellar ataxia type 
6 (Wessman et al., 2004; van den Maagdenberg et al., 2007). 
 
B) FHM 2 locus affecting the ATP1A2 gene (on chromosome 1q23) (De Fusco et 
al., 2003). The ATP1A2 gene encodes the A2 subunit of sodium-potassium 
pump ATPases. Sodium potassium pumps transport sodium ions out of the cell 
while importing potassium ions. ATPases modulate the re-uptake of potassium 
and glutamate from the synaptic cleft into glial cells. ATP1A2 mutations have 
been associated with a range of clinical phenotypes of FHM with and without 
cerebellar ataxia, and also with basilar migraine and alternating hemiplegia of 
childhood.  Many patients also suffer from epilepsy (De Vries et al., 2006). 
 
C) FHM 3 affecting the SCN1A gene (on chromosome 2q24) (Dichgans et al., 
2005). The SCN1A gene encodes the A1 subunit of neuronal voltage-gated 
sodium (Nav1.1) channels that play an important role in the generation and 
propagation of action potentials. Mutations in this gene have been associated 
with epilepsy syndromes, but migraine has not been reported in these epilepsy 
syndromes (Meisler and Kearney, 2005). A Q1489K mutation in three German 
FHM families of common heritage (Dichgans et al., 2005) and a L1649Q 
mutation in a North-American FHM family (Vanmolkot et al., 2007) confirm the 
relationship between SCN1A and FHM 3. Mutation scanning of a large number 
of other FHM families, however, suggests that the SCN1A gene is a rare cause of 
FHM (Dichgans et al., 2005; Vanmolkot et al., 2007). 
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Interestingly a common consequence of these mutations is an increase in glutamate 
availability at the synaptic cleft of cells (Goadsby, 2007). The FHM 1 mutation can 
have as a consequence enhanced glutamate release due to enhanced calcium flux at the 
presynaptic terminal (Schneggenburger and Neher, 2005). FHM 2 results in a smaller 
electrochemical gradient for Na+. One effect of this is the reduction or inactivation of 
astrocytic glutamate transporters, leading to a build-up of synaptic glutamate (De Fusco 
et al., 2003). The FHM 3 mutation can result in facilitation of high-frequency 
discharges that might also increase synaptic glutamate levels (Dichgans et al., 2005). 
Thus, the neurons at glutamatergic synapses can fire at a higher frequency than they do 
under normal conditions and this might explain the increased susceptibility to CSD (van 
den Maagdenberg et al., 2004; Wessman et al., 2007). 
 
Unlike FHM, there are very few genetic breakthroughs for common types of migraine 
and no genes have been identified yet, although genome-wide linkage studies have 
identified several chromosomal regions with significant or suggestive linkage for 
nonhemiplegic migraine (van den Maagdenberg et al., 2007), including  1p36, 6q25, 
9q34, 11q24, 19p13, 4q24 and Xq. Interestingly, the 11q24 locus which has 
demonstrated significant linkage to migraine with aura (Cader et al., 2003) maps, 
among other candidates, the GRIK4 gene which codes for the KA1 kainate receptor 
subunit (Mayer, 2007).   
 
If these mutations are directly responsible for the pathogenesis of migraine it is unlikely 
that they would have effects specific to one neural process, such as CSD. In agreement 
with this, new evidence suggests that FHM 1 mutation in mice reduces the expression of 
calcitonin gene-related peptide (CGRP) in trigeminal ganglia neurons (Mathew et al., 
2007), further supporting that a systemic dysfunction of sensory neural function at 
multiple levels is a more plausible explanation for the triggering and symptomatology 
of migraine. FHM shares many phenotypical similarities with common types of 
migraine, indicating common neurobiological pathways, and someone would expect a 
more prominent role of CGRP cells in the trigeminal ganglia in these mutations, 
considering the importance of CGRP in migraine pathophysiology (Goadsby et al., 
1990).  Instead the reduction of CGRP in trigeminal neurons of FHM 1 mutant mice 
points to a loss of balance of the vasoactive peptides.  In agreement with this, is 
evidence coming from a study in which FHM patients with known mutations in the 
CACNA1A and ATP1A2 genes do not show hypersensitivity to CGRP infusion, as 
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characteristically seen in migraine patients without aura. This indicates that the 
pathophysiologic pathways underlying migraine headache in FHM may be different 
from the common types of migraine and further questions whether CGRP antagonists 
would be effective in the treatment of FHM patients (Hansen et al., 2008).  
 
 
 
 
 
 
1.7 Cortical spreading depression and migraine 
 
Cortical spreading depression (CSD), discovered by Leão in 1944, is a self-propagating 
depolarisation of neurons and glia linked with depressed neuronal electrical activity 
(Leão, 1944) that moves at a rate of about 2-3 mm/min across the cerebral cortex.  Leão 
first observed that CSD leads to transient dilatation of pial arteries (Leão, 1944). 
Following this transient hyperperfusion, hypoperfusion ensues, which persists long after 
CSD waves have passed. Spreading depression has been demonstrated in almost all the 
grey matter regions of the central nervous system (CNS) (Somjen, 2001), although the 
cortex of primates, especially in humans, is relatively more resistant to CSD. Early 
observations from Lashley (Lashley, 1941) suggested an association between CSD and 
the migraine aura and several imaging studies of patients during migraine with aura 
showed unilateral regions of occipital hypoperfusion that tend to spread rostrally from 
the occipital cortex and persist into the headache phase (Sanchez-del-Rio and Reuter, 
2004). The aura is now believed to be a wave of CSD which spreads out from the 
occipital lobe across the cortex, resulting in an initial hyperaemic phase followed by an 
oligaemic phase (Olesen et al., 1990; Lauritzen, 1994; Olesen, 1998). Strong evidence 
supporting that an electrophysiological event such as CSD generates the aura in human 
visual cortex came only recently with the use of high-field functional MRI with near-
continuous recording during migraine visual aura in humans. With this method 
Hadjikhani and colleagues (2001) observed blood oxygenation level-dependent (BOLD) 
signal changes that demonstrated characteristics of CSD as time-locked to percept onset 
of the aura (figure 4). 
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Figure 4: Spreading suppression of cortical activation during migraine aura 
(A) A drawing showing the progression over 20 minutes of the scintillations and the 
visual field defect affecting the left hemifield, as described by the patient. (B) A 
reconstruction of the same patient’s brain, based on anatomical MR data. The posterior 
medial aspect of occipital lobe is shown in an inflated cortex format. MR signal changes 
over time are shown to the right. Each time course was recorded from one in a sequence 
of voxels that were sampled along the calcarine sulcus, in the primary visual cortex, 
from the posterior pole to more anterior location, as indicated by arrowheads. A similar 
BOLD response was found within all of the extrastriate areas, differing only in the time 
of onset of the MR perturbation. The MR perturbations developed earlier in the foveal 
representation, compared with more eccentric representations of retinotopic visual 
cortex. This finding was consistent with the progression of the aura from central to 
peripheral eccentricities in the corresponding visual field (A and C). (C) The MR maps 
of retinotopic eccentricity from this same subject, acquired during interictal scans. As 
shown in the logo in the upper left, voxels that show retinotopically specific activation 
in the fovea are coded in red (centered at 1.5° eccentricity), parafoveal eccentricities are 
shown in blue, and more peripheral eccentricities are shown in green. Adapted from 
(Hadjikhani et al., 2001). 
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It is not yet clear how CSD is triggered in human cortex during migraine aura. A 
number of diverse stimuli trigger CSD including direct cortical trauma, exposure to high 
concentrations of excitatory amino acids or K+, direct electrical stimulation, inhibition 
of Na+/K+-ATPase and energy failure (Somjen, 2001). As previously mentioned genetic 
predispositions and environmental factors may modulate individual susceptibility by 
lowering the CSD threshold (van den Maagdenberg et al., 2004), and cortical excitation 
may cause sufficient elevation in extracellular K+ and glutamate to initiate CSD (De 
Fusco et al., 2003).  
 
A serious debate has occurred over the years as to whether CSD and the resultant aura 
are responsible for the pain in migraine.  Bolay et al (2002) showed that CSD, evoked in 
the rat cerebral cortex by a pinprick or local electrical stimulation, activates trigeminal 
nerve terminals on cerebral blood vessels and reflex middle meningeal vasodilation and 
increases neural activity in the ipsilateral trigeminal nucleus. It was also demonstrated 
that the trigeminal activation produced by CSD causes inflammation in the meninges 
that occurs after the CSD has subsided (Iadecola, 2002). Previous studies have also 
shown that CSD induces Fos-like immunoreactivity in the rat cerebral cortex (Herrera et 
al., 1993) and in the ipsilateral trigeminal nucleus caudalis (TNC), (Moskowitz et al., 
1993; Bolay et al., 2002). CSD also causes plasma protein extravasation (PPE) in the 
dura mater and c-fos induction in the TNC, events that seem to be dependent on intact 
branches of the trigeminal and superior salivatory nuclei (Bolay et al., 2002).  
 
Contradicting preclinical data to these previous findings also exists. Ebersberger et al 
(2001) induced CSD in the rat cerebral cortex and assessed plasma extravasation in the 
dura mater and neuronal activity in deep laminae of the trigeminal nucleus in vivo. In 
this series of experiments CSD did not alter dural plasma extravasation compared to the 
CSD-free contralateral side and ongoing neuronal activity or receptive field stimulation-
evoked responses were not altered by a single CSD or repeated CSDs. In an in vitro 
model, the application of KCl to the dura at concentrations found extracellularly during 
CSD did not alter the release of CGRP and prostaglandin E2 from the dura (Ebersberger 
et al., 2001). It has been further questioned whether the c-fos induction by CSD 
(Moskowitz et al., 1993) is an actual downstream event or if it is an artefact due to 
hyperosmolar activation of trigeminal fibres (Ingvardsen et al., 1997), caused by 
application of potassium chloride (Moskowitz et al., 1993).  
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Further to the preclinical data that do not support links between CSD and migraine 
headache, clinical evidence supporting that migraine aura, may not be the trigger for the 
pain and other symptoms also exist (Goadsby, 2001):  
• Aura does not necessarily precede headache (Goadsby, 2001), as aura symptoms 
(and by extension CSD) occur in only a minority of migraine patients 
(Rasmussen and Olesen, 1992; Russell and Olesen, 1996). 
• Aura without headache is not uncommon (Goadsby, 2001) and therefore aura 
does not necessarily lead to head pain. 
• Migraine aura is not always contralateral to the headache (Goadsby, 2001). 
 
Strong evidence suggests that CSD is responsible for the clinical symptoms of aura and 
this phenomenon may provide important insights into some elements of the 
pathogenesis of migraine and therapeutic developments might shed more light on the 
relationship between aura and headache (Goadsby, 2007).  
  
 
 
 
 
1.8 Pathophysiology of migraine 
 
Migraine is a form of sensory processing disturbance with wide implications within the 
CNS (Goadsby, 2007). In order to understand the known pathophysiology of migraine, 
further to the genetics (paragraph 1.6) and the physiological basis of the aura (paragraph 
1.7), the elements to be considered are the physiology and pharmacology of the pain-
producing structures of the head. These include the dura mater and cranial vessels, and 
more appropriately their innervation which forms the trigeminovascular system. The 
central projections of the fibres innervating the cranial vessels to the caudal brainstem 
and upper spinal cord, and diencephalic modulatory systems that influence trigeminal 
pain transmission are of great importance (figure 5).  
 
Our initial understanding of the pathophysiology of migraine came from the early 
observations by Wolff, Ray and Penfield (Penfield, 1932, 1934; Ray and Wolff, 1940; 
Wolff, 1948) who identified cranial pain-producing structures, by observing that 
mechanical stimulation of the meninges and the meningeal and cranial vessels caused 
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severe headache in awake patients during cranial surgery. The importance of these 
structures in migraine pathophysiology is their rich innervation by primary afferents 
from neurons located mainly in the trigeminal ganglia as well as from the upper cervical 
ganglia (Mayberg et al., 1984; Arbab et al., 1986). As the key pathway for migraine 
pathophysiology is the trigeminovascular input from the meningeal vessels, it is 
essential to refer to the anatomy of the trigeminal ganglion and its peripheral 
(trigeminovascular) and central projections (trigeminocervical), to further understand 
the pathophysiology of migraine.  
 
 
 
 
 
 
Figure 5: Pathophysiology of the trigeminovascular system 
Sensory fibres innervating the cranial vessels arise from neurons which have their cell 
bodies within the trigeminal ganglion. Sensory inputs from the dural blood vessels (such 
as the superior sagittal sinus and middle meningeal artery) synapse on second order 
neurons in the trigeminocervical complex. These in turn project to the thalamus in the 
quinto/trigemino-thalamic tract. There are also connections between pontine neurons 
and the superior salivatory nucleus which results in a reflex activation of 
parasympathetic fibres (with resultant vasodilation), and these are relayed in the 
pterygopalatine (sphenopalatine) ganglion (Goadsby et al., 2002). 
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1.8.1 Trigeminal ganglion and trigeminal nerve 
 
The following is adapted from published reviews (Schaltenbrand and Walker, 1997; 
Crossman and D., 2000; Shankland, 2000; Go et al., 2001; Kandel et al., 2000). 
 
The trigeminal ganglion is the sensory ganglion of the trigeminal nerve and occupies the 
Meckel's cavity (cavum Meckelii) in the dura mater covering the trigeminal impression 
near the apex of the petrous part of the temporal bone. The trigeminal ganglion consists 
of pseudounipolar primary sensory neurons (the dendrite of these neurons are located in 
the trigeminal nerve, the cell bodies are located in the trigeminal ganglion and the axons 
protrude through the sensory root and into the ventrolateral midpons) and is analogous 
to the dorsal root ganglia (DRG) of the spinal cord, which contain the cell bodies of 
incoming sensory fibres from the rest of the body (Tandrup, 1995). 
 
The trigeminal ganglion gives rise to the trigeminal nerve (Vth cranial nerve), which is 
the largest of the cranial nerves and it has three major branches:  
• the ophthalmic nerve (V1) 
• the maxillary nerve (V2) 
• the mandibular nerve (V3) 
 
The ophthalmic and maxillary nerves are purely sensory, whereas the mandibular nerve 
has both sensory and motor functions. These three branches converge on the trigeminal 
ganglion from which a single large sensory root enters the brainstem at the level of the 
pons. Immediately adjacent to the sensory root, a smaller motor root emerges from the 
pons at the same level, and thus the trigeminal nerve is a mixed nerve containing both 
motor and sensory components. 
 
The motor root runs in front of and medial to the sensory root, and passes beneath the 
ganglion. The cell bodies of the motor fibres are located in the motor nucleus of the Vth 
nerve within the pons. Motor fibres are distributed (together with sensory fibres) in 
branches of the mandibular nerve and supply the muscles of mastication and the tensor 
tympani and tensor veli palatine muscles. 
 
The sensory fibres of the ophthalmic, maxillary and mandibular nerves supply the 
cutaneous exteroceptors of the face, the mucous membranes of the nasal and oral 
 39
cavities, and a large portion of the intracranial dura mater and vessels.  The sensory 
fibres, also called nociceptors, convey information regarding pain, temperature, touch, 
and proprioception. The areas of cutaneous distribution (dermatomes) of the three 
branches of the trigeminal nerve have sharp borders with relatively little overlap, unlike 
dermatomes in the rest of the body, which show considerable overlap (figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Superficial distribution of sensory fibres in the three divisions of the 
trigeminal nerve 
The trigeminal nerve has three divisions: ophthalmic, mandibular, and maxillary. 
Anterior structures of the head and face are innervated by the ophthalmic division. 
Posterior regions are innervated by the upper cervical (C) nerves. Adapted from 
(Crossman and D., 2000). 
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1.8.2 Primary sensory afferents 
 
Early anatomical studies provided evidence for the meningeal representation in the 
trigeminal ganglion by using horseradish peroxidase histochemistry (Messlinger et al., 
2006). Most of the nociceptors around meningeal vessels were found to project mainly 
to the ophthalmic division of the ipsilateral trigeminal ganglion and to a minor degree to 
the maxillary and mandibular divisions (Mayberg et al., 1984; Steiger and Meakin, 
1984). Further to the trigeminal ganglion projections to meningeal structures, neurons 
located in the upper cervical ganglia were also shown to contribute to the these 
projections (Mayberg et al., 1984; Arbab et al., 1986). 
 
The nociceptors that run adjacent to the blood vessels transmit nociceptive information 
mainly through Aδ- (thinly myelinated) and C- (unmyelinated) fibre types (Strassman et 
al., 1986; Schepelmann et al., 1999; Bartsch and Goadsby, 2003b) although other types 
of primary afferents transmitting somatic sensations have also been characterised 
(Millan, 1999) (table 5). The somatic pain associated with the Aδ-fibres is characterised 
by an initial extremely sharp pain and is referred to as the “first” pain. The “second” 
pain is referred to the more prolonged and delayed feeling of dull ache or burning pain 
as a result of C-fibre activation.  
 
The peripheral terminal of the nociceptor is where noxious stimuli are detected and 
transduced into inward currents that, if sufficiently large, begin to drive action 
potentials along the axon to the CNS and set a train of events that ultimately lead to a 
conscious awareness of the noxious stimulus (Woolf and Ma, 2007). The sensory 
specificity of the nociceptor is established by expression of ion channels which respond 
with a high threshold only to particular features of the mechanical, thermal, and 
chemical environment (Ramsey et al., 2006; Woolf and Ma, 2007) (figure 7). The high 
threshold of these transducers differentiates nociceptors from sensory neurons that 
respond to innocuous stimuli by expressing transducers with low thresholds (Woolf and 
Ma, 2007). Transmission of nociception occurs in response to calcium influx at the 
central terminal and releasing glutamate as well as multiple synaptic modulators and 
signalling molecules, which will activate postsynaptic receptors on second order 
neurons (Millan, 1999) (table 5). 
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Table 5: Characteristics of primary afferent sensory fibres 
 
 
Fibre type 
Aβ Aδ C 
    
Diameter (μm) >10 2-6 0.4-1.2 
    
Conduction 
velocity (m/sec) 30-100 12-30 0.5-1.2 
    
Myelination Thickly myelinated Thinly myelinated Unmyelinated 
    
Activation 
threshold Low High High 
    
Principal 
neurotransmitters 
released 
EAA SP, NKA, CGRP, EAA 
SP, NKA, CGRP, 
EAA 
    
Receptors activated 
post-synaptically 
AMPA NK1+2,CGRP1+2, 
NMDA/AMPA, 
mGlu 
NK1+2,CGRP1+2, 
NMDA/AMPA, 
mGlu 
    
Laminae in which 
neurons  terminate IIi, III, IV, V I/IIo, V I/IIo, V, X 
    
Types of  second 
order neurons 
contacted 
LTM, WDR NS, WDR, LTM NS, WDR 
    
Sensory 
modality 
transmitted 
Innocuous: light 
touch, vibration 
and pressure  
Noxious: sharp, 
pricking pain 
 
Sharp, stinging 
pain “First pain” 
Noxious: thermal, 
mechanical and 
chemical irritation  
Dull, burning pain 
“Second pain” 
 
AMPA; α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid, CGRP; calcitonin gene-related peptide, 
EAA; excitatory amino acids, LTM; low threshold mechanosensitive, mGlu; metabotropic glutamate, 
NK; neurokinin, NKA; neurokinin A, NMDA; N-methyl-D-aspartic acid, NS; nociceptive specific, SP; 
substance P, WDR; wide dynamic range. Adapted from (Millan, 1999). 
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Figure 7: Transduction and transmission of noxious stimuli on the peripheral and 
central terminal of the nociceptor 
Transduction is mediated by high-threshold transducer ion channels which depolarize 
the peripheral terminal activating voltage-dependent sodium channels. Transmission 
occurs in response to calcium influx at the central terminal releasing glutamate as well 
as multiple synaptic modulators and signalling molecules and is subject to both 
excitatory and inhibitory influences. Adapted from (Woolf and Ma, 2007)  
TRPV, transient receptor potential vanilloid family; TRPM, transient receptor potential 
melastatin family; TRPA, transient receptor potential ankyrin family; ASICs, acid-
sensing ion channels; P2, purinergic receptors; TREK, two-pore domain weak inward 
rectifying K+ channels-related K+ channel; TASK, two-pore domain weak inward 
rectifying K+ channels -related arachidonic acid-stimulated K+ channel; Nav, voltage-
gated sodium channel; MOR, mu-opioid receptor; DOR, delta opioid receptor; CB1, 
cannabinoid receptor 1; EP, E series of prostaglandin receptors; B2, Bradykinin 2 
receptor; CGRP, calcitonin gene-related peptide; BDNF, brain-derived neurotrophic 
factor; CCL3, Chemokine (c-c motif) ligand 3; NO, nitric oxide.  
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Absence of kainate receptors from “Millan’s table”– it’s all about history 
 
Upon activation of primary afferents, post-synaptic receptors on second order neurons 
are activated and transmit the nociceptive information to higher brain areas. The 
glutamate receptors, N-methyl-D-aspartic acid (NMDA) and α-amino-3-hydroxy-5-
methylisoxazole-4-proprionic acid (AMPA), as well as some of the metabotropic 
glutamate receptors have been shown to be post-synaptically activated during 
nociceptive transmission (Millan, 1999). Although the presence of kainate receptors in 
the spinal dorsal horn was known since the early 1990’s (Bettler et al., 1990; Gu and 
Huang, 1991; Bahn et al., 1994; Petralia et al., 1994), the lack of selective, 
pharmacological tools had hitherto hampered analysis of their putative role in the spinal 
transmission of nociceptive information (Fletcher and Lodge, 1996). In his extensive 
review Millan (1999) refers to the plausible role of kainate receptors in transmitting 
nociception based on studies in which the kainate ligand (2S,4R)-4-Methylglutamic acid 
(SYM 2081) was shown to desensitise kainate receptors and attenuate the mechanical 
allodynia and thermal hyperalgesia provoked by nerve injury (Sutton et al., 1999). 
However, it was unclear whether the kainate receptors possible involvement were 
engaged by small and/or large afferent fibres (Huettner, 1990). The presence of kainate 
receptors on central primary afferent terminals in the dorsal horn was not definitively 
demonstrated, and it was uncertain whether they were localised on intrinsic dorsal horn 
neurons or on the central terminals of small primary afferents (Bettler et al., 1990; 
Mitchell and Anderson, 1991).  In the late 1990’s Li et al. (1999) demonstrated for the 
first time post-synaptic activation of kainate receptors in the dorsal horn by activation of 
sensory primary afferents, and since then the pivotal role of kainate receptors in 
nociception has emerged (Ruscheweyh and Sandkuhler, 2002; Wu et al., 2007). A more 
detailed review on kainate receptors follows in section 1.13. 
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1.8.3 Anatomy and pharmacology of the neural innervation of the dura mater and dural 
and intracerebral blood vessels 
 
Free unencapsulated nerve endings of Aδ and C fibres have been shown by histological 
examination to surround most of the dura mater as well as dural vascular structures 
(Andres et al., 1987). These fibres arise from the trigeminal ganglion and the 
supratentorial part of the dura mater is innervated by fibres from all three branches of 
the trigeminal nerve, whereas midline structures, which include the large sinuses, are 
innervated by fibres which arise from the ophthalmic division. The anterior cranial 
fossae are mainly supplied by fibres from the maxillary branch. The posterior cranial 
fossae are innervated by branches arising from the mandibular branch of the trigeminal 
nerve and by branches from the upper cervical segments and the vagus and 
glossopharyngeal nerves (Steiger and Meakin, 1984).  
 
Using transganglionic neuronal tract tracing techniques on the middle meningeal artery 
(MMA), the superior sagittal sinus (SSS), the middle cerebral arteries and the basilar 
arteries, labelled cell bodies have been found in both the trigeminal ganglia (mainly in 
the ophthalmic division) and upper cervical DRG (Arbab et al., 1986) (Mayberg et al., 
1984; Liu et al., 2003; Liu et al., 2004). Sympathetic nerve fibres that arise from the 
superior cervical ganglia were shown to innervate both the dura mater and dural 
vasculature (Edvinsson and Uddman, 1981; Keller et al., 1989; Uddman et al., 1989). 
Parasympathetic fibres arise from the pterygopalatine (sphenopalatine) and otic ganglia 
(Uddman et al., 1989). 
 
Both the sensory and autonomic fibres that surround the cranial structures contain a 
variety of neuropeptides and neurotransmitters which can mediate contraction or 
dilation of the blood vessels (Edvinsson and Goadsby, 1994) (table 6).  It has been 
shown that migraine attacks involve changes in the regulation of tone of intra- or 
extracranial blood vessels (Olesen, 1991).  In human dural vasculature, noradrenaline 
and neuropeptide Y (NPY) cause potent vasoconstriction, while vasoactive intestinal 
peptide (VIP), substance P (SP) and calcitonin gene-related peptide (CGRP) are potent 
vasodilators.  
 
The functional importance of these peptides in migraine has been studied in depth 
(Edvinsson et al., 1983b; Edvinsson et al., 1983a; Edvinsson and Goadsby, 1995; 
Edvinsson, 1998). In migraine, there is a clear association between the headache and the 
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release of CGRP. During migraine attacks with or without aura in humans, CGRP levels 
are elevated in the extracerebral circulation, while other peptides studied, including SP, 
were unaltered (Goadsby et al., 1990). Treatment with sumatriptan aborts CGRP release 
in parallel with treating migraine (Goadsby and Edvinsson, 1993), indicating the 
concomitance between the headache and the release of CGRP. Intravenous infusion of 
human α-CGRP has been shown to cause a delayed migraine-like headache in patients 
(Lassen et al., 2002) and the CGRP receptor antagonist BIBN 4096 BS (olcegepant) 
(Doods et al., 2000) was effective in treating acute attacks of migraine (Olesen et al., 
2004b). Thus the development of further CGRP receptor antagonists for the treatment of 
migraine receives increasing interest (Herbert and Holzer, 2004; Rudolf et al., 2005; 
Recober and Russo, 2007; Salvatore et al., 2008) .  
 
 
 
 
 
Table 6: Pharmacology of the three systems of perivascular nerve fibres 
innervating the cranial circulation 
 
Perivascular 
fibres 
 
Sensory 
 
Sympathetic 
 
Parasympathetic 
 
Originated 
ganglia 
 
 
 
Trigeminal ganglia 
 
Superior cervical 
ganglia 
 
Sphenopalatine 
ganglion, otic 
ganglion, carotid 
miniganglia 
 
 
Pharmacology 
 
SP, CGRP, 
NKA, PACAP 
 
 
 
NA, NPY, ATP 
 
AChE, VIP, PH, 
PACAP, NOS 
Vasomotor 
action 
 
dilation 
 
contraction 
 
dilation 
NA, noradrenaline; NPY, neuropeptide Y; ATP, adenosine; VIP, vasoactive intestinal peptide; PHI, 
peptide histidine; AChE, acetylcholinesterase; PACAP, pituitary adenylate cyclase-activating peptide; 
NOS, nitric oxide synthase; SP, substance P; CGRP, calcitonin gene-related peptide; NKA, neurokinin A 
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Evidence for the importance of CGRP in migraine also comes from experimental 
animal models. Stimulation of the cat superior sagittal sinus led to increased release of 
CGRP and VIP levels while there was no change in SP or NPY (Zagami et al., 1990). 
When the dura mater is electrically stimulated in rats it causes dilation of dural blood 
vessels (Williamson et al., 1997a), caused by CGRP release from trigeminal sensory 
nerves that innervate the cranial blood vessels since this effect is abolished by the rat 
CGRP receptor antagonist CGRP8-37 (Williamson et al., 1997a). Significant attenuation 
of the neurogenic meningeal vasodilator response is similarly seen with triptans, such as 
sumatriptan (Williamson et al., 1997c). Intravenous administration of CGRP also causes 
dural blood vessel dilation that is similarly abolished by the CGRP receptor antagonist 
CGRP8-37. CGRP-induced dilation however is not abolished by sumatriptan, indicating 
that it is likely the triptans act pre-junctionally to prevent CGRP release, rather than on 
the smooth muscles of the blood vessels (Williamson et al., 1997c). In the TCC, CGRP 
receptor antagonists inhibited trigeminovascular neurons activated by L-glutamate, 
demonstrating a possible central site of action for CGRP receptor antagonists (Storer et 
al., 2004a).   
 
Although SP and CGRP are largely colocalised, there is a selective release of CGRP 
rather than SP and no clinical evidence support the involvement of SP in migraine 
pathophysiology (Goadsby et al., 1990). Trigeminal sensory C fibres arise from neurons 
in the trigeminal ganglia in which CGRP and SP are colocalised, whereas sensory Aδ 
fibres arise from trigeminal neurons containing predominantly CGRP and glutamate 
(Uddman et al., 1989; Edvinsson and Hargreaves, 2000). The detection of CGRP in the 
extracerebral circulation of migraine patients during an attack may reflect a greater 
density of Aδ fibres innervation of the cerebral circulation or it could reflect preferential 
activation of Aδ over C fibres or differential release of CGRP from C fibres pools 
(Edvinsson and Hargreaves, 2000). Released CGRP is a potent vasodilator of the pain 
producing intracranial blood vessels. The marked changes of CGRP levels during 
migraine and the abundant presence of CGRP carrying afferents from the trigeminal 
ganglion in the TCC (figure 8), indicate activation of the trigeminal system (Goadsby 
and Edvinsson, 1998).  
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Figure 8:  Localisation of calcitonin gene-related peptide-like in the 
trigeminocervical complex 
Representative examples of the distribution calcitonin gene-related peptide (CGRP; 
labelled with fluorescein isothiocyanate) fibres in the dorsal region of the cervical spinal 
levels C2 (A, B), C1 (C, D) and trigeminal nucleus caudalis (TNC; E, F) are shown. 
CGRP staining showed fibres in lamina I and outer lamina II of the C1-C2 levels as 
well as strong immunoreactivity in fibres in the superficial layers of TNC (Andreou et. 
al, unpublished data). 
 
 
 
 
 
 
 
50 µm
200 µm
200 µm 50 µm
E F
A B
C D
 48
1.8.4 Anatomy of the trigeminal brainstem nuclear complex and trigeminal projections  
 
The pseudounipolar neurons of the trigeminal and upper cervical ganglia that innervate 
the pain producing cranial structures project centrally and terminate on second order 
neurons in the TCC. The sensory root of the trigeminal nerve enters the lateral pons 
where it terminates in the sensory nuclei of the TCC on second order neurons.  The 
TCC extends from the rostral pons down to the upper cervical spinal cord levels and is 
composed of the principal trigeminal nuclei (Vp) and the spinal trigeminal nucleus 
(Vsp) (subdivided into the nucleus oralis-Vo, the subnuclear interpolaris-Vi, and the 
nucleus caudalis-Vc).  The TCC is organised somatotopically, with the three trigeminal 
divisions being represented in a sequence from ventrolateral to dorsomedial (Strassman 
et al., 1994) (figure 10). 
 
The subnucleus caudalis (Vc), also known as the trigeminal nucleus caudalis (TNC) or 
medullary dorsal horn (MDH) extends from the obex to the cervical spinal cord and is 
analogous to the dorsal horn of the spinal cord (Olszewski, 1950).  It is composed of 
separate layers similar in appearance to the spinal cord dorsal horn with the outermost 
layer, the subnucleus marginalis corresponding to lamina I.  Ventral to this lies the 
subnucleus gelatinosus (lamina II), and the subnucleus magnocellularis which 
corresponds to laminae III and IV.  The TCC extends from the trigeminal nucleus 
caudalis to the segments of C2–C3 in the rat, cat, and monkey (Bartsch and Goadsby, 
2003a). 
 
The TNC, as well as the other nuclei of the spinal trigeminal nucleus and the principal 
trigeminal nuclei, are organised in a ventrodorsal direction (figure 9): 
 
• Mandibular afferents are mainly represented on the dorsal part of each 
subnucleus. 
 
• Ophthalmic afferents terminate ventral in the trigeminal subnuclei or on the 
ventrolateral aspect of the TNC (Hu et al., 1981). 
 
• Maxillary afferents terminate between the mandibular and ophthalmic 
representations in the trigeminal subnuclei. 
 
A B
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Primary afferent sensory fibres converge on second order neurons in laminae I–VI, 
which constitute the dorsal horn, and on second order neurons in the TNC.  According 
to their responses when activated by different stimuli, these second order neurons have 
been classified into three categories (Millan, 1999) and all three have been identified in 
the TCC (Hu, 1990): 
 
1. Nociceptive-specific (NS) neurons are silent at rest and become activated in 
response to high intensity, noxious stimuli and receive inputs from Aδ- and C-
fibres. 
 
2. Non-nociceptive low-threshold (LT) neurons that respond to innocuous 
stimulation only. 
 
3. Wide-dynamic range (WDR) neurons exhibit a dynamic response over a broad 
stimulus range eliciting an incremental response to both innocuous and noxious 
stimuli.  WDR neurons also receive considerable convergent inputs from 
extracranial cutaneous and intracranial visceral structures and may respond to  
            C-, Aδ- and Aβ- fibres. 
 
An organisation pattern of cutaneous, primary afferent inputs to the dorsal horn of the 
spinal cord has been suggested with C-fibres projecting in lamina I, outer lamina II and 
laminae VI and X, Aδ-fibres terminating in lamina I, outer lamina II and laminae III-V, 
and Aβ-fibres terminating in laminae II(inner)-VI and X. This is however not a strict 
organisation, as it does not quantitatively differentiate between various laminae as 
concerns primary afferent input, and the cell types (NS, WDR or LT) are also 
qualitatively, rather than quantitatively represented (Hu, 1990; Millan, 1999). 
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Figure 9: Cytoarchitecture of the trigeminal brainstem nuclear complex and the 
somatotopical organisation of the spinal trigeminal nucleus 
The TCC extends from the rostral pons down to the upper cervical spinal cord levels 
and consists of a complex of sub nuclei divided into the principal sensory nucleus (Vp), 
at which a major part of the trigeminal nerve terminates, and the spinal trigeminal 
nucleus (Vsp). The Vsp is further divided into three sub-nuclei; the nucleus oralis (Vo), 
interpolaris (Vi) and caudalis (Vc) arranged in a rostrocaudal manner. V3, mandibular; 
V2, maxillary; V1, ophthalmic division (Wilkinson, 1986; Nieuwenhuys et al., 1988). 
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Earlier studies have shown that the spinal trigeminal nucleus, especially the TNC, has 
an important role in the mediation of pain and temperature sensations from the head and 
facial regions (Mosso and Kruger, 1973; Dubner and Bennett, 1983). Sensory inputs 
from the dural blood vessels (such as the superior sagittal sinus and the middle 
meningeal artery) synapse on second order neurons in the TCC and nociceptive 
electrical and mechanical stimulation of the superior sagittal sinus results in Fos 
expression in this nuclei complex (Kaube et al., 1993b; Hoskin et al., 1996; Goadsby 
and Hoskin, 1997). The sensory central projections of the superficial temporal artery 
and the SSS in rats terminate in the TNC, the trigeminal nucleus interpolaris and the 
dorsal horn in the segment C1-C3 (Liu et al., 2003; Liu et al., 2004). Stimulation of the 
superior sagittal sinus or certain other dural components increases neuronal activity in 
the TNC (Davis and Dostrovsky, 1986; Strassman et al., 1986; Bartsch and Goadsby, 
2003b; Bolton et al., 2005) and most of these also have facial receptive fields located in 
the ophthalmic division (Davis and Dostrovsky, 1986). Electrical stimulation of the SSS 
causes increased metabolic activity and blood flow in the TNC and in C1 and C2 of the 
spinal dorsal horn (Goadsby and Zagami, 1991). CGRP-like immunoreactivity, which 
represents CGRP carrying afferents from the trigeminal ganglion (Henry et al., 1993), is 
abundant in the TCC (figure 9) and stimulation of the trigeminal ganglion causes 
increase release of CGRP and SP (Goadsby et al., 1988). 
 
Clinical correlates, that indicate an important role of the brainstem in migraine, come 
from imaging studies, which showed activation of the brainstem during migraine attacks 
(Weiller et al., 1995), and this activation is migraine specific (Bahra et al., 2001). Both 
experimental and clinical evidence suggest that abnormal neuronal modulation at the 
level of the brainstem is clearly implicated in migraine pathophysiology (Goadsby et al., 
2002).  
 
1.8.5 Ascending pathways of the trigeminal system 
 
The majority of the secondary neurons in the TCC decussate at the level of the medulla 
and travel up the brainstem through the ventral trigeminal tract, which ascends in close 
relationship with the contralateral medial lemniscus, and carry sensory information from 
the face and the meninges to higher brain areas. Their role is not only to facilitate the 
perception and detection of noxious stimuli, but also to communicate with cognitive 
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circuits which control mood associated with pain, the attention to and memory of pain 
as well as the tolerance of pain (Craig et al., 1994). 
 
The most important ascending pathways in migraine pathophysiology are: 
• The trigeminothalamic tract (also called the quintothalamic tract). The axons 
transmitting information from the trigeminal nerve synapse at the ventral 
posteromedial nucleus (VPM) of the contralateral thalamus (ipsilateral 
projections have been reported in some species, associated with the 
spinothalamic tract carrying sensory information from the body (Gaze and 
Gordon, 1954). 
 
• The trigeminohypothalamic tract. These neurons are located bilaterally in the 
TCC and their axons synapse mainly to the lateral preoptic, anterior, lateral, 
perifornical, and caudal hypothalamic nuclei (Burstein et al., 1998). 
 
• The spinomesencephalic and spinoreticular tract. The mesencephalon modulates 
painful input before it reaches the level of consciousness. The reticular 
formation is responsible for the automatic orientation of the body to painful 
stimuli (Kandel et al., 2000).  
 
1.8.6 The thalamus and trigeminal nociception 
 
The following discussion has been adapted from published work (Sherman and 
Guillery, 2001; Percheron, 2003; Jones, 2006). 
 
The thalamus is a nuclear complex located in the diencephalon and is composed of 
functionally and histologically distinct nuclei (figure 10). The two major components of 
the thalamus are the dorsal thalamus and the ventral thalamus. The dorsal thalamus is 
comprised of roughly 15 nuclei with relay cells that project to the cortex. The ventral 
thalamus, the major portion of which is the thalamic reticular nucleus, consists of 
reticular GABAergic cells that project into the dorsal thalamus to inhibit relay cells.  
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The internal medullary lamina cells divide the thalamus into the lateral, medial and 
anterior nuclei. The ventral posterior nuclear group contains the main somatosensory 
relay nuclei and it lies within the ventral part of the lateral nuclei area. In primates the  
ventral posterior nuclear group can be divided into the ventral posterior medial (VPM) 
nucleus, ventral posterior medial parvicellular (VPMpc) nucleus, ventral posterior 
lateral (VPL) nucleus and the ventral posterior inferior (VPI) nucleus. The ventral 
posterior thalamic area in rats and mice differ from primates with the major differences 
being: 
 
• The absence of the VPI nucleus in rats and mice. In some cases the term 
ventrobasal complex (VB) is more commonly used to describe both the VPM 
and VPL nuclei (Yokota, 1989).  
 
• The absence of intrinsic interneurons within the VB complex of rats and mice 
(Barbaresi et al., 1986; Harris, 1986). In primates, interneurons (mainly 
GABAergic) are located amongst the relay cells and they participate in feed-
forward inhibitory circuits, contributing to the modulation of afferent sensory 
inputs destined for the cortex. In the mouse and rat, interneurons are essentially 
missing from all thalamic nuclei except the lateral geniculate nucleus (Arcelli et 
al., 1997). 
 
• In canines and primates some ipsilateral thalamic projections from trigeminal or 
spinal neurons have been reported (Gaze and Gordon, 1954), whereas only 
contralateral projections have been found in rodents (Matsushita et al., 1982; 
Kemplay and Webster, 1989). 
 
• The rat VPM has a much larger volume dedicated to the vibrissal representation 
(Vahle-Hinz and Gottschaldt, 1983), than either canines or primates. In rats the 
vibrissae serve an important sensory function of exploring the environment. 
There is a strict somatotopic organization within the VPM with the different 
horizontal arrangements of vibrissae represented at different rostrocaudal levels 
(Waite, 1973).  
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Figure 10: Anatomy of the dorsal thalamus 
The dorsal thalamus is a complex structure which is divided into three nuclei complexes 
by the Y-shaped internal medullary lamina. The ventral posterior nucleus (VPM) is the 
main relay for sensory tracts conveying discriminative sensation to the primary (SI) 
somatosensory cortex. The VPM nucleus is located in its medial aspect and conveys 
sensory information from the cranio-facial region. Adapted from: http//mind-
brain.com/thalamus.php. 
 
 
 
 
 
At the level of the thalamus, a large portion of cells in the VPM nucleus display 
trigeminocervical convergence (Raboisson et al., 1989; Shields and Goadsby, 2005, 
2006). This fact combined with evidence of thalamic activation in many functional 
studies of migraine (Afridi and Goadsby, 2006), indicates an important role for the 
thalamus as a relay for trigeminovascular nociception. It is believed that the thalamus 
has a special role in “regulating” the flow of nociceptive information to the cortex 
(Aguilar and Castro-Alamancos, 2005).  
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Anatomical studies in rats showed direct projection of neurons located in spinal 
trigeminal nuclei to the contralateral VPM (Kemplay and Webster, 1989; Cliffer et al., 
1991; Iwata et al., 1992). Neurons in VPM receive convergent trigeminal 
viscerosomatic inputs classified by cutaneous receptive fields (Shields and Goadsby, 
2005, 2006). Recordings of facial receptive fields in VB demonstrated a somatotopic 
organisation of neurons with craniofacial structures represented medially in the VPM 
and the remaining somatic structures represented medially in the VPL (Emmers et al., 
1965; Waite, 1973; Angel and Clarke, 1975; Ohye, 1990) (figure 11). Neurons with 
inputs from the ophthalmic dermatome are located mainly at the dorsal aspect of VPM 
(Cropper and Eisenman, 1986; Rhoades et al., 1987; Dallel et al., 1988) and relay 
neurons can be LTM responding to tactile stimulation of the skin and vibrissae, as well 
as NS or WDR (Guilbaud et al., 1980; Guilbaud et al., 1981; Cropper and Eisenman, 
1986). Normal responses to facial receptive fields of individual VPM neurons represent 
the integration of input activity transmitted through both the Vp and the Vsp pathways 
(Friedberg et al., 2004). A large number of neurons in the VPM receive contralateral 
projections from the TNC (Tiwari and King, 1974; Ganchrow, 1978; Hu et al., 1981). In 
cat and primates the VPM receives projections from all trigeminal nuclei (Whitlock and 
Perl, 1961; Burton and Craig, 1979; Matsushita et al., 1982) and as in the rat, NS and 
WDR neurons are found mainly in the “shell” region of the VB complex (Perl and 
Whitlock, 1961; Tiwari and King, 1974; Ganchrow, 1978; Willis et al., 1979; Honda et 
al., 1983; Yokota et al., 1985; Yokota, 1989). Unlike the rat trigeminothalamic 
projections, in cats and primates an ipsilateral projection from Vp to the medial aspect 
of VPM has been demonstrated (Burton and Craig, 1979; Jones et al., 1986). In all 
species the ventral posterior nucleus is the principal thalamic relay conveying 
nociceptive information to primary somatosensory cortex (Rowe and Sessle, 1968; Abe, 
1978; Patrick and Robinson, 1987; Percheron, 2003). 
 
The VB complex is also the main thalamic area at which somatic and visceral 
nociception converges (Angel and Clarke, 1975; Guilbaud et al., 1980; Berkley et al., 
1993; Zhang and Davenport, 2003). Noxious heat is also encoded by VB nociceptive 
neurons which display the same thermal thresholds as those activating second order 
neurons and cause withdrawal responses  (Mitchell and Hellon, 1977; Peschanski et al., 
1980). 
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Figure 11: Somatic sensory map in the ventral posterior thalamic nucleus 
Adapted from (Ohye, 1990). 
 
 
 
 
 
In vivo electrophysiological studies in experimental animals demonstrate that 
trigeminovascular nociceptive stimulation activates neurons in the VPM nucleus, in 
addition to other areas. Stimulation of the cat SSS increased blood flow and metabolic 
activity in the thalamus (Lambert et al., 1988; Goadsby et al., 1991). Metabolic activity 
increases substantially in the VPM but remains unchanged in the VPL while more 
subtle increases were also observed in posterior thalamic nuclei (Goadsby et al., 1991). 
Ablation of the trigeminal ganglion blocked the increased metabolic activity in the 
thalamus (Goadsby et al., 1991). Electrical stimulation of the SSS and the MMA in cats 
and rats results in increase firing in the VPM and the majority of these cells have 
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cutaneous receptive fields located on the head or face (Zagami and Lambert, 1990; 
Shields and Goadsby, 2005; Shields et al., 2005; Shields and Goadsby, 2006). Receptive 
fields of these neurons were generally small and responsive to innocuous and 
nociceptive stimulation (Zagami and Lambert, 1990). Topical application of capsaicin 
and bradykinin to the SSS and MMA also resulted in increased firing of thalamic 
neurons (Davis and Dostrovsky, 1988a, b; Zagami and Lambert, 1990, 1991). 
Systematic studies of the thalamus reveal that trigeminovascular nociceptive 
information is relayed in several thalamic nuclei of which the VPM is of major 
importance. The remaining nuclei include the posterior medial (POm) thalamus, the 
zona incerta (ZI), intralaminar complex and ventrolateral nucleus (VL) (Zagami et al., 
1990).  
 
The pharmacology of the VPM also shows interesting insights into migraine 
pathophysiology. Both microiontophoretically applied and intravenous naratriptan 
reversibly modulates nociceptive neurotransmission by trigeminovascular thalamic 
neurons in the VPM in response to stimulation of the SSS and indicate the VPM nucleus 
as a target for the triptans (Shields and Goadsby, 2006). Propranolol (a β blocker) 
reversibly inhibits the response to SSS stimulation through blockade of β1 adrenoceptors 
and both propranolol (Shields and Goadsby, 2005) and valproate (anti-convulsant) were 
able to inhibit responses to L-glutamate ejection, (Shields et al., 2003; Shields and 
Goadsby, 2005). These results suggest that the VPM may be an additional target for 
anti-migraine medications. 
 
Functional magnetic resonance imaging (fMRI) studies of nociceptive 
neurotransmission in human demonstrated that thermal stimulation of the trigeminal 
dermatomes activates the VPM nucleus (DaSilva et al., 2002). Functional imaging 
studies in humans show consistent thalamic activation in spontaneous attacks of 
migraine and in human models of trigeminal nociceptive stimulation (Kobari et al., 
1989; Bahra et al., 2001; DaSilva et al., 2002; Afridi and Goadsby, 2006). Additional to 
the pain symptoms, sensitivity to both light and sound; symptoms that accompany the 
migraine headache- have been reported during thalamic injury (Cummings and 
Gittinger, 1981).  
 
Thalamocortical neurons in the VPM receive modulatory inputs from several sources. 
An important component of the thalamic involvement is that it receives modulatory 
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inputs from the brainstem regions implicated in migraine as shown by functional 
imaging (Weiller et al., 1995; Bahra et al., 2001; Afridi et al., 2005a) and in particular 
monoaminergic centres, such as the dorsal raphe nucleus (DRN) and the locus coeruleus 
(Goadsby, 2002; Goadsby et al., 2002). Modulatory inputs in the thalamus activate 
metabotropic and ionotropic receptors and are further distinguished by their inputs to 
the reticular nucleus, which itself has modulatory input to VPM neurons, and possibly a 
high degree of convergence onto relay cells (Sherman and Guillery, 2001). Sources of 
modulatory inputs to the sensory thalamus are shown in table 7 and some of the nuclei 
with interest in migraine and nociception are discussed below. It should be noted that 
other modulatory inputs also exist in the thalamus but their importance is not well 
characterised. One example is dopaminergic innervation, the origin of which is diverse, 
and thus more complex. Dopaminergic neurons of the hypothalamus, periaqueductal 
gray, ventral mesencephalon, and the lateral parabrachial nucleus all project bilaterally 
to the monkey thalamus (Sanchez-Gonzalez et al., 2005).  
 
 
 
 
Table 7: Sources of modulatory inputs and major  neurotransmitters to 
the sensory thalamus 
Modulatory input Neurotransmitter 
cortex glutamate 
reticular nucleus GABA 
raphe nuclei serotonin 
locus coeruleus noradrenaline 
pontine tegmental nuclei acetylcholinesterase 
hypothalamus histamine 
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The Reticular nucleus and GABAergic modulation 
 
The reticular nucleus (RT) is a thin layer of cells on the dorsolateral and ventral aspects 
of the thalamus. The VB complex of rodents, unlike that of higher mammals is largely 
devoid of GABAergic interneurons (Barbaresi et al., 1986; Porter et al., 2001). The 
principal source of GABAergic modulatory inputs in rodents therefore arises from the 
RT and the nucleus serves as an important modulatory input in primates brain (Ross et 
al., 1993). All of the cells in the RT are GABAergic (Houser et al., 1980)  and make 
multiple contacts with VB neurons (Peschanski et al., 1983), while RT neurons receive 
glutaminergic axons from VB neurons. This circuit is responsible for the stimulus 
induced feed-back inhibition observed in VPM neurons and it has been shown that 
activation of RT neurons causes inhibition of spontaneous and evoked activity in VB 
complex neurons (Mushiake et al., 1984).  
 
GABA agonists in animal models of migraine seem to mimic GABAergic modulation 
in the VPM, mainly through GABAA ionotropic receptors (Shields et al., 2003) and the 
effective anti-convulsants in migraine therapy valproate is thought to have a 
GABAergic action (Loscher, 1999; Shields et al., 2003).  
 
The rostral raphe nuclei and serotonergic modulation 
 
The raphe nuclei are a moderate-size cluster of nuclei found in the brainstem. Imaging 
studies are consistent with activation of monoaminergic brain stem regions, including  
raphe nucleus comprising serotonergic neurons and the locus coeruleus comprising 
noradrenergic neurons, and the periaqueductal gray (PAG) during migraine (Weiller et 
al., 1995). Serotonergic fibres project to the thalamus from the rostral raphe complex 
including the dorsal raphe nucleus (Consolazione et al., 1984) and the nucleus raphe 
medianus (Consolazione et al., 1984; Peschanski and Besson, 1984). The adjacent PAG 
has also been shown to have serotonergic inputs to the thalamus (Consolazione et al., 
1984).  
 
Electrical stimulation of the DRN can modulate both spontaneous and nociceptive 
induced activity in thalamic parafascicular neurons (Storozhuk et al., 1995), while 
electrical stimulation of the dorsal and median raphe nuclei elicits metabolic changes in 
several thalamic and cortical regions in rats, some of which are involved specifically in 
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the processing of pain from the head and face (Cudennec et al., 1987; Cudennec et al., 
1988). Microinjection of opiates into the PAG results in elevated levels of 5-HT 
metabolites in the telencephalon (Algeri et al., 1980) and depresses the responses of 
ventrobasal neurons to noxious stimulation (Kayser et al., 1983), in a similar fashion as 
when injected into the DRN (Kayser et al., 1983). Stimulation of the PAG in rats both 
facilitates and inhibits nociceptive transmission on VB neurons (Emmers, 1979) which 
probably reflects differential effects of 5-HT1 and 5-HT2 receptor activation. 
Microiontophoretically applied serotonin inhibits the spontaneous firing of rat 
parafascicular neurons in a dose dependent manner, as well as the responses to noxious 
stimuli (Andersen and Dafny, 1982). 5-HT has both facilitatory and inhibitory actions 
when microiontophoresed in the VB complex (Phillis and Tebecis, 1967; Eaton and 
Salt, 1989), likely due to different receptor mechanisms.  
 
Noxious trigeminal stimulation with capsaicin results in  Fos expression in the DRN 
along with other brainstem nuclei (Ter Horst et al., 2001). Microiontophoresis of 
naratriptan onto thalamocortical neurons within the VPM nucleus inhibited the response 
to SSS stimulation and L-glutamate ejection. In addition to its action on serotonin 5-
HT1B/1D receptors, this inhibition was also mediated by activation of 5-HT1A receptors 
(Shields and Goadsby, 2006), further supporting that the thalamus may be a therapeutic 
target in migraine.  
 
Hypothalamus 
 
Although a number of studies show modulation of trigeminal and spinal responses by 
hypothalamic inputs (paragraph 1.8.7), little is known about the hypothalamic 
modulation of the thalamus. Morimoto et al., (Morimoto et al., 1988) showed that 
neuronal activity of the VB complex, responding to skin warming, is affected by 
alterations of hypothalamic temperature. Thus thermal information from the peripheral 
thermoreceptors is modulated by hypothalamic temperature at the level of the relay 
nuclei of the thalamus (Morimoto et al., 1988). 
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1.8.7 Descending nociceptive projection to the TCC related to migraine 
 
The trigeminal nucleus has been shown to receive projections from a variety of 
nociceptive modulatory structures in the brainstem (figure 12), some of which are 
briefly discussed below. It is noteworthy that other areas outside the brainstem also send 
descending axons to the TCC, including the somatosensory cortex and the thalamus. For 
example, the spinal cord is the largest target for dopaminergic projections from the 
subparafascicular thalamic nucleus (Commissiong et al., 1978; Takada et al., 1988; 
Moriizumi and Hattori, 1992; Takada, 1993). Furthermore a major component of the 
spinal dorsal horn and the trigeminal system is the network of intrinsic local 
interneurons. 
 
Nucleus Raphe Magnus and reticular nuclei 
 
The nucleus raphe magnus (NRM) and the adjacent reticular formation are known to 
modulate sensory responses of neurons in the spinal trigeminal nucleus (Sessle et al., 
1981) and have been shown to send serotonergic and non-serotonergic projections to 
both the trigeminal nucleus oralis and caudalis and to the spinal cord in the cat and rat 
(Lovick and Robinson, 1983; Lovick and Wolstencroft, 1983). These projections 
mediate sensory modulation of both spinal and trigeminal responses simultaneously. 
Stimulation of this area can either suppress or facilitate nociceptive spinal neurons and 
nociceptive reflexes (Zhuo and Gebhart, 1990) whereas lesioning or inactivation of the 
NRM attenuates both the suppression and the facilitation of nociceptive transmission 
(Behbehani and Fields, 1979). These results led to the idea that NRM and the adjacent 
reticular formation contain two populations of neurons that, when activated have 
opposing efferent effects. Two physiological classes of putative nociceptive modulatory 
cells in the NRM were first identified by Fields et colleagues (Fields et al., 1983; Fields 
et al., 1991). One population of cells was hypothesized to mediate nociceptive inhibition 
(OFF cells), whereas activation of a distinct neuronal population was thought to mediate 
nociceptive facilitation (ON cells). Both ON and OFF cells are non-serotonergic 
(Potrebic et al., 1994; Gao and Mason, 2000) . ON cells are excited by noxious 
stimulation, whereas increase in OFF cell discharge is associated with nociceptive 
suppression. Serotonergic neurons within the NRM comprise a distinct physiological 
and functional class of neurons (Gao and Mason, 2000) and it is believed that tonically 
released serotonin contributes to anti-nociception (Sorkin et al., 1993; Mason, 2001), 
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and these neurons seem to have a further differential function depending on the 
awake/sleep cycle (Mason, 2001). The primary effect of serotonin on nociceptive dorsal 
horn neurons and nocifensive movements is inhibitory (Yaksh and Wilson, 1979). 
During waking serotonergic cell discharge is highest, and therefore high levels of 
serotonin in the dorsal horn would be expected to suppress nociceptive transmission. 
During slow wave sleep serotonergic cell discharge is greatly reduced, and thus lowered 
levels of serotonin in the dorsal horn would be expected to result in a relative decrease 
in the suppression of nociceptive transmission that would appear as a disinhibition 
(Mason, 2001). 
 
Stimulation of the NRM has been shown to produce potent inhibition of TNC 
nociceptive and non-nociceptive neuronal responses (Chiang et al., 1994; Lambert et al., 
2008), possibly via the OFF cells pathway. NRM has been also shown to be modulated 
by cortical mechanisms, as the inhibitory effects of this nucleus on trigeminal neurons 
can be antagonised by multiple waves of CSD, further suggesting an indirect 
modulation of the TCC by cortical activation via the cortico-NRM-trigeminal neuraxis 
(Lambert et al., 2008).  Cortical activation could result in activation of the ON cells 
pathway and/or inhibition of the OFF cell pathway in the NRM. 
 
Parabrachial Area 
 
The parabrachial area, including the A7 adrenergic cell nucleus and the Kölliker-Fuse 
nucleus send direct adrenergic or noradrenergic fibres to the TCC. Stimulation of the 
parabrachial area has been shown to produce potent inhibition of TNC nociceptive and 
non-nociceptive neuronal responses (Chiang et al., 1994). 
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Figure 12: Schematic representation of the descending inhibitory pathways to the 
trigeminal nucleus caudalis related to nociception 
The periaqueductal gray (PAG) receives input from the insular cortex (Ins), the 
amygdala (Am), and the hypothalamus (Hyp) and projects to the  nucleus raphe magnus 
(NRM) and the adjacent reticular formation, including the nucleus reticularis 
gigantocellularis (NRG) within the rostral ventromedial medulla.  Serotonergic 
pathways then descend to the medullary dorsal horn (MDH) and spinal dorsal horn 
(SDH).  Other descending pathways arise bilaterally from the parabrachial (PB). Locus 
coeruleus (LC) and Kölliker-Fuse (KF) nuclei, and there is a direct projection from the 
somatosensory cortex (SI) to the subnucleus interpolaris.  Adapted from (Messlinger 
and Burstein, 2000) 
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Periaqueductal gray 
 
Electrical stimulation of the PAG and lesions in the region of the PAG in humans have 
been shown to treat somatic pain, and in some cases this has been shown to trigger 
migraine-like headache in previously headache-free individuals (Raskin et al., 1987; 
Haas et al., 1993; Veloso et al., 1998; Goadsby, 2002). Imaging studies have further 
shown increased activation in the rostral brainstem during spontaneous and triggered 
migraine attacks in imaging studies and the activated area in the brainstem includes the 
PAG (Weiller et al., 1995). In animal models relevant to migraine it has been shown 
that electrical and chemical activation of the ventrolateral column of the PAG (vlPAG), 
can inhibit trigeminovascular specific nociception in the cat and rat (Knight and 
Goadsby, 2001; Knight et al., 2002; Knight et al., 2003; Knight et al., 2005). 
Interestingly it has also been demonstrated that microinjection of the 5-HT1B/1D receptor 
antagonist naratriptan into the vlPAG selectively inhibits responses to dural electrical 
stimulation in the TCC raising the possibility that the triptans may exert part of their 
anti-migraine efficacy within the PAG (Bartsch et al., 2004). 
 
Hypothalamus 
 
To date numerous hypothalamic nuclei have been implicated in the descending 
modulation of pain and nociceptive processing. It is widely accepted that the 
hypothalamus plays a major role in the group of primary headaches resulting in pain 
and autonomic involvement termed trigeminal autonomic cephalalgias (TAC’s) 
(Goadsby and Lipton, 1997). Clinical evidence indicating endocrine abnormalities have 
identified altered production of melatonin, cortisol, testosterone, lutenising-hormone 
and prolactin during cluster headache.  Similar findings in chronic migraine support the 
involvement of the hypothalamus in the pathophysiology of both cluster headache and 
chronic migraine (Peres et al., 2001).   
 
Experimental evidence for a role of the hypothalamus in migraine has been provided 
from a variety of studies.  Malick et al. (Malick et al., 2001) demonstrated that 
stimulation of the dura mater in the rat produced Fos expression in the ventromedial, 
paraventricular and dorsomedial hypothalamic nuclei resulting in suppression of 
appetite and increases in arterial blood pressure.  Stimulation of the SSS in the cat has 
also demonstrated hypothalamic activation with up-regulation of Fos in the supra-optic 
 65
and posterior hypothalamic nucleus consistent with a role for hypothalamic structures in 
modulation of nociceptive processing (Benjamin et al., 2004). 
 
 
 
 
1.9. Central sensitization and migraine 
 
Sensitization is the process whereby afferent activity is increased for an unchanged 
stimulus (Goadsby, 2005c). Central sensitization refers to this process occurring on 
second order neurons and can be defined as altered behavioural of neurons, 
characterized by increased excitability, increase synaptic strength and enlargement of 
their receptive fields (McMahon et al., 1993; Woolf and Doubell, 1994; Woolf and 
Salter, 2000). Clinically, central sensitization is manifested as a state of either 
hyperalgesia- an exaggerated pain in response to a stimulus that normally causes mild 
pain, or allodynia- a pain response to a normally non painful stimulus, and exaggerated 
pain response referred outside the original pain site (Dodick and Silberstein, 2006).  
 
During a migraine headache about 80% of migraine patients develop cutaneous 
allodynia, characterised by increased skin sensitivity, mostly within the referred area of 
pain of the ipsilateral head (Selby and Lance, 1960; Burstein et al., 2000). The 
underlying mechanism of cutaneous allodynia is believed to involve sensitization of the 
TCC (Goadsby, 2005c). As trigeminocervical neurons receive convergent inputs from 
both dural structures and from the skin of the periopthalmic area, sensitization of these 
neurons will alter the perception of pain of normal skin or scalp (Bartsch and Goadsby, 
2003a). Stimulation of nociceptive afferent of the dura mater leads to a sensitization of 
second-order neurons receiving cervical input. This mechanism might be involved in 
the referral of pain from trigeminal to cervical structures and might contribute to the 
clinical phenomena of cervical hypersensitivity in migraine (Bartsch and Goadsby, 
2003b). 
 
Central sensitization is associated with abnormal neuronal hyperexcitability in the TCC, 
due to an increase of the sensory inputs arriving from nociceptors on peripheral 
trigeminal fibres that supply the affected area, which is a consequence of peripheral 
sensitization (Strassman et al., 1996). Topical application of inflammatory agents on the 
rat dura, which induces long-lasting activation of the trigeminovascular pathway 
 66
(Ebersberger et al., 1997; Burstein et al., 1998; Schepelmann et al., 1999), provokes 
long lasting sensitization in trigeminocervical neurons that receive convergent inputs 
from the intracranial dura and extracranial periorbital skin. This neuronal sensitization is 
manifested as increased responsiveness to mechanical stimulation of the dura, to 
mechanical and thermal stimulation of the skin, and expansion of dura and cutaneous 
receptive fields (Burstein et al., 1998). These changes are parallel to an increase of the 
extracellular glutamate concentration of second order neurons in the TCC (Oshinsky 
and Luo, 2006), while CGRP does not seem to mediate the excitability of 
trigeminovascular neurons (Levy et al., 2005),  and suggest an important contribution of 
glutamate and its receptors in allodynia (Oshinsky and Luo, 2006). At least, NMDA 
receptor activation seems to be pivotal for the induction of central sensitization in dural 
neurons  (Woolf and Thompson, 1991). 
  
About two thirds of the patients developing cutaneous allodynia report that untreated 
migraine attacks will result in a spread of allodynia to the other side of the head or the 
forearm (Selby and Lance, 1960; Burstein et al., 2000), indicating the involvement of 
higher extra-trigeminal processes. The limb or upper body allodynia seen in 
migraineurs, and the extend of cutaneous allodynia could be due to the development and 
spread of neuronal sensitization from second order neurons in the TCC, to third order 
neurons in the thalamus (Burstein et al., 2000; Dodick and Silberstein, 2006), and these 
consideration led to the study of thalamic processing in experimental animals of 
trigeminovascular activation (Zagami and Lambert, 1990; Goadsby and Gundlach, 
1991; Zagami and Lambert, 1991). 
 
 
 
1.10 Treatment of migraine 
 
Efficient treatment of migraine depends on correct diagnosis and different approaches 
are suitable for individual patients, depending on the presence of secondary factors, the 
identification of migraine triggers, such as hormones and the frequency of attacks. 
Generally pharmacotherapeutic treatment of migraine can be acute or preventive 
depending on the frequency of attacks and individual needs and in severe cases of 
chronic sufferers both approaches can be used.   
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1.10.1 Acute treatment 
 
Acute treatment is used to stop further progression of headache symptoms once they 
have started and is sufficient when attacks are more infrequent. Attacks should be 
treated at the earliest possible stage, as it has been shown that this approach can prevent 
the headache from progressing and reduces the need for multiple medications (Mathew, 
2003; Burstein et al., 2004; Burstein and Jakubowski, 2004; Goadsby et al., 2008). 
Optimisation of the treatment of acute attacks of migraine also involves the use of 
effective doses of medications, the avoidance of medications that could cause 
medication overuse headaches and the treatment of associated symptoms. Acute 
treatment can be achieved either by non-specific analgesics, which can be efficient for 
the treatment of headache pain and analgesic for other biological symptoms, such as 
nonsteroidal anti-inflammatory drugs, or by specific acute headache treatments, which 
specifically treat migraine attacks and include ergot derivatives and the triptans.  
 
Nonsteroidal anti-inflammatory drugs (NSAID) are known to have anti-inflammatory, 
analgesic and antipyretic properties and their effect is thought to be due to the inhibition 
of the synthesis of prostaglandins involved in the development of pain that accompanies 
injury or inflammation.  Although prostaglandins have vasodilatory actions,  they do not 
cause migraine-like headache when given by infusion to humans (Peatfield et al., 1981). 
The absence of any pathology of an inflammatory response in humans during migraine 
(Nissila et al., 1996) and the poor efficacy of some anti-inflammatory drugs in migraine, 
such as trachykinin and endothelin receptor antagonists  (Narbone et al., 2004; 
Peroutka, 2005), limits the hypothesis supporting the involvement of inflammation in 
migraine.  Thus, it is likely that the treatment of migraine attacks of NSAID is due to 
their effect on brain areas involved in migraine pathophysiology (Jurna and Brune, 
1990; Kaube et al., 1993a). The NSAID ibuprofen, diclofenac and indomethacin were 
shown to attenuate nociceptive activation in the thalamus (Jurna and Brune, 1990). 
Acetylsalicylic acid, one of the most commonly used substances in the treatment of 
headache and other pain syndromes, as well as the cyclooxygenase inhibitor ketorolac, 
reduced trigeminovascular activity in the cat TCC. The results suggest that a central 
action might contribute to the analgesia produced by these non-steroid anti-
inflammatory agents. 
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Ergot alkaloits or their derivatives have being used for the acute treatment of migraine 
for many years and the most widely used in clinical practice have been ergotamine 
tartrate and dihydroergotamine (DHE). Both ergotamine and DHE have vasoconstrictor 
properties and binding affinities to 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2, α1 
and α2 adrenoceptors and D2 dopamine receptors. Ergots have been shown to bind on 
receptors in areas involved in migraine pathophysiology (Goadsby and Gundlach, 1991; 
Hoskin et al., 1996) and  to inhibit trigeminovascular nociception in the 
trigeminocervical complex (TCC) following intravenous and microiontophoretic 
administration (Lambert et al., 1992).  
 
The triptans are 5-hydroxytryptamine (5-HT; serotonin) agonists with high affinity to 5-
HT1B/1D receptors (Humphrey et al., 1990; Goadsby, 2000). Most of the members of the 
triptans family also display some binding affinity for 5-HT1F (i.e. sumatriptan) (Beer et 
al., 1993) and 5-HT1A receptors (Shields and Goadsby, 2006). The triptans were 
developed on the basis of clinical observations which indicated the involvement of 
serotonin in migraine pathophysiology. These observations include: 
 
• increased 5-hydroxyindoleacetic acid (the main metabolite of serotonin) in the 
urine of patients during migraine attacks (Sicuteri et al., 1961; Curran et al., 
1965)  
• decreased platelet 5-HT levels at the onset of migraine (Curran et al., 1965)  
• intravenous 5-HT could abort headache (Kimball et al., 1960; Anthony et al., 
1967)  
 
Sumatriptan and its precursor were the first molecules developed that could mimic some 
of the actions of serotonin without many of its side effects, and sumatriptan is now a 
commonly used triptan for the acute treatment of migraine (Humphrey et al., 1990). 
Other triptans have also been developed and used in migraine treatment including 
almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan and zolmitriptan. The 
triptans are the most effective migraine abortive agents and can treat not only the 
headache but also relieve the nausea, vomiting, photophobia and phonophobia 
associated with an attack. They are effective against migraine with and without aura, 
though if taken during the aura they are less effective against the headache (Bates et al., 
1994; Olesen et al., 2004a).  
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The triptans have modulatory actions at several sites along the trigeminovascular 
nociceptive pathway (Goadsby et al., 2002; Tepper et al., 2002) (figure 13). 5-HT1B, 5-
HT1D and 5-HT1F receptor mRNA are expressed in the human trigeminal ganglia and 
afferents (Rebeck et al., 1994; Bouchelet et al., 1996; Hou et al., 2001). The use of 5-
HT1B and 5-HT1D receptor specific antibodies demonstrated a differential distribution of 
these receptor subtypes within the human trigeminovascular system. Only 5-HT1B 
receptor protein was detected on dural arteries. In contrast, only 5-HT1D receptor protein 
was detected on trigeminal sensory neurons including peripheral and central projections 
to dural blood vessels and to the medulla, confined to discrete areas associated with the 
trigeminal sensory system (Longmore et al., 1997). The localisation of the 5-HT1F 
receptor to the trigeminal nucleus caudalis (TNC) and the differential distribution of the 
5-HT1B/1D receptors make them prime candidates for involvement in the 
pathophysiology of migraine (Bruinvels et al., 1994; Longmore et al., 1997) (figure 4). 
Triptans may act as vasoconstrictors, activating 5-HT1B receptors on smooth muscle of 
cranial arteries (Tfelt-Hansen et al., 2000). Alternatively 5-HT1D receptors are located 
on trigeminal ganglion cells (Bonaventure et al., 1998). Activation of these receptors 
partially explains the ability of triptans to inhibit the release of calcitonin gene-related 
peptide (CGRP), a potent vasodilator from stimulated nerve endings (Goadsby and 
Hargreaves, 2000). Triptans also act centrally to modulate firing of second (Goadsby 
and Hargreaves, 2000; Goadsby et al., 2002) and third (Shields and Goadsby, 2006) 
order neurons in response to trigeminovascular nociceptive stimulation. Further to their 
action on different loci of the ascending pathway involved in migraine, activation of 5-
HT1B/1D receptors in descending pain modulatory pathways from the periaqueductal gray 
has also been shown as a potential mechanisms of action (Bartsch et al., 2004).   
 
1.10.2 Preventive treatment 
 
Preventive therapy aims to reduce the frequency and severity of migraine attacks and is 
normally recommended when: 
 
• incidence of attacks is more than two or three per month 
• attacks are severe and impair normal activity 
• acute treatment has failed or produces unwanted side effects 
• the patient is unable to cope with the severity and frequency of attacks  
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How prophylactic treatments work is not clear but it appears to modify the sensitivity of 
the brain that underlies migraine (Goadsby et al., 2002). Drugs given for preventive 
therapy include β-adrenergic-receptor antagonists (such as propranolol), serotonin 
antagonists (such as pizotifen), γ-aminobutyric acid (GABA) modulators (such as 
valproate) and topiramate. The later is also thought to have at least partial action on 
kainate receptors (Gryder and Rogawski, 2003; Diener et al., 2007). Some anti-
convulsants also seem to provide some promising results in nociception prevention 
(Dickenson and Ghandehari, 2007). 
 
 
 
 
 
 
 
Figure 13: Possible sites of triptan action on the trigeminovascular system 
Possible sites of action of triptans on intracranial blood vessels, first and second order 
trigeminovascular neurons. Adapted from (Goadsby et al., 2002). 
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1.11 Glutamate as a neurotransmitter in the central nervous system  
 
Glutamate (figure 14) is the major excitatory neurotransmitter in the mammalian CNS 
and as such glutamate receptors play a vital role in the mediation of excitatory synaptic 
transmission and it’s involvement in nociception is well documented (Carpenter and 
Dickenson, 2001). 
 
Excitatory synaptic transmission is mediated primarily through ionotropic glutamate 
receptors (iGluR), which are ligand gated ion channels and metabotropic glutamate 
receptors (mGluR) which act by coupling to G-proteins. To date there is significant 
evidence suggesting that both iGluR and mGluRs play multiple roles in synaptic 
plasticity and some are involved in migraine pathophysiology (Mitsikostas et al., 1999; 
Storer and Goadsby, 1999; Sang et al., 2004; Vikelis and Mitsikostas, 2007). 
 
Glutamate in the brain is synthesized de novo by astrocytes and neurons, since the 
blood-brain-barrier limits the entry of the plasma glutamate in most regions of the brain 
(Hawkins et al., 1995; Hertz et al., 1999; Smith, 2000). Glutamate is synthesised in 
neural tissues by two major pathways:  
a. from α-Ketoglutarate (α-KG), taken from the tricarboxylic cycle of the glucose 
metabolism, and donor amino acids by means of transamination  
 
b. from glutamine by the action of the glial-specific enzyme glutaminase 
 
 
 
 
 
 
 
 
                             Figure 14: Glutamate chemical structure 
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Vesicles accumulate glutamate to a very high concentration and it is released to 
synapses by calcium-dependent exocytosis. After release, synaptic glutamate is very 
rapidly inactivated by cellular uptake (Clements et al., 1992). Presently, five different 
glutamate transporters have been cloned, at least one of which is astrocyte-specific and 
accounts for a major part of glutamate removal from synaptic clefts, although a minor 
fraction of released glutamate is re-accumulated into the neurons from which it was 
released (Hertz et. al, 1999; Rothstein et al., 1996). Glutamate in the astrocytes is stored 
in much lower levels, due to the presence of the enzyme glutamine synthetase or 
glutaminase. Glutamine synthetase is a glial-specific enzyme (Tansey et al., 1991) that 
converts glutamate into glutamine as part of the recycling of synaptically released 
glutamate (Schousboe et al., 1997). 
 
Glutamine has no known neurotransmitter action and a substantial amount of glial 
glutamine is released extracellularly. Accordingly, the glutamine concentration in the 
extracellular space between astrocytes and neurons is relatively high. Glutamine is a 
very effective precursor for glutamate, which undergoes re-uptake from the extracellular 
space into neurons. Hydrolysis of glutamine to glutamate requires no energy and is 
catalyzed by phosphate-activated glutaminase, an enzyme different to glutamine 
synthetase. Therefore, while neurons cannot generate glutamine from glutamate, both 
neurons and glia can form glutamate from glutamine (Schousboe et al., 1997; Hertz et 
al., 1999). Excess of glutamate in neurons and astrocytes can be also catabolised and 
one route is the oxidative deamination by the enzyme glutamate dehydrogenase (Kugler, 
1993) (figure 15).  
 
The restriction of glutamate entry from the blood circulation into the brain (Hawkins et 
al., 1995), the rapid uptake of released glutamate by glutamate transporters on the glial 
cells that surround the glutamatergic synapses (Rothstein et al., 1996; Lehre and 
Danbolt, 1998) and the presence of the glial glutamine synthetase which converts 
glutamate into the non-neurotransmitter glutamine (Tansey et al., 1991), are well 
developed systems, used to prevent neuronal damage due to the neurotoxic action of 
excess extracellular glutamate concentration (Choi, 1988). 
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Figure 15: Metabolic interactions that occur at glutamatergic synapses between 
neurons and astrocytes 
Glutamate can be synthesised in neurons from α-Ketoglutarate (α–KG), taken from the 
tricarboxylic cycle of the glucose metabolism, and donor amino acids by means of 
transamination. Transmitter glutamate is accumulated in vesicles containing a very high 
glutamate concentration and released to the synapses by calcium-dependent exocytosis. 
After release, synaptic glutamate is extremely rapidly inactivated by cellular uptake by 
glutamate transporters, from which the astrocyte-specific accounts for a major part of 
glutamate removal from synaptic clefts. In the astrocytes, glutamate is converted to 
glutamine by the action of the glial-specific enzyme glutamine synthetase (GS). 
Glutamine has no neurotransmittion actions and it is up taken from the extracellular 
space into neurons. Hydrolysis of glutamine to glutamate requires no energy and is 
catalyzed by glutaminase. Glutamate in the neurons can be catabolised by the enzyme 
glutamate dehydrogenase (GDH). 
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1.11.1 Glutamate transporters 
 
High affinity excitatory amino acid transporters (EAATs) are essential to terminate 
glutamatergic neurotransmission and to prevent excitotoxicity. So far, five structurally 
distinct transporters have been identified from animal and human tissues: 
glutamate/aspartate transporter (GLAST; EAAT1 in human), glutamate transporter-1 
(GLT-1; EAAT2 in human), excitatory amino acid carrier-1 (EAAC1; EAAT3 in 
human), excitatory amino acid transporter 4 (EAAT4) and excitatory amino acid 
transporter 5 (EAAT5).  EAAT family members display about 50-55% homology. The 
regional and cellular distributions of the EAATs differ in the CNS. Rothstein et al. 
(1994) demonstrated that GLAST is expressed in astroglia, as well as in a small number 
of neurons. GLT-1 is an astroglia-specific transporter and is distributed throughout the 
brain and the spinal cord. EAAC1 was found to be presented in the cortex, 
hippocampus, caudate-putamen and spinal cord and be confined to pre- and post-
synaptic neurons. EAAT4 is localized mainly in cerebellar Purkinje cells, whereas 
EAAT5 is retina-specific.  
 
In the cervical spinal cord, it was shown that EAAC1 like-immunoreactivity was 
present in lamina II. GLAST like-immunoreactivity was also present in lamina II, in 
both astroglia and neurons and around the central canal (lamina X). GLT-1 was highly 
expressed in astroglial cells in laminae I-III and the area around the central canal (figure 
16) (Tao et al., 2005), and finally, though EAAT4 was initially found to be neuronal in 
the brain, it has been co-localized with astroglia in the spinal cord. (Rothstein et al., 
1994; Hu et al., 2003).  EAAC1, in addition to its expression in the spinal cord neurons, 
is detected in the DRG and distributed predominantly in small DRG neurons (Tao et al., 
2005). Some of these EAAC1-positive DRG neurons are positive for CGRP or are 
labelled by isolectin B4 (Tao et al., 2005), a marker of non-peptidergic neurons.  
 
Recent studies have identified three different vesicular transporters (VGLUT1-3) 
(Fremeau et al., 2002).  VGLUT1 and VGLUT2 are expressed throughout the central 
nervous system. Their complementary expression pattern in the brain defines two 
district classes of glutamatergic synapses (Fremeau et al., 2001).  Fremeau et al. 
(Fremeau et al., 2001), suggested that VGLUT1 is expressed in terminals with low 
probability of release and activity-depended potentiation, whereas VGLUT2 is 
expressed in terminals displaying high probability of release and high-fidelity 
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neurotransmission. The explanation of such a difference is not clear, but it may be 
related to differences in the cytoplasmic C-termini of VGLUT1 and VGLUT2, resulting 
in different protein-protein interactions that could affect the mode and rate of synaptic 
vesicle recycling (Persson et al., 2006). VGLUT3 is expressed in a variety of cells 
including GABAergic, monoaminergic neurons as well as astrocytes and its role is not 
yet very clear (Fremeau et al., 2002). 
 
 
 
 
 
 
Figure 16: Localisation of glutamate transporters in the dorsal root ganglion and 
the spinal cord 
EAAC1 is expressed mainly in small dorsal root ganglion cells (A) and distributed 
predominantly in the superficial dorsal horn of the spinal cord (B). GLAST (C) and 
GLT-1 (D) are expressed highly in the superficial dorsal horn and the region around the 
central canal. Scale bars: 10 μm in A and 125 μm in B, C, and D. Taken from (Tao et 
al., 2005).  
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In the spinal cord both VGLUT1 and VGLUT2 are expressed, though the spinocervical 
tract was found to contain dense labeling for VGLUT2 (Persson et al., 2006).  This 
suggests that VGLUT2 is the transporter responsible for the vesicular accumulation of 
glutamate at the spinocervical tract terminals, and thus most glutamatergic fibre systems 
in the spinal cord, should display high probability of release, because of their use of 
VGLUT2 as vesicular transporter (Persson et al., 2006). 
 
The VGLUTs are currently considered as the best glutamate markers for staining 
glutamatergic cells; their presence is a strong indication that glutamate is accumulated 
in vesicles from which it can be released. Staining studies found these transporters in 
populations of axons that are known to be glutamatergic and their expression in cultured 
cells results in glutamate uptake and the subsequent conversion of neurons to a 
glutamatergic phenotype (Bellocchio et al., 2000; Todd et al., 2003). In agreement with 
this, Todd et al (2003) demonstrated that in the rat lumbar spinal cord, glutamate 
transporters were not co-localised in glycinergic, serotonergic, cholinergic or 
GABAergic axons.   
 
Recent evidence suggests that spinal glutamate transporters might play an important 
role in normal sensory transmission. Intrathecal application of the selective glutamate 
transporter blocker DL-threo-β-Benzyloxyaspartic acid (TBOA) resulted in significant 
and dose-dependent spontaneous nociceptive behaviours, and in remarkable 
hypersensitivity in response to thermal and mechanical stimuli (Liaw et al., 2005). 
TBOA on the dorsal surface of the spinal cord also resulted in a significant elevation of 
extracellular glutamate concentrations (Liaw et al., 2005). These findings indicate that a 
decrease of spinal glutamate uptake can lead to excessive glutamate accumulation in the 
spinal cord, which might, in turn, result in over-activation of glutamate receptors, and 
production of spontaneous nociceptive behaviours and sensory hypersensitivity (Tao et 
al., 2005). However, the glutamate transporters seem to also have opposing actions in 
pathological pain in animal models. Inhibition or transient knockdown of spinal GLT-1 
led to a significant reduction of nociceptive behaviour in the formalin model, whereas 
different glutamate transporter inhibitors (TBOA, dihydrokainate, threo-3-
hydroxyaspartate) reduced formalin-induced nociceptive responses and complete 
Freund's adjuvant-evoked thermal hyperalgesia (Tao et al., 2005). Different potential 
mechanisms by which glutamate transporters are involved in pathological pain have 
been suggested; however their exact function is not completely understood.  
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1.11.2 Glutamate and migraine 
 
Findings from both animal and human studies suggest a link between glutamate and 
migraine and further suggest that glutamate plays a key role in migraine mechanisms 
(Vikelis and Mitsikostas, 2007). Migraine pain-relay centres, including the trigeminal 
ganglion, TNC, and thalamus, contain glutamate-positive neurons (Greenamyre et al., 
1984; Kai-Kai and Howe, 1991) and glutamate activates neurons in the TNC (Hill and 
Salt, 1982; Salt and Hill, 1982).  
  
Migraineurs have elevated levels of neuronal amino acids in the plasma, including 
glutamate, glutamine, glycine, cysteic acid and homocysteic acid, and glutamate levels 
are further increased during a migraine attack (Ferrari et al., 1990; Alam et al., 1998), 
although contradictory evidence also exists (Cananzi et al., 1995). Increased peripheral 
glutamate, if correlated with increased brain levels, suggests that migraineurs have a 
persistent neuronal hyperexcitability that becomes heightened during a migraine attack. 
In support of this theory is the finding that migraineurs exhibit signs of central 
sensitization during an attack (Burstein et al., 2000) which is a process of excessive 
activation of neurons in the dorsal root ganglion or the TNC following peripheral 
sensory stimulation (Woolf and Decosterd, 1999). Glutamate release and glutamate 
receptor activation mediates central sensitization (Burstein, 2001).  
 
Glutamine levels are also increased in the cerebrospinal fluid (CSF) during migraine 
attacks and CSF concentrations of glutamate were higher in migraineurs than in 
controls, suggesting an excess of neuroexcitatory amino acids in the CNS (Martinez et 
al., 1993). The increased levels of glutamate, particularly in migraine with aura patients 
may be relevant to their neurological symptoms (D'Andrea et al., 1991). This is further 
supported by the mutations linked to FHM, which result in an increase in glutamate 
availability at the synaptic cleft of cells and may explain the increased susceptibility to 
CSD (van den Maagdenberg et al., 2004; Wessman et al., 2007). Furthermore a case 
report detailed the history of a patient with hemiplegic migraine, seizures, and episodic 
ataxia whose genetic screening revealed the SLC1A3 mutation on the excitatory amino 
acid transporter EAAT1. Functionally, this mutation reduces the glial cell's ability to 
clear glutamate from the synaptic cleft, which would contribute to post-synaptic 
hyperexcitation (Ramadan and Buchanan, 2006). CSD in the neocortex of a variety of 
species including man has been demonstrated to be dependent on activation of the N-
methyl-D-aspartate (NMDA) receptor (Faria and Mody, 2004). Topiramate a preventive 
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given for migraine treatment increases the cortical levels of glutamine, possibly by 
acting on the metabolic pathway of glutamate and GABA (Moore et al., 2006).  
 
In vivo studies using microdialysis and blood flow measurements demonstrated 
increased levels of glutamate in the TNC (Bereiter and Benetti, 1996) during and post 
stimulation of dural structures (Goadsby and Classey, 2000). This paralleled changes in 
sensory thresholds of facial receptive fields as recorded from secondary neurons in the 
rat TNC (Oshinsky and Luo, 2006), thus further supporting the involvement of 
glutamate in central sensitization (Ramadan, 2003). Triptans seem to act post-
synaptically in the TNC (Goadsby et al., 2001) and pre-synaptically by decreasing 
glutamate release from primary afferents (Travagli and Williams, 1996). Glutamatergic 
neurons in the trigeminal ganglion are 5-HT1B/1D/1F receptor positive and this may 
indicate that 5-HT1 receptor activation could possibly inhibit the release of glutamate 
pre-synaptically (Ma, 2001).  
 
Glutamate plays a crucial role in the transmission of nociceptive information in the VB 
complex. It is involved in signalling from spinothalamic tract and leminiscal pathways 
and corticothalamic afferents (Broman and Ottersen, 1992). Extracellular levels are 
increased following experimentally produced pain (Silva et al., 2001). It triggers post-
synaptic excitatory potentials by activating multiple glutamate receptors. (McCormick 
and von Krosigk, 1992; Salt and Eaton, 1995; Dougherty et al., 1996; Li et al., 1996; 
Salt and Turner, 1998; Salt et al., 1999b; Salt et al., 1999a).  
 
The presence of glutamate in the transmission of sensory information, implicates the 
involvement of glutamate receptors that modulate glutamate responses, both in the 
trigeminal ganglia, the TCC, thalamus and sensory cortex in migraine pathophysiology 
(Vikelis and Mitsikostas, 2007).  
 
 
 
1.12 Classification of glutamate receptors  
 
Glutamate receptors (GluR) are categorised in two distinct classes, ionotropic and 
metabotropic receptors. The ionotropic glutamate receptors (iGluRs) contain cation-
specific ion channels, whereas the metabotropic glutamate receptors (mGluRs) are 
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coupled to guanosine 5′-triphosphate (GTP)-binding proteins (also known as G-
proteins) and act through the production of second messengers (figure 17). It is thought 
that glutamate activates post-synaptic ionotropic receptors which mediate fast synaptic 
transmission, and metabotropic receptors which modulate glutamate’s release, post-
synaptic responses, as well as the activity of non-glutamatergic synapses (Dingledine et 
al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 17: Classification of glutamate receptors 
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1.12.1 Ionotropic glutamate receptors 
 
Ionotropic glutamate receptors (iGluRs) have been divided into three subtypes (figure 
17) and named after the agonists which were first identified to selectively activate them: 
 
• N-methyl-D-aspartate (NMDA) 
• α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA)  
• 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate)  
 
AMPA and kainate receptors are also referred to as non-NMDA receptors, since notably 
AMPA receptors are activated by kainate, and kainate receptors with certain subunit 
compositions by AMPA (Kew and Kemp, 2005). In recent years, cloning studies have 
demonstrated that AMPA and kainate receptors are distinct receptor complexes and 
several agonists and antagonist that differentially act on AMPA or kainate receptors 
have been developed (Ozawa et al., 1998; Kew and Kemp, 2005).   
 
Expression cloning in Xenopus oocytes, homology cloning and polymerase chain 
reaction (PCR)-based strategies were used to clone cDNAs encoding iGluR. So far 16 
cDNAs have been isolated: 4 for AMPA receptor subunits (GluR1-4), 5 for kainate 
receptor subunits (iGluR5, 6, 7, KA1 and 2), and 7 for NMDA receptor subunits (NR1, 
2A, 2B, 2C, 2D, 3A and 3B; figure 17), (Ozawa et al., 1998; Kew and Kemp, 2005).  
 
Although the overall amino acid characteristics of iGluR subunits across the three 
families are only 20-30% homologous, they share common structural features. The 
subunits have an extracellular amino terminal domain, followed by a first 
transmembrane domain (TMI) and then a pore forming membrane-residing domain that 
forms a re-entrant loop entering from and exiting to the cytoplasm. The second (TMII) 
and third (TMIII) transmembrane domains are linked by a large extracellular loop and 
the TMIII domain is followed by an intracellular carboxy terminus. The iGluR ligand 
binding domains comprise polypeptides in both the amino terminus (S1 domain) and the 
extracellular loop between TMIII and TMIV (S2 domain) (figure 18).  
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Figure 18:  Ionotropic and metabotropic glutamate receptor subunits schematic 
representation  
A. Schematic representation of an ionotropic glutamate receptor’s (iGluR) family 
subunit. The extracellular amino terminal domain is followed by a first transmembrane 
domain (TMI) and then a pore forming membrane-residing domain that does not cross 
the membrane. The second (TMII) and third (TMIII) transmembrane domains are linked 
by a large extracellular loop and the TMIII domain is followed by an intracellular 
carboxyl terminal. The iGluR ligand binding domains, comprise polypeptides in both 
the amino terminus (S1 domain) and the extracellular loop between transmembrane 
domains 3 and 4 (S2 domain). B. Schematic representation of a metabotropic flutamate 
receptor’s (mGluR) family member illustrating the extracellular bi-lobed N-terminal 
agonist binding domain connected via a cysteine-rich region to the transmembrane 
heptahelical domain with an intracellular C-terminus. Glutamate binds within the bi-
lobed N-terminal domain whilst the transmembrane heptahelical domain contains the 
binding sites for both positive and negative allosteric modulators. 
 
 
 
1.12.2 Metabotropic glutamate receptor 
 
Metabotropic glutamate receptors (mGluRs), modulate glutamate release, post-synaptic 
response, as well as the activity of other synapses (Dingledine et al., 1999).  They are 
G-protein-coupled receptors (GPCRs). Eight subtypes have been identified and 
classified into three groups (I-III) based upon their sequence homology, transduction 
mechanism and pharmacological profile (figure 17). Group I includes mGluR1 and 5 
receptors, which couple to Gq and activate phospholipase C. Group II (mGluR2 and 3) 
and group III (mGluR4, 6, 7 and 8) receptors couple to Gi/Go and inhibit adenylyl 
cyclase. Group I receptors are mostly located post-synaptically, thus their activation 
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increases excitability. On the other hand, group II/III receptors are generally pre-
synaptic and their activation reduces glutamate release (Kew and Kemp, 2005). 
mGluRs belong to family 3 of the GPCR superfamily and similar to all GPCRs, mGluR 
contain a heptahelical domain in the membrane region (figure 18). In addition, like all 
members of family 3, mGluR are characterised by a large extracellular amino terminal 
domain where the glutamate binding site is found (Kew and Kemp, 2005). Moreover, it 
was shown that the closed conformation of this domain is required for receptor 
activation (Bertrand et al., 2002; Bessis et al., 2002). 
 
 
 
 
 
1.13 Kainate receptors 
 
Kainate receptors, originally described by Watkins group (Davies et al., 1979; Watkins 
and Evans, 1981), constitute a separate group from the NMDA and AMPA receptors, 
although they share many structural characteristics. Like the other ionotropic glutamate 
receptor subunits they possess an extracellular N-terminus that, together with a loop 
between TMII and TMIII, forms the ligand binding domain, and a re-entrant loop that 
forms the lining of the pore region of the ion channel (figure 18).  
 
The kainate receptor is constituted by the iGluR5, 6, 7, KA1 and 2 subunits, which form 
tetrameric assemblies giving rise to functional receptor-channels (Dingledine et al., 
1999). iGluR5-7 subunits are also known as “low-affinity subunits” due to the low 
binding affinity that they show (in the range of 50-100 nM), whereas the KA1 and 2 
subunits are known as the “high affinity subunits”, since they display high affinity [3H] 
kainate binding (in the range of 5-15 nM) (Pinheiro and Mulle, 2006). iGluR5-7 are of 
similar size of 900 amino acids and KA1 and 2 are slightly larger proteins of 
approximately 970 amino acids (Ozawa et al., 1998). There is 75%-80% homology 
between iGluR5, 6 and 7, and 68% between KA1 and 2, whereas the two subclasses 
share only 45% homology (Pinheiro and Mulle, 2006). The kainate receptor subunits 
share less than 40% homology with the AMPA iGluR1-4 subunits and less than 20% 
with NMDA receptors (Huettner, 2003). 
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Functional kainate receptors that can be formed by combination of the different 
kainate subunits. The nine different colours indicate the nine known combinations of 
functional receptors.  
From studies in which kainate receptors were expressed in Xenopus oocytes or in 
transfected HEK 293 cells, it is known that the iGluR5-7 can form functional 
homomeric receptors. The high-affinity KA2 subunit can only form functional receptors 
when it forms tetramers combined with the GluR subunits, whereas not much work has 
been done for the KA1 subunit. Several studies have also demonstrated that the iGluR5-
7 subunits can co-assemble into heteromeric glutamate receptors (Huettner, 2003). Bahn 
and colleagues (1994) demonstrated by using in situ hybridisation that KA1 and 2 
subunits coexist with functioning iGluR5-7 subunits in the same population of cells, 
suggesting that the native kainate receptors may be heteromeric tetramers composed of 
different combinations of dimmers of these subunits (table 8).  
 
 
 
 
Table 8: Functional kainate receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iGluR5 iGluR6 iGluR7 KA1 KA2 
iGluR5 iGluR5/iGluR5 iGluR5/iGluR6 iGluR5/iGluR7 NKRs iGluR5/KA2 
iGluR6 iGluR6/iGluR5 iGluR6/iGluR6 iGluR6/IGluR7 NKRs iGluR6/KA2 
iGluR7 iGluR7/iGluR5 iGluR7/iGluR6 iGluR7/IGluR7 NKRs iGluR7/KA2 
KA1 NKRs NKRs NKRs NFRs NFRs 
KA2 KA2/iGluR5 KA2/iGluR6 KA2/iGluR7 NFRs NFRs 
IGluR5/KA2 heteromeric receptors, 
IGluR5/IGluR6 heteromeric receptors, 
IGluR6/KA2 heteromeric receptor, 
IGluR5 homomeric receptors, IGluR6 homomeric receptors, 
IGluR7 homomeric receptors, 
IGluR5/IGluR7 heteromeric receptors, 
IGluR6/IGluR7 heteromeric receptors,   
IGluR7/KA2 heteromeric receptors, NKRs, not known receptors;  
NFRs, not functional receptors 
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The iGluR5-7 subunits undergo both splice variation at the C-terminal domain and 
RNA editing, which increase the number of subunit isoforms, giving rise to a large 
number of possible receptors with different pharmacological and functional properties 
(Chittajallu et al., 1999). There are three known splice variance for iGluR5 (iGluR5a, b 
and c), two for iGluR6 (iGluR6a and b) and two for the iGluR7 subunit (iGluR7a and b) 
(Bettler and Mulle, 1995; Jaskolski et al., 2005). The KA1 and 2 subunits do not 
undergo any known process of alternative splicing or RNA editing (Pinheiro and Mulle, 
2006). The physiological properties of the iGluR5-7 subunits are not affected by 
alternative splicing (Jaskolski et al., 2004). The genes coding for the different kainate 
receptors have been identified in both humans and animals, and human molecular 
genetic studies have demonstrated alterations that might occur on these genes and their 
association to diseases (Szpirer et al., 1994; Pinheiro and Mulle, 2006) (table 9). 
 
 
 
Table 9: Kainate receptors and human genetics of disease 
Subunit Gene Locus Associated disease Reference 
 
iGluR5 
 
GRIK1 
 
21q22.1 
 
• Juvenile absence 
epilepsy 
• region implicated in 
Down’s syndrome 
 
 
(Gregor et al., 1994; 
Sander et al., 1997) 
iGluR6 GRIK2 6q16.3-q21 • Schizophrenia 
• Early-onset 
Huntington’s  disease 
• Autism 
 
(Paschen et al., 1994; 
Rubinsztein et al., 
1997; Motazacker et 
al., 2007) 
iGluR7 GRIK 3 1p34-p33 • Schizophrenia 
 
(Puranam et al., 1993) 
KA1 GRIK4 11q22.3 • Depression 
• Migraine 
 
(Cader et al., 2003; 
Paddock et al., 2007) 
KA2 GRIK5  19q13.2 • Schizophrenia 
 
(Szpirer et al., 1994) 
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Kainate receptors are not permeable to Ca2+, but they display high permeability to 
intracellular Cl- and extracellular Na+. K+ also leaves the intracellular space through the 
kainate channels and finally polyamine interaction with the receptors is prevented  
(Chittajallu et al., 1999; Huettner, 2003). These channel properties have been studied in 
homomeric iGluR5 and 6 receptors and heteromers with KA2 receptors, and are due to 
the introduction of the amino acid arginine at the Q/R(glutamamine/arginine)  RNA 
editing site, in the second membrane domain of iGluR5 and 6 subunits. Thus, unedited 
iGluR5 and 6 kainate receptors display permeability to Ca2+, Na+ and K+ and polyamine 
molecules interactions are allowed (Chittajallu et al., 1999). The Q/R site editing is 
incomplete during development and significant amounts of both edited and unedited 
versions of the iGluR5 and 6 subunits co-exist in the adult brain (Ozawa et al., 1998). 
The Q/R RNA editing does not occur in the iGluR7 subunits. iGluR6 subunit’s 
permeability to Ca2+ also depends on the I/V (isoleukin/valine) and I/Y 
(tyrosine/cystaine) sites and fully edited subunits are impermeable to Ca2+ (Kohler et al., 
1993). Another important property of kainate receptors is that they do not desensitise as 
rapidly as AMPA receptors.  
 
 
1.13.1 Localisation of kainate receptors  
 
Kainate receptors are found throughout many regions of the brain, as shown by 
immunostaining and in situ hybridisation. iGluR6/7 and KA2 showed moderate staining 
in the olfactory bulb, cortex, caudate putamen, hypothalamus, brainstem, thalamus and 
amygdala, and light to moderate staining in the hippocampus and the cerebellar layers 
(Petralia et al., 1994). Similar results were obtain with radioligand binding studies using 
[3H]kainate (Ozawa et al., 1998). Localisation of specific subunits at the mRNA level 
by in situ hybridisation revealed functional differences between neuronal kainate 
receptors in different areas, that may reflect their distinct subunit composition and their 
diverse roles in synaptic transmission (Ozawa et al., 1998). Despite the moderate 
presence of kainate receptors demonstrated by immunocytochemistry and in situ 
hybridisation, electrophysiological recordings provided greater understanding of the 
presence and pharmacology of kainate receptors in different areas (Kullmann, 2001; 
Huettner, 2003; Lerma, 2003). For the purpose of this thesis focus will be given on 
structures involved in ascending pain pathways. 
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Presence of kainate receptors in ganglia and their function 
 
The presence of kainate receptors in DRG was the first indication of their existence, 
which was shown after depolarization of dorsal root fibres by exposure to kainate 
(Davies et al., 1979). Treatment of DRG with kainate also produced selective blockade 
of action potential conduction along C-fibres, suggesting that certain primary afferent 
C-fibres possess kainate receptors which may be activated physiologically by released 
glutamate at their central terminations (Agrawal and Evans, 1986). The blockade of 
action potential conduction along C-fibres following treatment of DRG with kainate is 
very likely due to the rapid desensitisation of kainate receptors with prolonged agonist 
exposure (Huettner, 1990). Native kainate receptors were pharmacologically 
characterised in the DRG by Huettner (1990), confirming the expression of functional 
kainate receptors on the small diameter sensory neurons that comprise of Aδ- and C-
fibres. In situ hybridisation and Northern blot analysis showed the presence of kainate 
receptors in DRG and demonstrated that the iGluR5 subunit is the predominant subunit 
expressed (Bettler et al., 1990; Partin et al., 1993; Sato et al., 1993). In agreement with 
these results, functional kainate receptors were eliminated by iGluR5 deletion in DRG 
cells from iGluR5 knockout mice exhibiting an absolute requirement for the iGluR5 
subunit (Kerchner et al., 2002).  Recording from cells expressing kainate receptors 
suggest that homomeric iGluR5 receptors predominate in DRG (Bettler et al., 1990), 
although in a study with iGluR5 and iGluR6 mice the significance of the iGluR6 
subunit on Aδ- and C-fibres was also shown (Youn and Randic, 2004). In the trigeminal 
ganglia, reverse transcriptase-PCR and recordings from kainate expressing cells, 
demonstrated the presence of heteromeric iGluR5/KA2 receptors (Sahara et al., 1997). 
 
It has been proposed that kainate receptors are transferred from the DRG neurons along 
the primary afferents and function as autoreceptors in the dorsal horn (Agrawal and 
Evans, 1986; Hwang et al., 2001) and may be activated physiologically by released 
glutamate at their central terminations (Agrawal and Evans, 1986; Huettner et al., 2002). 
Evidence from immunocytochemical studies also exists for peripheral transport of 
kainate receptors on sensory, both myelinated and unmyelinated axons (Carlton et al., 
1995; Coggeshall and Carlton, 1998).  It has been shown that activation of these 
receptors on peripheral axons leads to increased activity along the sensory root and thus 
to peripheral nociceptive transduction (Agrawal and Evans, 1986; Ault and Hildebrand, 
1993).  
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Presence of kainate receptors in the spinal cord and their function 
 
Anatomical studies demonstrated a low presence of kainate receptors in the spinal cord 
(Tolle et al., 1993; Petralia et al., 1994). More recent evidence, demonstrated the 
presence of different kainate subunit mRNA in cultured spinal neurons (Dai et al., 2002) 
and the localisation of all kainate receptors’ subunits at both pre- and post-synaptic sites 
in the rat dorsal horn by confocal and electron microscopy (Hwang et al., 2001; Lu et 
al., 2003; Lucifora et al., 2006). Several electrophysiological studies have also provided 
physiological evidence for functional pre- and post-synaptic kainate receptors in spinal 
neurons (Budai and Larson, 1994; Li et al., 1999; Kerchner et al., 2001b; Kerchner et 
al., 2001a; Wilding and Huettner, 2001). Primary afferent synapses in the dorsal horn of 
the spinal cord represent an example where both pre- and post-synaptic kainate 
receptors may play a role in transmission at individual contacts (Huettner, 2003).  
 
Original evidence for post-synaptic kainate receptors in the spinal cord, was obtained by 
Li et al. (1999) in studies of rat spinal cord slices and confirmed from 
electrophysiological recordings from dorsal horn neuronal cultures (Lee et al., 1999; 
Kerchner et al., 2001a). Whole-cell recording in layer II of the dorsal horn revealed that 
high-intensity single-shock stimulation of primary afferent sensory fibres produces a 
fast, kainate-receptor-mediated excitatory post-synaptic current (EPSC). This kainate 
receptor-mediated component of transmission was most pronounced for stimulation 
intensities that were sufficient to activate high threshold Aδ- and C-fibres. Activation of 
low-threshold afferent fibres generates typical AMPA-receptor-mediated EPSCs only, 
indicating that kainate receptors may be restricted to synapses formed by high-threshold 
nociceptive (pain-sensing) and thermoreceptive primary afferent fibres (Li et al., 1999). 
The presence of post-synaptic receptors in the spinal cord, activated by kainate was also 
shown in vivo by microiontophoretic application of kainate (Budai and Larson, 1994). 
Kainate evoked responses, as well as noxious and innocuous receptive fields were 
inhibited by the 2,3-benzodiazepine compound, 4-(8-Methyl-9H-1,3-dioxolo[4,5-
h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride (GYKI 52466), supporting the 
possible involvement of these receptors in spinal nociception. However, the pure 
selectivity of kainate agonists on kainate receptors versus AMPA receptors, and the 
non-selectivity of GYKI 52466 do not lead to clear conclusions.  
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The presence of pre-synaptic receptors in primary afferents in the superficial laminae of 
the spinal cord, has been demonstrated by light and electron microscopy, on both 
myelinated and non myelinated primary afferent fibres (Hwang et al., 2001; Lucifora et 
al., 2006). The dominant subunit expressed on pre-synaptic terminals in laminae I-III is 
the iGluR5 (Lucifora et al., 2006). Pre-synaptic kainate receptors are largely formed in 
DRG and transferred in primary nerve terminals that project mainly in outer laminae of 
the spinal cord (Kerchner et al., 2001a). Kerchner et al. (2002), using knockout mice, 
provided evidence that both iGluR5 and 6 subunits contribute to the receptors expressed 
by DRG and spinal neurons. In cultured dorsal horn neurons isolated from iGluR5 
knockout mice, responses to kainate were still present and were completely insensitive 
to iGluR5 selective antagonists. In neurons from iGluR6 knockout mice, functional 
kainate receptors expression was reduced, suggesting that iGluR6 is more important 
than iGluR5 for the assembly of functional kainate receptors in dorsal horn neurons. 
However, application of iGluR5 kainate antagonists in wild-type and iGluR6 cells 
blocked post-synaptic responses produced by kainate, indicating the existence of 
iGluR5 kainate receptors on dorsal horn neurons, but probably in lower stoichiometry 
than the iGluR6 subunit (Kerchner et al., 2002). 
 
For many years the function of kainate receptors on primary afferents in the spinal cord 
was not known (Agrawal and Evans, 1986). More recently, Kerchner et al., (2001a) 
proved in vitro that presynaptic kainate receptors regulate spinal sensory transmittion, 
by applying kainate and the iGluR5 subunit agonist (RS)-2-alpha-amino-3-(3-hydroxy-
5-tert-butylisoxazol-4-yl) propanoic acid (ATPA) in DRG-dorsal horn neuronal cultures 
and spinal cord slices. More specifically, it was shown in the presence of AMPA 
antagonist, that kainate suppressed spontaneous NMDA receptor-mediated EPSCs in 
cultures of spinal dorsal horn neurons and EPSCs in dorsal horn neurons evoked by 
stimulation of synaptically coupled DRG cells in DRG-dorsal horn neuron co-cultures. 
In addition ATPA was able to suppress DRG-dorsal horn synaptic transmission to a 
similar extent as kainate, but it had no effect on excitatory transmission between dorsal 
horn neurons. In recordings from dorsal horn neurons in spinal slices, kainate and 
ATPA were able to suppress NMDA and AMPA receptor-mediated EPSCs evoked by 
dorsal root fibre stimulation. Together, these data suggest that kainate receptor agonists, 
acting at a pre-synaptic locus, can reduce glutamate release from primary afferent 
sensory synapses (Kerchner et al., 2001a; Kerchner et al., 2002).  
 
 89
Further studies  provided evidence for expression of pre-synaptic kainate receptors by 
spinal cord inhibitory interneurons (Kerchner et al., 2001b; Lu et al., 2005). Confocal 
and electron microscopy revealed the presence of kainate receptors on 20-35% of 
GABAergic terminals in laminae I-III of the dorsal horn of the spinal cord (Lu et al., 
2005).  In spinal cord slices endogenous glutamate released upon stimulation of primary 
afferent fibres was shown to reduce evoked inhibitory post-synaptic currents (IPSCs) 
via the activation of kainate receptors and this suppression of inhibition was prevented 
by GABAB receptor antagonists (Kerchner et al., 2001b). As glutamate-containing 
sensory fibres come into close proximity with the GABA/glycine terminals of local 
interneurons, diffused glutamate from primary afferents will activate pre-synaptic 
kainate receptor on neighbouring interneurons. It has been suggested that kainate 
receptors activation on interneurons enhances GABA/glycine release via an action 
potential-independed action, leading to a negative feedback pathway on GABAergic 
synapses mediated by subsequent activation of GABAB autoreceptors (Kerchner et al., 
2001b). In such a scheme, pre-synaptic kainate receptors exert a facilitatory action on 
GABA release (figure 19) and highlight a novel role for these receptors in regulating 
sensory transmission.  
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Figure 19: Location and function of kainate receptors on dorsal horn neurons 
Superficial spinal dorsal horn kainate receptors are strategically placed to regulate 
sensory transmission. (1) Glutamate acting on iGluR5-carrying kainate autoreceptors on 
primary afferent terminals has been shown to inhibit further glutamate release. (2) 
Glutamate released from primary afferents following high-intensity, but not low 
intensity stimulation, acts on kainate receptors on superficial dorsal horn neurons, 
inducing an excitatory post-synaptic potential, thus promoting the transmission of 
nociceptive information. In addition, the kainate receptor-mediated depolarization may 
remove the magnesium blockade from neighbouring NMDA receptors, allowing Ca2+ 
entry that is necessary for the induction of long-term potentiation. (3) Glutamate 
released from primary afferents diffuses to neighbouring terminals of inhibitory 
interneurons. There, glutamate acts on kainate receptors, inducing a membrane 
depolarization that allows Ca2+ entry through voltage-gated calcium channels. Elevated 
Ca2+ levels in the terminal promote spontaneous release of glycine and GABA that by 
acting on GABAB autoreceptors inhibits release of inhibitory transmitter. Figure 
adapted from (Kerchner et al., 2001b).  
GluR, Glutamate receptor subunit; AMPAR, α-amino-3-hydroxy-5-methylisoxazole-4-
proprionic acid receptors; NMDA, N-methyl-D-aspartic acid receptors; GABA/R, γ-
aminobutyric acid/receptors; GlyR, glycine receptors; VGCC, voltage-gated calcium 
channels.  
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Presence of kainate receptors in the thalamus and their function 
 
Kainate receptors in the thalamus have been shown with [3H]kainic acid 
autoradiography studies, in situ hybridisation and immunocytochemistry (Monaghan 
and Cotman, 1982; Bettler et al., 1990; Wisden and Seeburg, 1993; Paschen and 
Djuricic, 1994; Petralia et al., 1994). However, the exact synaptic location of kainate 
receptors is still uncertain, although they are known to be present in both the 
ventrobasal thalamus and the thalamic reticular nucleus (Salt, 2002; Binns et al., 2003). 
In the primate thalamus, in situ hybridisation showed that only iGluR6 transcripts were 
expressed at detectable levels (Ibrahim et al., 2000b), while all five kainate receptor 
subunits’ mRNA were expressed in the human thalamus (Ibrahim et al., 2000a). The 
possible presence of the iGluR5 subunit in the thalamus was also shown by in situ 
hybridisation (Bettler et al., 1990; Paschen and Djuricic, 1994). By comparing results 
from [3H]kainic acid autoradiography and kainate mRNA expression Ibrahim et al., 
(2000a) suggested both post- and pre-synaptic localisation of kainate receptors. 
 
Recently, it was shown that iGluR5-containing kainate receptors in neurons of the 
ventrobasal thalamus play a critical role in sensory function (Salt, 2002; Binns et al., 
2003). It has been shown that iGluR5-selective agonists applied by microiontophoresis 
activate post-synaptic relay neurons, but the selective iGluR5-antagonist 3S, 4aR,6S, 
8aR)-6-((4-carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-
carboxylic acid (LY382884) failed to reduce these responses; thus it has been suggested 
that kainate receptors do not appear to mediate post-synaptic responses in these neurons 
(Binns et al., 2003). In the same study however, application of the same antagonist 
inhibited responses to receptive field mechanical stimulation, and thus suggested that 
pre-synaptic kainate receptors regulate GABAergic transmission (Binns et al., 2003). 
Therefore, iGluR5-mediated disinhibition appears to be important in sensory processing 
in the ventrobasal thalamus (Salt, 2002). 
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Presence of kainate receptors in the cortex and their function 
 
 
Both pre- and post-synaptic kainate receptors are present in thalamocortical synapses in 
the somatosensory cortex (Wu et al., 2007). In genetically modified mice with deletions 
of iGluR5 and/or 6 it has been shown that both subunits are involved in synaptic 
transmission in the antireor cingulated cortex (ACC) (Wu et al., 2005), which is 
critically involved in nociception and pain perception (Wu et al., 2007). Functional 
iGluR5-carrying receptors have also been found on interneurons in the ACC and 
activation of interneuronal iGluR5-carrying receptors caused action potential dependent 
GABA release, showing that iGluR5 is mainly somatodendritic but not pre-synaptic on 
interneurons (Wu et al., 2006).  
 
1.13.2 Kainate receptors in nociception 
 
The localisation of the kainate receptors along the spinothalamic pathway, especially in 
both spinal cord and DRG neurons, has implicated these receptors in spinal nociception 
and in the transmission of pain perception. Evidence has begun to accumulate indicating 
that iGluR5 glutamate receptors play an important role in nociception and central 
sensitization (Ruscheweyh and Sandkuhler, 2002; Wu et al., 2007). In iGluR5 and 6 
knockout mice, it has been shown that deletion of any of the subunits does not affect 
nociceptive responses in the tail-flick reflex and hot-plate test (Ko et al., 2005). 
However, the same study reported that in iGluR5-deficient mice, responses to capsaicin 
and formalin-induced inflammatory pain were substantially reduced, whereas no 
significant differences were observed in iGluR6 knockout mice (table 10). These 
evidence point to a relatively selective activation of kainate receptors in chronic, but not 
acute pain. This might reflect a specific function of kainate receptors at synapses with 
high glutamate release.  
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Table 10: Kainate receptors in nociception on genetic models 
 
Adapted from (Wu et al., 2007). 
 
 
 
 
 
Although electrophysiological studies have implicated iGluR5 agonists as potential anti-
nociceptive drugs, mixed results have been reported for the effects of kainate receptor 
antagonists in animal pain models (Ruscheweyh and Sandkuhler, 2002; Wu et al., 2007) 
(table 11). Non-selective AMPA/kainate receptor antagonists, including 2,3-Dioxo-6-
nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) and 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) have been shown to produce anti-nociception in 
animal models of peripheral neuropathy and Fos expression (Mao et al., 1992; 
Mitsikostas et al., 1999). Stanfa and Dickenson (1999) demonstrated that the relatively 
selective iGluR5 receptor antagonist LY382884 as well as the non-selective 
AMPA/kainate receptor antagonists NBQX and (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-
yl)ethyl]decahydroisoquinoline-3-carboxylic acid monohydrate (LY293558), produced 
anti-nociception in the carrageenan inflammation model in rats, as well as reducing C-
fibre evoked response in normal animals. In neuropathic primate models, LY382884 
was also effective in reducing the increased responses of spinothalamic tract cells to 
weak mechanical stimuli and to thermal stimuli. In normal animals it preferentially 
inhibited the responses of spinothalamic tract neurons to weak mechanical stimuli over 
those induced by noxious mechanical stimuli. The increased effectiveness of the iGluR5 
receptor antagonist on the pathological activity could be related to the increase in 
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kainate receptors in the spinal cord dorsal horn that occurs after induction of peripheral 
neuropathy and peripheral inflammation (Palecek et al., 2004). In addition, the mixed 
AMPA/iGluR5 receptor antagonist LY293558 produced analgesia in the capsaicin 
model in humans (Sang et al., 1998). A more recent study, which used a range of new 
decahydroisoquinoline iGluR5-selective competitive antagonists, demonstrated that 
these selective compounds can reverse capsaicin-induced mechanical allodynia and 
carrageenan-induced thermal hyperalgesia (Jones et al., 2006). However, similar results 
in these models were obtain by administration of the kainate ligand (2S,4R)-4-methyl 
glutamic acid (SYM 2081) (Turner et al., 2003). Anti-nociceptive effects were also 
observed by intrathecal administration of the iGluR5 receptor agonist ATPA, which 
reduced responses to thermal and mechanical stimulation in rats (Wu et al., 2003). 
Taken together, these data suggest that iGluR5 receptors play an important role in 
persistent, but not acute pain. However, most of the studies to date have been conducted 
using compounds that lack a high degree of selectivity for iGluR5 versus AMPA or 
iGluR6 receptors (Pinheiro and Mulle, 2006), therefore limiting the strength of this 
conclusion. In addition, most of these studies used intraperitoneal drug application and 
it is not clear if the anti-nociceptive effects of kainate receptor antagonists are due to 
actions on kainate receptors in the spinal cord or elsewhere. 
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Table 11: Pharmacological manipulation of kainate receptors in nociceptive 
animal models 
 
Adapted from (Wu et al., 2007) 
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1.13.3 Kainate receptors in trigeminovascular nociceptive processing and migraine 
 
Although a variety of studies have indicated the involvement of kainate receptors in 
nociception, very few studies have investigated their possible involvement in migraine 
pathophysiology.  
 
Sahara et al. (1997), using patch clamp techniques, showed that in trigeminal ganglia  
cell cultures, small diameter neurons responded to both L-glutamate and kainate. In 
addition, reverse transcriptase-PCR showed that although all five known kainate 
receptor subunits are expressed on trigeminal ganglia neurons the dominant receptors 
are possibly heteromeric iGluR5/KA2 receptors. In the TCC and caudal brainstem the 
presence of kainate receptors was demonstrated at both pre- and post-synaptic sites (Hill 
and Salt, 1982; Salt and Hill, 1982; Petralia et al., 1994; Onodera et al., 2000; Hegarty 
et al., 2007) and functional responses from kainate receptors responding to kainate 
receptor agonists and/or antagonists have been recorded (Hill and Salt, 1982; Salt and 
Hill, 1982).  
 
Non-selective AMPA/kainate receptor antagonists have been shown to produce anti-
nociceptive effects in both animal and human migraine studies (Mitsikostas et al., 1999; 
Storer and Goadsby, 1999; Sang et al., 2004), suggesting a possible role of kainate 
receptors in migraine. The non-NMDA receptor blocker GYKI 52466 lead to a dose-
dependent inhibition of trigeminovascular-evoked responses in the TCC. In another 
study where Fos expression was assessed in the TCC following intracisternal capsaicin 
administration, the AMPA/kainate receptor antagonists CNQX and NBQX reduced Fos 
expression (Mitsikostas et al., 1999). The relatively higher selectivity of these 
antagonists for AMPA over kainate receptors however, limited any conclusions for the 
specific role of kainate receptors in the trigeminovascular system (Lester et al., 1989; 
Paternain et al., 1995; Lee et al., 1999; Kong and Yu, 2006). Indirect evidence 
connecting kainate receptors with migraine also comes from a small human study at 
which the AMPA/iGluR5 antagonist LY293558 given intravenously was effective in 
treating headache pain in two thirds of patients and also relieved nausea, photophobia 
and phonophobia symptoms during migraine attacks (Sang et al., 2004). This 
compound, now called tezampanel has completed the Phase IIb trials and in a 
randomized, double-blind, placebo-controlled, parallel-group trial LY293558 was 
comparable to sumatriptan by injection at providing pain relief, and elicited fewer side 
effects (Murphy et al., 2008). However, due to the AMPA action of the LY293558 
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antagonist, it is not clear if the observed effects are due to specific actions on kainate 
receptors or due to combined AMPA/kainate effects.  
 
With the recent discovery of more selective kainate agents, kainate receptor and 
particularly iGluR5 subunit, involvement in migraine pathogenesis has received fresh 
impetus. The competitive iGluR5-selective receptor antagonist (3S,4aR,6S,8aR)-6-
[[(2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl]-methyl]decahydro-3-
isoquinolinecarboxylic acid (LY466195) and the Ethyl (3S,4aR,6S,8aR)-6-(4-
Ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3-carboxylic ester were 
effective in blocking dural plasma protein extravasation and in reducing Fos expression 
in the TCC after stimulation of the trigeminal ganglion (Filla et al., 2002; Weiss et al., 
2006). Important clinical correlates also exist from a double-blind study, in which the 
selective iGluR5 antagonist LY466195 was effective in relieving head pain in migraine 
patients (Johnson, KW, International Headache Research Seminar, Copenhagen, 25 
March 2007). Topiramate is a clinically effective migraine preventive (Bussone et al., 
2006; Mulleners and Chronicle, 2008) and it has been shown to reduce 
trigeminovascular activation and to inhibit CSD (Akerman and Goadsby, 2005a, b). It 
has been suggested that the pharmacology of topiramate includes modulation of kainate-
evoked neural responses (Rosenfeld, 1997), further supporting the kainate receptor as a 
target for future migraine therapeutics. 
 
“Non-kainate” receptors in trigeminovascular nociceptive processing and migraine 
 
Since glutamate plays a key role in migraine mechanisms (Ramadan, 2003) it is 
accepted that pharmacological manipulation of its receptors will play a key role in 
migraine mechanisms.  Part of this section has been adapted by Vikelis and Mitsikostas 
(2007) and includes studies on NMDA, AMPA and mGluRs, while the combined 
kainate/AMPA studies have been mentioned above.     
     
Glutamate receptors and especially NMDA and AMPA are abundant throughout the 
CNS (Ozawa et al., 1998; Kew and Kemp, 2005) and similar to kainate  receptors their 
pharmacological manipulation demonstrated effectiveness in anti-nociception 
(Fundytus, 2001; Bleakman et al., 2006). 
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NMDA pharmacology seems to underline CSD mechanisms. Scheller and colleagues 
(2000) reported that application of NMDA induced CSD (Scheller et al., 2000). NMDA 
blockade prevented CSD, whereas AMPA receptor antagonists had no effect (Lauritzen 
and Hansen, 1992; Nellgard and Wieloch, 1992). Interestingly magnesium depletion, 
which releases the voltage-dependent block of the NMDA receptor channel has been  
shown to induce CSD (Mody et al., 1987).  
 
NMDA, AMPA and group III mGlu receptors were found to modulate noxious 
responses within second order trigeminal neurons after meningeal irritation by capsaicin 
(Mitsikostas et al., 1998; Mitsikostas et al., 1999; Mitsikostas and Sanchez del Rio, 
2001). It was concluded that since this model may be predictive for treatment of 
vascular headaches (Moskowitz and Macfarlane, 1993) these receptors may also serve 
as potential targets for the development of new anti-migraine drugs. Fos expression 
induced after electrical stimulation of SSS was reduced after treatment with the NMDA 
anatagonist dizocipline maleate (MK 801) in cats (Classey et al., 2001) further 
suggesting that NMDA receptors provide a potential therapeutic target for migraine due 
to trigeminovascular activation from meningeal afferents. The role of NMDA receptors 
can be more complex in central pain pathways. It has been shown that NMDA 
antagonists can increase Fos in the NRM, DRN and PAG, which are part of the 
descending anti-nociceptive system (Hattori et al., 2004). In another study the NMDA 
receptor’s antagonist MK 801, and the AMPA receptor’s antagonist GYKI 52466 
significantly and dose-dependently decreased neuronal activity induced by electrical 
stimulation of the SSS within the TCC (Storer and Goadsby, 1999). NMDA receptors 
are found throughout the TCC and mainly on second order neurons that come in close 
proximity to CGRP-carrying primary afferents (figure 20).  
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Figure 20: Presence of NMDA receptors in the trigeminocervical complex 
Representative examples of the distribution of NR1-like NMDA receptors staining 
(labelled with texas red-avidin) in the dorsal region of the cervical spinal levels C2 (A, 
B, C), C1 (D, E, F) and trigeminal nucleus caudalis (TNC; G, H, I) are shown. 
Photomicrographs show NR1-like receptors in C2 (A) and a higher magnification 
indicates scattered cells in deeper laminae-IV-V of C2 (B). NR1 positive cells are 
localised in a close proximity to calcitonin gene-related peptide (CGRP; labelled with 
fluorescein isothiocyanate) fibres in C2 (C). High magnification photomicrographs 
show the intracellular aspect of NR1-like NMDA receptor in laminae I and II in C1 
cervical level (D; note the punctuate appearance of the staining restricted to the 
cytoplasm in the soma), the CGRP-like staining in laminae I and outer lamina II, and 
their co-location in these laminae (E). Photomicrographs show NR1-like staining in the 
trigeminal nucleus caudalis (TNC; G) and their co-location with CGRP in the 
superficial laminae of the TNC (H). An example from TNC section stained for CGRP 
and NeuN (labelled with texas red; I), indicates that not all neurons express the NR1 
protein. (J–O). Double labelling of NR1 and GFAP positive astrocytes in green. Only 
few astrocytes were shown to express NR1-like NMDA receptor (M–O; white arrows) 
Scale bars = 50 µm (D–F, H, J–O), 100 µm (A–C, I), 500 µm (G). (Andreou et al.; 
Unpublished data). 
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Additional evidence for a link between glutamate and migraine arises from human 
studies. Kaube et al. (2000) studied the effect of ketamine, a non-competitive antagonist 
at the NMDA receptor in patients with severe, disabling auras resulting from FHM, 
demonstrating efficacy in about 50% of the patients. ADX10059 is a potent, selective, 
negative allosteric modulator of the mGluR5 receptor and in a study for the acute 
treatment of migraine ADX10059 showed a statistically significant higher number of 
patients pain-free 2 hours after dosing compared to placebo 
(http://www.addexpharma.com/press-releases/news-releases/3-january-2008-
adx10059/). 
 
 
 
 
1.14 Proposed experiments 
 
Migraine pathophysiology involves activation or the perception of activation of the 
trigeminovascular system. Glutamate, the major excitatory neurotransmitter in the CNS, 
is implicated in elements of the pathophysiology of the disorder, including 
trigeminovascular activation, central sensitization and cortical spreading depression.  
The pharmacology of glutamatergic trigeminovascular responses in brain areas involved 
in migraine pathophysiology is relevant to the development of new therapies for this 
disabling condition. The kainate receptor, a member of the iGluRs family, is present in 
key structures of the ascending trigeminovascular pathway, including the trigeminal 
ganglia, the TCC and the thalamus. Kainate receptors have been implicated in the 
transmission of pain perception and evidence suggests a potential role of these receptors 
at synapses with excess glutamate release.  Kainate receptor acting antagonists were 
effective in treating headache pain in clinical trials with mild side effects.  
 
The aim of the studies presented in this thesis was to investigate further the possible 
involvement of the iGluR5 kainate receptor in the pathophysiology of migraine, both at 
the peripheral site of the trigeminovascular system and at central synapses, and to 
investigate their role in varying aspects of the trigeminal nociceptive processing in 
animal models of trigeminovascular activation. 
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Chapter 2: Methods 
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2.1 Animals 
 
Male Sprague-Dawley rats (n = 173), of weight 280-405 g were used in the experiments 
reported in this thesis. The animals were supplied by B&K Universal, UK and from 
Charles River Laboratories, USA.  All animals were maintained on a 12-hour light/dark 
cycle, with food and water freely available in compliance with UK Home Office and 
Institutional Animal Care and Use Committee (IACUC) regulations.  All experiments 
were conducted under a personal and project licence issued by the UK Home Office 
under the Animals (Scientific Procedures) Act 1986 and in accordance with guidelines 
of the University of California, San Francisco IACUC. 
 
 
2.2 Anaesthesia 
 
In all experiments anaesthesia was induced with 60 mgkg-1 intraperitoneal 
pentobarbitone sodium (Sigma-Aldrich Ltd., St. Louis, MO, U.S.A or Ovation 
Pahrmaceuticals, Inc., IL, USA) and maintained by intravenous injections of 10-20 
mgkg-1 α-chloralose (Sigma-Aldrich) in a solution of 2-hydroxy-β-cyclodextrin (Sigma-
Aldrich) or infusion  of pentobarbitone sodium (25-35 mgkg-1h-1) through the 
cannulated femoral vein, as previously reported in our group (Storer et al., 2004a; 
Holland et al., 2006). A sufficient depth of anaesthesia was judged from the absence of 
withdrawal reflexes, and gross fluctuations in blood pressure and respiratory 
parameters. When neuromuscular blocker (pancuronium bromide – 1 mgkg-1 initially, 
maintenance with 0.4 mgkg-1) was used, only fluctuations in blood pressure and 
respiration were used to asses the level of anaesthesia. All experiments were conducted 
under terminal anaesthesia and at the end of each experiment animals were given a 
lethal dose of pentobarbital sodium (Lethobarb®, 200 mgml-1 – 1 ml, Fort Dodge 
Animal Health, Southampton, UK; or Euthasol, 600 mgml-1 – 0.2 ml, Virbac AH, 
Texas, USA). 
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2.3 Surgery  
 
All surgical procedures took place with the aid of a dissecting microscope (Opmi 99, 
Zeiss, UK). 
 
2.3.1 Cannulation of blood vessels and trachea 
 
The left femoral artery and vein were exposed and cannulated with polythene tubing 
(external diameter 0.96 mm, Smiths Medical International Ltd., Kent, UK) for blood 
pressure recordings and intravenous administration of anaesthetic and neuromuscular 
blocker. In those experiments where intravenous administration of test compounds was 
used, the right femoral vein was also cannulated. The cannula was secured with braided 
silk sutures and its patency was confirmed by a free backflow of blood and maintained 
by periodic flushes of isotonic saline. The trachea was exposed by blunt dissection and 
intubated with endotracheal polythene tubing (external diameter 2.7 mm) for artificial 
ventilation. Upon cannulation of the trachea and femoral vessels, rats were placed in a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA – Model 1600).  
 
2.3.2 Animal Maintenance 
 
Throughout the surgery and experimental observation the blood pressure was 
continuously monitored via the femoral arterial line which was connected to a saline 
filled transducer (Ohmeda DTX Plus pressure transducer with PM-1000 transducer 
amplifier from CWE Inc.) and maintained at 80-130 mmHg. Through the saline filled 
transducer animals received a constant rate of saline at 3 mlh-1. Animals were artificially 
ventilated with oxygen-enriched air, 2-2.5 ml, 80 to 100 strokes per minute (Small 
Rodent Ventilator model 7025; Ugo Basile, Varese, Italy). The end-tidal CO2 was 
monitored (Capstar-100; CWE Inc., Ardmore, PA) and kept between 3.5 and 4.5% by 
altering either the rate of respiration or stroke volume. Arterial blood gas parameters 
were measured (GEM Premiere 3000, Instrumentation Laboratory, UK) at regular 
intervals during the experiment and maintained within the normal physiological 
parameters: pH; 7.35–7.45, pCO2; 4.5-6.0 pKa. Temperature was maintained with a 
rectal thermometer at 37.5 ºC via a homoeothermic blanket system (TC-1000 
Temperature Controller; CWE). Outputs from the blood pressure transducer amplifier, 
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the CO2 analyser, and the homeothermic blanket were connected to a data recorder 
(Vetter Analog, SDR Clinical Technology, Middle Cove, Australia) and then to an 
analogue-to-digital converter (Power 1401; CED, Cambridge, UK). Physiological 
parameters were displayed with an online data analysis system (Spike2 version 5; 
CED).  
 
2.3.3 Cranial surgery for the intravital microscopy studies 
 
Exposure of the middle meningeal artery   
 
A midline incision of approximately 2.5 cm was made in the skin covering the dorsal 
surface of the skull and the skin and the right or left masseter muscle were retracted to 
expose the underlying parietal bone. A small cranial window, approximately 5 x 5 mm 
was drilled using a sharp-tipped dental drill (Volvere GX®, Nakanishi Dental, Japan), 
until the blood vessels of the dura mater were clearly visible through the intact thinned 
skull. The drilling was performed in the presence of cooling saline to prevent any 
damage due to overheating.  Any bleeding from the skull was halted with bone wax 
(Ethicon; Livingston, UK) and the closed cranial window was bathed in warm mineral 
oil (Sigma-Aldrich) to prevent dehydration. Drilling was followed by an hour of rest 
period. 
 
2.3.4 Cranial surgery and laminectomy for electrophysiological experiments in the 
trigeminocervical complex  
 
Exposure of the middle meningeal artery  
 
For the electrophysiological experiments an identical procedure as described in section 
2.3.3 was followed. The final layer of the thinly drilled bone however was gently peeled 
away using forceps in order to expose the underlying MMA (figure 21).  Prevention of 
dehydration of the exposed dura mater was also ensured by bath application of warm 
mineral oil (Sigma-Aldrich). 
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Laminectomy 
 
Electrophysiological recordings were performed in the TCC at the level of the cervico-
medullary junction and thus a C1 laminectomy was performed.  The skin and muscles 
of the dorsal neck were incised and separated.  Any bleeding was halted by gentle 
application of small cotton wool pellets (Richmond Dental, Charlotte, NC, USA). The 
bone of the first cervical vertebrae was exposed and partially drilled away on the 
ipsilateral side to the exposed MMA (figure 21). The drilling was performed in the 
presence of cooling saline to prevent any damage due to overheating. The atlanto-
occipital membrane and underlying dura mater was incised (ophthalmic scissors, Fine 
Scientific Tools, UK) and removed to expose the underlying dorsal cervical spinal cord 
immediately before electrode placement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Surgical preparation and experimental setup for electrophysiological 
experiments in the trigeminocervical complex  
MMA; middle meningeal artery, TNC;  trigeminal nucleus caudalis,  C1;  cervical level 
1 
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2.3.5 Cranial surgery for electrophysiological experiments in the ventroposteromedial 
thalamic nucleus  
 
Exposure of superior sagittal sinus 
 
The skin of the dorsal surface of the skull was divided and the parietal bone was 
exposed as described in section 2.3.3. A rectangular window (approximately 2 x 7 mm) 
was drilled along the midline suture and its margins were approximately 1 mm caudal 
and rostral of the bregma and lamda reference points (Paxinos et al., 1985). The bone 
was cooled by constant irrigation with isotonic saline during drilling to prevent heat 
damage to the underlying sinus. The rectangular section of bone was then gently lifted 
away from the intact dura exposing the superior sagittal sinus (SSS; figure 22). The site 
was covered with warm mineral oil. 
 
 
 
 
 
 
Figure 22: Surgical preparation and experimental setup for electrophysiological 
experiments in the ventroposteromedial thalamic nucleus  
SSS; superior sagittal sinus 
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Exposure of the parietal cortex overlying the ventroposteromedial thalamic nucleus  
 
A small window (approximately 2 x 2 mm) was drilled in the presence of cooling saline 
on the superior surface of the right parietal bone.  Its rostral margin was approximately 
2 mm caudal to bregma and its mediolateral margin was 2 mm from midline, thus 
approximately 1 mm lateral to the cranial bone along the exposed SSS (figure 21). This 
thin “bone wall” separating the SSS and the parietal cortex served as a “natural 
insulation” between the stimulating electrode placed later along the SSS and the cortex. 
The final layer of the thinned bone was gently lifted away from the intact dura mater 
exposing the parietal cortex (figure 22). Any bleeding was halted by gentle application 
of small cotton wool pellets. Isotonic saline was used to prevent dehydration instead of 
mineral oil, as the later could block the iontophoretic electrode (section 2.5.1) upon 
contact. The dura mater was carefully incised and retracted to expose the underlying 
parietal cortex just before the microiontophoretic recording electrode was lowered into 
the thalamus.  
   
2.4 Placement of stimulating electrodes and stimulating parameters  
 
2.4.1 Placement of stimulating electrode for the intravital microscopy studies 
 
To study neurogenic vasodilation (see section 3.1), a platinum bipolar stimulating 
electrode (NE-200x, Clark Electromedical Instruments, UK) was placed on the surface 
of the thinned cranial window, approximately 200 μm from a branch of the MMA using 
a micromanipulator (Narishige, Japan).  The electrode was positioned carefully so that it 
was neither over the MMA or depressing the skull, thus preventing any blood flow 
impairment.  The electrode was connected to a Grass S88 stimulator (Grass 
Instrumentation, West Warwick, RI, USA) and the surface of the cranial window was 
stimulated for 10 s using electrical square wave stimuli at a frequency of 5 Hz, duration 
of each pulse 1 ms (figure 23), with increasing voltage until maximal dilation was 
observed. Subsequent electrically induced responses in the same animal were then 
evoked using that voltage (Williamson et al., 1997a; Akerman et al., 2002c).   
 
 
 
 108
 
 
 
 
 
 
Figure 23: Square wave electrical pulses and stimulating parameters 
 
 
 
2.4.2 Electrode placement and stimulation of the middle meningeal artery  
 
A platinum bipolar stimulating electrode was placed on the dura mater straddling the 
MMA using a micromanipulator.  Square-wave stimuli (0.5 Hz) of 100 µs duration (S88 
stimulator) was applied to activate trigeminal afferents. To allow optimal recordings 
from neurons in the TCC the stimulus intensity (voltage) was adjusted down to just 
supra-maximal levels, so as not to over stimulate the neuron, and varied from 10 to 16 
V. 
 
2.4.3 Electrode placement and stimulation of the superior sagittal sinus  
 
Two platinum wire stimulating electrodes, with horizontally levelled tips of 
approximately 2 mm length each, were placed onto the SSS using a micromanipulator 
(David Kopf). Every effort was taken to minimise contact between the cortex and 
stimulating electrodes and fresh insulating mineral oil was applied. Trigeminovascular 
afferents were activated by stimulating the SSS with square-wave pulses. Supra-
maximal stimulating voltages were initially used but once a suitable unit was identified 
this was reduced to threshold levels to reduce the risk of current spread to the cortex. 
The stimulating parameters used in these experiments were: 0.5 Hz , 100 - 250 µs, 12 - 
30 V.  
 
 
 
frequence (Hz) 
duration (s) 
voltage (V) 
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2.5 Preparation and placement of recording electrodes  
 
2.5.1 Microiontophoretic electrode filling  
 
In all electrophysiological studies carbon-fibre seven-barrelled microiontophoretic 
electrodes were used (Carbostar 7S®; Kation Scientific, Minneapolis, U.S.A.). These 
consisted of a seven-barrelled glass pipette incorporating a carbon fibre recording 
electrode (Impedance @ 1 KHz: 0.4 - 0.8 MΩ) (Gottschaldt et al., 1988), with an 
exposed tip length of 15 - 20 µm and diameter of 2-3 µm (figure 24). The general 
condition of an electrode tip was checked by careful microscopic examination before 
filling. To avoid blocking of the tip of the micropipette all solutions were filtered 
(Anotop 10®, 0.02 μm inorganic membrane filter, Whatman Int. Ltd., UK) to remove 
particulates. Barrels were filled at least one hour prior to use with non-metallic syringe 
needles (Microfil® 34G, WPI, Sarasota, USA). Internal glass filaments within the 
iontophoresis barrels allowed self filling of aqueous solutions. The proximal ends were 
covered (Parafilm M®, American National Can, Chicago, USA) to reduce the risk of 
retrograde tracking of solutions and contamination of barrels prior to use, as well as the 
formation of salt bridges between barrels (Shi 1990). After ensuring complete filling 
under a microscope (Opmi 99), the electrode was lowered 1 mm into a saline bath in 
order to avoid microcrystal formation at the tip.  The electrical impedance of the filled 
barrels was then measured (Impedance Check, FHC, ME, USA) and the resulted 
impedance values depended on the solution used (table 12).  
 
 
 
 
 
Table 12: The impedance of various barrels containing different        
solutions measured at 1 KHz to outward currents 
Solutions filling the barrels  Impedance (MΩ) 
Electrolyte solutions  10-15  
Amino acid solutions 20-40  
Amine or alkaline solutions 50-100 
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Figure 24: Light and scanning microscopic images of the carbostar-7S electrode 
A. Light microscopic image showing the carbon fibre tip protruding from the glass 
shank of 6 fused-together iontophoresis barrels. The stiffness of the carbon fibre 
provides good mechanical stability for the electrode and the sharp tip allows easy tissue 
penetration. B. Ultrastructure of the carbostar-7S electrode as revealed by scanning 
electron microscopy. The fused-together glass micropipettes form a seal around the 
protruding carbon fibre. 
 
 
 
2.5.2 Placement of electrodes in the trigeminocervical complex  
 
Electrodes were fitted to a hydraulic microdrive (Model 650 Micropositioner, Burleigh) 
mounted on a micromanipulator, which was in such rotation to form approximately 90° 
angle with the exposed spinal cord.  Upon the connection of the electrodes to a head-
stage amplifier and an iontophoretic pump (section 2.6), they were lowered into the 
region of the cervico-medullary junction at 5 μm increments. A small current of 
approximately 20 nA was passed through the barrels as the electrode was lowered to 
reduce the risk of barrel blocking. At a depth of 100 μm, the iontophoretic current was 
switched off and the electrode was left for 20 minutes at rest to allow normalization of 
the equilibrium at the tip of each barrel. The microdrive was then used to advance the 
electrode in 5 μm steps while searching for trigeminovascular nociceptive responsive 
neurons within the TCC. Throughout electrophysiological recordings the frame was 
rested on a vibration free air table (TMC, Peabody, MA, USA).  
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2.5.3 Stereotaxis and identification of the ventroposteromedial thalamic nucleus 
 
Electrodes were fitted to a hydraulic microdrive mounted on a micromanipulator, which 
was positioned exactly 90° to the horizontal axis and then lowered into the region of the 
VPM according to the stereotaxic co-ordinates of Paxinos and Watson (1997). The 
coordinates used were: 3.12-3.5 mm caudal to bregma, 3.3-3.6 mm from midline and 5-
5.2 mm dorsal to the parietal cortex. As before, a small current of approximately 20 nA 
was passed through one of the barrels as the electrode was lowered into the brain (using 
the micromanipulator). At this depth receptive fields on the head and face were tested as 
the electrode was slowly advanced using the micromanipulator. When it became 
apparent that the electrode was in the VPM due to the responses to stimulation of the 
facial receptive field, a rest period of approximately 20 minutes was allowed. The 
microdrive was then used to advance the electrode in 5 μm steps while searching for 
trigeminovascular nociceptive responsive neurons within the VPM nucleus.  
 
 
2.6 Equipment and settings  
 
2.6.1 Electrophysiological recordings 
 
The signal from the recording electrode was fed via a head-stage amplifier (NL100AK, 
Neurolog, Digitimer, Herts, U.K) to an AC preamplifier (gain x1000; Neurolog 
NL104A, Digitimer, UK). The head-stage amplifier was grounded to the animal by a 
reference silver electrode inserted either into the dorsal neck muscles or subcutaneously. 
The signal was then filtered through Neurolog filters (bandwidth approximately 500 Hz 
- 10 kHz; Neurolog NL125) and next through a 50/60 Hz noise eliminator (Humbug, 
Quest Scientific, North Vancouver, BC, Canada).  The filtered signal was then further 
amplified through a second stage variable amplifier (gain approximately x50 - 90; 
Neurolog NL106), from which the output was split in two. One output was fed to a 
gated amplitude discriminator (Neurolog NL201), then displayed on an oscilloscope 
(OS 7020A, Goldstar Precision Co., Korea) and an audio amplifier (Neurolog NL120) 
to assist with the discrimination of single unit activity from background noise. The 
second output was fed to an analogue-to-digital converter (Power 1401), and then to a 
personal computer (Dell Computer Corporation, Berks, UK) running Spike® 2, version 
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5 software (Cambridge Electronic Design) which was used to collect and analyse data 
(figure 25). Outputs from the microiontophoresis current generator (Dagan 6400, Dagan 
Corporation, MN, U.S.A.) and the Grass stimulator were also connected to the 
analogue-to-digital converter and then displayed on the computer running the Spike 
software. A second oscilloscope was used to display the captured signal upon 
stimulation with the Grass stimulator. The stereotaxic frame, as well as the table on 
which it was mounted, were grounded to the earth of the mains electrical supply. 
 
Equipment and settings used for microiontophoresis in electrophysiological 
experiments 
 
A microiontophoresis current generator provided ejection and retention currents 
(Bloom, 1974). Barrels were connected to the current generator (Dagan 6400, Dagan 
Corporation, MN, U.S.A.) through a head-stage by individual teflon coated silver wires 
(0.25 mm, WPI). The distal end of the wire – which was placed in the drug solution – 
was stripped of 1 cm of coating. Care was taken to avoid damage to the teflon coat 
while inserting wires into the barrels. The head-stage was grounded to the stereotaxic 
frame. The polarity of the ejecting and retaining current was then set on the 
microiontophoresis pump and a retaining current of 5 nA was applied in each barrel. 
Upon placement of the electrode into the neuronal tissue the resistance of each barrel 
was measured and values of between 16 and 120 MΩ were recorded.  
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Figure 25: Schematic diagram of the preparation and equipment used in the 
electrophysiological experiments 
A recording electrode is lowered into the trigeminocervical complex, and the electrical 
signal is fed through a series of amplifiers and filters to a pair of oscilloscopes and a 
personal computer for analysis.  A bipolar stimulating electrode is placed on the middle 
meningeal artery and connected to a Grass S88 stimulator.  Silver teflon wire was used 
to connect the iontophoretic pump with the microiontophoretic electrode. The same 
setup was used for electrophysiological recordings in the ventroposteromedial thalamic 
nucleus.  
NL, Digitimer neurolog product number; NE, Clark Electromedical product; CWE, 
Instruments for physiology and respiration; CED, Cambridge Electronic Design 
products  
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2.6.2 Intravital microscopy experiments 
 
A branch of the middle meningeal artery was viewed through the thinly drilled cranium 
with an intravital microscope (Microvision MV2100; Finlay Microvision, 
Warwickshire, UK), and the image displayed on a monitor. The vessel diameter was 
constantly measured using a video dimension analyser (Living Systems 
Instrumentation, Burlington, VT) and displayed on an online data analysis system 
(Spike2v5 software) To measure the current passing through the cranial window during 
stimulations, the stimulating electrode was connected through a resistor (1 KΩ) to an 
oscilloscope (Goldstar Precision), which displayed the passing current through the 
electrode (figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Overview of the intravital set-up in the rat 
The magnified image of the dural artery is displayed on a monitor and recorded.  The 
diameter of the blood vessel is constantly measured via the video dimension analyser.  
A second output from the video dimension analyser passes to the CED 1401, which 
converts the signal to enable on-line analysis via the Spike software on the computer. 
The stimulating electrode was connected in parallel through a resistor (1 KΩ) to an 
oscilloscope, which displayed the current passing though the electrode. 
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2.7 Principles and limitations of intravital microscopy 
 
Intravital microscopy is a well developed animal model relevant to migraine (Bergerot 
et al., 2006), which permits the direct study of the peripheral end of the 
trigeminovascular system (also see section 3.1). The model was developed by 
Williamson and colleagues and utilises video microscopy to visualise dural blood 
vessels and a video dimension analyser to measure directly blood vessel diameter 
through a thinned closed cranial window (Williamson et al., 1997a; Williamson et al., 
1997b). Electrical stimulation of the cranial window causes reproducible dural and pial 
blood vessel dilation via activation of the trigeminal nerve, which is thought to be via 
the release of CGRP from presynaptic trigeminal nerve endings (neurogenic dural 
vasodilation; section 3.1) (Williamson et al., 1997a; Akerman et al., 2002b). This 
method is suited to studying the peripheral component of the trigeminovascular 
pharmacological system and mainly uses systemic administration of potential anti-
migraine compounds. Intravital microscopy has proved highly predictive of anti-
migraine efficacy, although not all anti-migraine drugs are useful in this model 
(Akerman et al., 2001; Akerman et al., 2002a; Akerman et al., 2003b). As the method 
does not investigate the central component of the trigeminovascular system, the efficacy 
of many anti-migraine compounds that act centrally may not be seen using this model. 
In addition, any minor changes at the peripheral site of the trigeminal nerve might be 
masked by the intense electrical stimulation that is used to drive CGRP release and 
subsequent vasodilation.  
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2.8 Principles and limitations of microiontophoresis in electrophysiological 
experiments 
 
The following summary has been adapted from published work (Curtis, 1964; Bloom, 
1974; Stone, 1985).  
 
Microiontophoresis utilises the flow of electric charge through an aqueous solution 
which contains an ionised compound to eject drugs with a high degree of anatomical 
precision. The solution which fills each barrel of the microiontophoretic electrode is 
connected to the iontophoresis machine by a suitable lead. Establishing a potential 
difference between a drug solution and the external medium surrounding the barrel tip 
causes the movement of ions through the solution resulting in drug ejection. By 
convention the direction of current flow is taken to indicate the flow of positive charge 
– outward and inward refer to the transport of positive charges out of or into a 
micropipette, respectively. If an outward current is applied to a solution containing 
positively charged drug molecules (cations), the cationic (+) molecules will flow in the 
same direction as the current because of electrostatic forces. Alternatively if an inward 
current is applied to the same solution, cations will be retained in the barrel, while 
anions (-) will move in the opposite direction (figure 27). The use of a multibarrelled 
electrode and a multichannel iontophoretic generator allows a number of different drugs 
to be released near the same neuron and, in addition, barrels for control and a dye for 
marking the recording site can be used in the same experiment. The iontophoretic 
technique is suitable for applying chemical substances close to receptors upon neurons 
within the nervous system.  
 
This technique will only work with compounds that are both water soluble and 
ionisable. In the case of compounds that are available as salts and readily dissociate in 
solution iontophoretic ejection is easily applied. Although many of the biologically 
active substances are in the ionic form, some of them may not be dissolved in aqueous 
solutions. With more complex organic molecules it is often necessary to add small 
quantities of acid or alkali to the solution. This exploits the presence of specific proton 
donor or acceptor moieties on the parent molecule - for example if a compound has an 
amine side-group (-NH2), this basic moiety will act as a proton-acceptor in an acidic 
environment. It is then protonated forming a charged amide (-NH3+) side-group - 
rendering the whole molecule more amenable to microiontophoretic ejection (and also 
more water soluble).   Adjusting of the pH however might affect the compound’s 
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stability. Additionally, for any substance the individual electrical charge carried by the 
molecule must be present at a pH that does not cause significant biological effects on 
neurons’ excitability. For example, topiramate is fully polarised as an anion in an 
aqueous solution at pH 12. Ejection of control (H2O, OH-) however at this pH results in 
increase in firing rate (figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: The principles of microiontophoresis 
Two micropipette barrels are shown, each containing an ionic solution. The tips of both 
barrels are in close proximity to the cell body of the neuron under study. In barrel 1, X+ 
ions are being ejected by the outward flow of current (10-100 nA) (current is by 
convention taken to mean the flow of (+) charge), while Y- anions are retained. In barrel 
2, Z+ ions are retained by a smaller (-5 nA) retaining current flowing in the opposite 
direction. This retaining current however results in the ejection of Y- anions from the 
barrel. It is assumed that this has a negligible biological effect, due to the small 
retaining current used.  
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Figure 28: Effect of pH on the electrical charge carried by topiramate and pH 
effects 
A. Topiramate’s chemical structure. B. Graph illustrating the gross charge of topiramate 
as function of pH. C. Effect of control H2O (OH-) at pH 12 on L-glutamate-evoked 
activity.  
 
 
 
 
 
 
When no active iontophoretic ejection of molecules is used, drug efflux could naturally 
occur from the tip of the micropipette into the surrounding environment and thus small 
amounts of the molecules may diffuse down a concentration gradient. This effect is 
minimized by application of a small current of the opposite polarity to the ejecting 
current and is known as the retaining or holding current (figure 27). Though these 
currents will retain the desired molecule, they will result in the ejection of oppositely 
charged ions in the solution. As individual retaining currents are small (no more than 5-
10 nA) it is assumed that this ejection has minimal biological effects. In the 
iontophoretic current generator this is achieved by utilising a second battery in parallel 
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to the first having a reverse polarity, providing a retaining and ejecting voltage (figure 
29).  
 
When multi-barrelled pipettes are used however, neurons are exposed to retaining and 
ejecting currents from several barrels and the sum of these currents may influence the 
excitability of the neuron. In an attempt to counter this, a barrel containing 200 mM  
NaCl is used for “current balancing”. A current is continuously applied to the balance 
barrel and this current is equal in magnitude to the algebraic sum of all currents being 
passed through the drug-containing barrels, but of opposite signs (figure 30). 
 
 
 
 
 
 
 
 
 
Figure 29: Iontophoretic circuit permitting ejecting and retaining current 
The circuit includes a crossover facility which allows through a switch retaining as well 
as ejecting currents. A series of resistors Rs is also included to minimize the effects of 
fluctuation of electrode resistance and a current monitoring device is placed across a 
small series resistor Rx. Adapted from (Stone, 1985) 
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Figure 30: The principle of “current balancing”. 
 In this schematic diagram barrels 1 and 2 are being used for drug ejection and barrel 3 
for current balancing. The direction and magnitude of the current in barrel 3 (-65 nA) is 
adjusted automatically to counter the net current flowing from the other barrels (+65 
nA). Theoretically the neuron under study should not be influenced by current flow. 
 
 
 
 
 
 
 
‘Osmotic artefact’ is a phenomenon that may occur with the bulk flow of the solution 
which carries the active ion, in case the solution in the pipette is present at a 
significantly lower concentration than the biological fluids, which are in contact with 
the tip. To minimise this phenomenon iso-osmotic ionised compounds are usually used. 
The compounds are at a concentration of 150-200 mM, since the solution which is iso-
osmolar with body fluids is approximately 165 mM. If the substances are not 
sufficiently soluble, a solution of sodium chloride is normally used so that the total 
solute concentration is approximately 165 mM. Despite the concentration of the 
solution within each barrel, the amount of ions ejected for a given current is 
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independent of the concentration (see section 2.8.1). Additionally, drug leakage could 
be also caused by flow of fluid due to the hydrostatic pressure of the column of the 
solution within the barrel. This is minimized by using micropipettes with reduced tip 
diameter of 2-3 µm.  
 
As discussed above, if a microiontophoretic electrode is located extracellularly very 
close to a neuronal membrane, the passage of current through a barrel to ground and the 
solution’s concentration may be sufficient to cause a change of neuronal excitability. 
Thus it is important to use a control to estimate the effect of these factors. This contains 
a suitable ionic solution. This is ejected with a current of the same direction and 
magnitude as the drug under study. As the pH of the drug solutions may be adjusted by 
the addition of H+ or OH- ions, and these will also be ejected with the drug, ejection of 
H+ or OH- ions may directly affect neuronal excitability. Changes in pH also affect 
ionotropic glutamate receptors. For example, protons inhibit most native and 
recombinant kainate receptors except from iGluR6/KA1 heteromers (Mott et al., 2003). 
This must be taken into account in any studies and thus the pH of the control should be 
the same as the test compounds. 
 
One of the great strengths of microiontophoresis is the anatomical precision that it 
provides in pharmacological studies. It allows drugs to be delivered to small numbers of 
– or even individual – cells. The relatively short length of the recording electrode tip has 
important electrophysiological properties. Short electrode tips are superior at 
discriminating the electrical activity of individual neurons. As it is unlikely that the 
ejected drugs diffuse over large distances, it can be assumed that the drug is present in a 
confined area and that the electrode is recording electrical activity from this same area. 
It has been calculated that the extracellular action potentials of a single neuron can be 
recorded within a distance of approximately 50 µm of the cell body, depending on the 
size of the soma and of the dendritic field and the type of cell (Mountcastle et al., 1957). 
Further to that the distance from which the drug is being applied cannot exceed 40-60 
µm (Curtis, 1964). The relative ease with which the diffusion and the ejection of 
substances are controlled, aids the application of drugs upon localised areas, while 
mechanical displacement and tissue damage remains minimal by the extremely small 
volume of solvent which is ejected. It is reasonable to assume therefore that any 
alteration in the excitability of a neuron is due to the effects of the ejected drug on that 
cell.  When drugs are administered systemically, such as intravenously or intrathecally, 
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it is not possible to localise their effects. This is particularly a problem in thalamic 
studies, as the drugs may have actions at more distal sites, such as the terminals of 
primary trigeminal nerves or in the TCC.   
 
2.8.1 Quantifying the microiontophoretic drug ejection and diffusion after ejection 
 
One of the difficulties of microiontophoresis is to calculate the quantity of the molecule 
that gets ejected. The number of ions ejected from a solution in a micropipette is 
proportionate to the charge flux through the solution. In its most simple form, the molar 
flux (Q) of an ion produced by an ejection current is:  
 
Q = It / FZ      Q: molar flux (number of ions ejected from a solution)  
           I: current 
                                        t: transport number (the ability of an ion to carry charge) 
                                        F: Faraday constant (96485 coulomb/mole)  
                                        Z: valency of the ion (the number of electrons that an atom  
                                              donates or accepts to form the duplet state or octet state)
         
Several other factors, however, influence the molar flux including the molecular weight 
(M) of the ion. The total flux of ions produced by a given quantity of charge is 
proportionate to M – as the molecular weight of a molecule increases, less will be 
ejected per unit of charge. The transport number (t) of any particular ion in a solution is 
the fraction of the applied current carried by that ion. Unfortunately the value of t for a 
drug may vary dramatically between micropipettes and even different barrels of the 
same multi-barrelled pipette. It is affected by a diverse range of factors including: the 
age of the micropipette, the pH of the solution, the concentration of small ions (such as 
Na+ and Cl-) in the solution, electrostatic interactions between the ion and the glass wall 
of the pipette and the nature of the receiving medium. The value of t can only be 
estimated for a particular compound and even if it can be given a value, calculating the 
molar flux is further complicated by drug ejection by non-microiontophoretic means. 
These include drug ejection by electro-osmosis and hydration effects (section 2.8.2). 
 
What is important to note is that the solutions concentration does not influence the 
molar flux and thus the concentration of the compound into the barrel will have no 
effect on its ejecting potency. From the definition of transport number from the above 
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equation, a change of the drug concentration does not affect the amount of compound 
ejected by iontophoretic current, as there is no term involving the solution’s 
concentration in the equation. This is because the assumption is often made that all the 
charge passing through the micropipette tip is carried by the drug ion. It has been 
further calculated that for concentrations between 20 mM and 1 M, as well as for a 
current above 2 nA (barrel resistance up to 100 MΩ) the amount of drug ejected is 
linear of to the ejecting current (Purves, 1981).  Some deviations might however appear 
in practice. For example when a solution contains Na+ and Cl- ions, these will also carry 
some of the ejecting current. The same occurs when the pH is adjacent since H+ and 
OH- ions will also carry some of the charge. Another factor that may contribute to 
iontophoretic ejection is the absorption of   molecules to the glass wall within the 
micropipette, due to ionic charges. This is more obvious when passing current through a 
peptide solution (positively charged) which is in a low concentration (3 mM); and can 
be avoided by using higher concentration. Since concentration plays no role on the 
actual amount of ion ejected with microiontophoresis, it is better to use iso-osmotic 
solutions in order to avoid osmotic artefacts. 
 
As can be seen it is very difficult to quantify the amount of drug ejected by this 
technique. The concentration of a drug that any given neuron is exposed to cannot be 
known. One partial exception is when a micropipette is used to study the effects of a 
drug on the same cell. In this case all variables should remain constant and the quantity 
of drug ejected will be proportionate to the ejecting current. Experiments thus provide  
qualitative information concerning the receptors and ion channels involved in 
modulating trigeminovascular nociceptive neurotransmission.  
 
Upon ejection of a compound, any further movement of the ejected molecules is 
dependent on diffusion. That is because the electrical force that drives 
microiontophoretic ejection is limited to the micropipette barrel and the immediate 
environment of its tip. According to Ohm’s Law (R = V/I), the flow of electrical current 
(I) requires a potential difference (V) between two points in a circuit. As the electrical 
resistance (R) of the external medium – in this case nervous tissue – is generally 
substantially less than the internal environment of the micropipette, only a small 
potential gradient exists beyond the micropipette tip and current will therefore not flow. 
The tip may be considered to act as a point source of the drug and any further 
movement is dependent on diffusion. Diffusion constants differ between molecules and 
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the conditions determining the extent of diffusion will differ between experiments – 
even for the same molecule. This introduces a further variable in any attempt to quantify 
the results of drug studies.  
 
2.8.2 Drug ejection by electro-osmosis and hydration effects 
 
Electro-osmosis is essentially the opposite of microiontophoresis. When an aqueous 
solution is in contact with a glass surface anions are tightly adsorbed onto the surface of 
the glass. A fixed layer of negative charge - an electrical “double layer” – is formed on 
the glass surface leaving the bulk of the fluid volume carrying a positive charge. The 
passage of current therefore causes the flow of the fluid volume in the direction of the 
current. The dissolved compound (especially if (+) charged) then moves with the fluid. 
This obviously favours compounds that are positively charged – it may even counter 
microiontophoretic ejection of anions. Electro-osmosis may contribute significantly to 
drug ejection from a micropipette – especially in dilute solutions or when the drug is 
poorly ionised (figure 31). 
 
Hydration effects also influence the ejection of a compound from a micropipette. Water 
molecules are electrostatically attracted to any ion in aqueous solution. They form a 
hydration shell surrounding the ion. A drug – even one that is poorly ionised – that is 
soluble in water will be dissolved in this hydration cell. If an electric current flows 
through the solution the ion will move under its influence. As the ion migrates so does 
its hydration shell - and any drug dissolved within it. Microiontophoresis in this case is 
only indirectly responsible for drug ejection (figure 31). 
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Figure 31: Principles of drug ejection by electro-osmosis and hydration  
A. In electro-osmosis anions are adsorbed onto the surface of the glass micropipette. 
The solution containing the drug molecule Z has a net positive charge. The fluid then 
moves en-mass in the direction of the current (in this case outward) carrying molecules 
of Z with it. If Z is positively charged electro-osmosis will enhance its ejection – the 
opposite may occur if Z is an anion. B. Hydration effects may also result in drug 
ejection. A shell of water molecules surrounds ions in solution. Molecules of a drug, Z, 
may become trapped in this shell and be ejected along with the ions. Adapted from 
(Stone, 1985). 
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2.9 Drugs used in electrophysiological studies 
 
A detailed description of the drugs used in all studies is provided below. The specific 
drugs used in each study will be discussed in each chapter separately.  
 
2.9.1 Drugs used by microiontophoresis 
 
All active drugs used by iontophoresis were dissolved either in sterile deionised water 
or 100 mM of NaCl. Pontamine Sky Blue which was used for marking the site of 
recordings was dissolved in 100 mM sodium acetate (pH 6.5). The pH was adjusted by 
adding small amounts of 100 mM NaOH to the solutions, thus increasing their 
ionisation, making them more amenable to microiontophoretic ejection and in some 
cases also improving their solubility. The isoelectric point (pI; the pH value at which the 
molecule carries no charge) and the gross charge of molecules along the pH range was 
estimated with the Marvin version 5 software (ChemAxon Ltd, Budapest, Hungary). 
The drugs used in the microiontophoretic studies are listed in table 13 and the gross 
charge of the molecules along the pH range is given. The barrel concentration, pH and 
ejection polarity for each compound as used in these experiments are given in table 14. 
When selecting a pH which confers an adequate charge upon a particular drug, the 
dissociation constants and the stability of the compound were considered, together with 
the possibility that direct pharmacological effects may be produced by H+ or OH- ions.  
 
Anions (-) were retained in their barrels with small positive currents (5 nA) while 
cations (+) were retained with negative currents (-5 nA). Ejection currents in directions 
opposite to the retaining currents were used, ranging from 5 to 100 nA. As any effect 
following microiontophoretic drug ejection on cell firing rate could be a current or pH 
artefact, the effects of suitable control were also tested. The control consisted of ejection 
of either Na+ or Cl- ions – matching the polarity of the ejected drug – and also H+ or 
OH- ions in those cases where pH alterations had been made to the solutions. The 
control was ejected at the same parameters as the drug under investigation.  
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Tables 13: Structure and gross charge of drugs used by microiontophoresis  
 
Chemicals’ IUPAC (International Union of Pure and Applied Chemistry) Name is 
provided in brackets. pI; isoelectric point 
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Tables 13 (continued): Structure and gross charge of drugs used by 
microiontophoresis  
Chemicals’ IUPAC (International Union of Pure and Applied Chemistry) Name is 
provided in brackets. pI; isoelectric point 
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Table 14: Parameters of compounds used in all microiontophoretic studies  
Drug Concentration pH Ejection 
Polarity 
Source 
L-Glutamate 
monosodium 
 
200 mM 8.0 (-) Sigma-Aldrich 
Iodowillardiine 
 
50 mM 8.0 (-) Tocris Cookson 
Fluorowillardiine 
 
50 mM 8.0 (-) Tocris Cookson 
SYM 2081 
 
50 mM 8.0 (-) Tocris Cookson 
NMDA 50 mM 8.0 (-) Sigma-Aldrich 
CNQX 50 mM 8.0 (-) Tocris Cookson 
UBP 302 
 
50 mM 8.0 (-) Tocris Cookson 
LY466195 
 
50 mM 7.5 (-) Lilly 
Laboratories 
NAS-181 
 
50 mM 5.5 (+) Tocris Cookson 
GR127935 
hydrochloride 
 
20 mM 5.5 (+) Tocris Cookson 
Naratriptan 
hydrochloride 
25 mM 5.5 (+) Glaxo Wellcome 
Research and 
Development 
(S)-WAY100135 
 
10 mM 5.5 (+) Tocris Cookson 
(-)-Bicuculline 
methiodide 
 
100 mM 5.5 (+) Tocris Cookson 
D-Serine 50 mM 8.0 (-) Tocris Cookson 
NaCl 200 mM 7.5-8 (+/-) 
Automated 
Current 
Balancing 
Sigma-Aldrich 
Pontamine Sky 
Blue 
 
2.5% (w/v) 6.5 (-) BDH Laboratory 
Supplies 
 
Sigma-Aldrich Ltd., St. Louis, MO, U.S.A. 
Tocris Cookson, Avonmouth, U.K; Ellisville, Missouri ,USA 
BDH Laboratory Supplies, Poole, UK 
Lilly Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA 
Glaxo Wellcome Research and Development, Herts., UK  
(+): cation (-): anion 
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2.9.2 Intravenous administration of LY466195 and topiramate 
 
The effects of intravenous doses of LY466195 (kindly provided by Lilly Laboratories) 
on the responses following dural vessels’ stimulation and on the glutamate agonists 
NMDA, Iodowillardiine and Fluorowillardiine-evoked firing were studied in the 
thalamus. The effects of iv doses of LY466195 in the TCC were tested only on cell 
firing in response to dural vessels’ stimulation. LY466195 was dissolved in de-ionised 
sterile water and doses of 10, 50 and 100 μgkg-1 were used for recordings in the VPM 
and doses of 50, 100 and 200 μgkg-1 were used for recordings in the TCC.  
 
Topiramate (kindly provided by Johnson & Johnsons) was only tested on cell firing of 
third order neurons in response SSS stimulation in the VPM at a dose of 30 mgkg-1. 
Topiramate was dissolved in de-ionised sterile water and sonication was used to help 
the solubility of the molecule. All solution were filtered (0.02 μm inorganic membrane 
filter) and given by a slow intravenous injection over one minute, following by flushing 
of the cannula with saline. Vehicle control ejections were achieved by intravenous 
injection of 0.3 ml de-ionised water for injection. 
 
Binding affinities of the major compounds used 
 
 
As the antagonists and the glutamate receptor agonists used in this thesis were chosen 
according to their selectivity over different glutamate receptors and receptor subunits 
(Jane et al., 1997; More et al., 2004; Weiss et al., 2006), binding affinities are shown in 
table 15.  Due to the different approaches used for calculating the binding affinities for 
each drug, affinity is expressed as either Ki – the molar concentration of a competitive 
ligand that would occupy 50% of the receptor, or as Kd – the molar concentration of a 
radio-labelled ligand which occupies 50% of the receptor.  
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Table 15: Receptor binding affinities of the major kainate compounds used at 
human recombinant glutamate receptors   
 Agonists Antagonists 
Receptor Subunit Fluorowillardiine 
(Ki; nM) 
Iodowillardiine 
(Ki; nM) 
UBP 302 
(Kd; nM) 
LY466195 
(Ki; μM) 
iGluR5 1820 ± 416 0.24 ± 0.06 402 0.05 ± 0.02 kainate 
iGluR6 none none 36180 > 100 
iGluR1 14.7 ± 1.3 163 ± 42 75 ± 7 
iGluR2 25.1 ± 5.2 176 ± 29 269 ± 22 
AMPA 
iGluR4 305 ±107 972 ± 155 
104520 
312 ± 62 
NMDA NR1/NR2 none none none 2.5 ± 0.9 
 
 
 
 
2.10 Drugs used for intravital microscopy 
 
Calcitonin gene-related peptide (CGRP, rat; Tocris Cookson Inc.) induced vasodilation 
was achieved via intravenous infusion of 1 µgkg-1 CGRP (Tocris Cookson). CGRP was 
initially dissolved in distilled water, aliquoted, and frozen. Subsequent dilutions were 
made in 0.9% saline before injection at a dose of 1 µgkg-1. Iodowillardiine and UBP 302 
were dissolved in saline with pH corrected to 8.0-8.5. Doses of 5, 10 and 20 mgkg-1 of 
Iodowillardiine and a 50 mgkg μgkg-1   of UBP 302 were used. When more than one 
drug was given intravenously, an interval time of at least 5 minutes was set before 
administering the second compound. In these experiments the line was always flushed 
with saline prior to administration of the second compound. As stated above, all 
solutions were filtered and given by slow intravenous injection over one minute, 
followed by flushing of the cannula with saline. Vehicle control ejections were achieved 
by intravenous injection of 0.3 ml of pH adjusted saline.  
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2.11 Electrophysiological recordings 
 
2.11.1 Receptive fields and cell characterisation in the trigeminocervical complex 
 
Receptive fields were sought on the ipsilateral craniofacial region for all cells. The 
cutaneous receptive field was assessed in all three divisions of the trigeminal 
innervation and identified as the electrode was lowered in the spinal cord.  The 
receptive field was characterised for non-noxious (gentle brushing with a blunt probe) 
and noxious (pinch with toothed forceps) responses. Once a neuron sensitive to 
stimulation of the ophthalmic dermatome of the trigeminal nerve was identified it was 
tested for convergent input from the dura mater in response to electrical stimulation.  
Cells were classified as LTM if they responded only to non-noxious stimuli, NS if they 
responded to noxious stimulation only, and WDR if they responded to both (Hu et al., 
1981).  
 
2.11.2 Receptive fields and cell characterisation in the ventroposteromedial complex 
 
Receptive fields were sought on the contralateral craniofacial region for all cells. For 
those cells with a receptive field not involving the vibrissae, non-noxious and noxious 
stimuli were provided as in the TCC and cells were classified as LT, NS and WDR. The 
majority of cells however had receptive fields limited to the vibrissae and furry buccal 
pad, which is not surprising given the large volume dedicated to the representation of 
vibrissae within the rat VPM (Vahle-Hinz and Gottschaldt, 1983). With such cells each 
vibrissa was manipulated with a fine needle mounted on a probe, taking care not to 
deflect surrounding vibrissae, to find the whisker(s) that triggered a response upon 
deflection. 
 
2.11.3 Analysis of the neuronal responses to electrical stimulation of the middle 
meningeal artery (MMA) and the superior sagittal sinus (SSS) 
 
To record the response of units following electrical stimulation of the MMA, post-
stimulation histograms were constructed (figure 32). Each histogram was constructed by 
calculating the number of spikes recorded per 1 ms bin (with a total sweep length of 50 
ms) elicited by 25 electrical stimuli. The main body of the response was found to occur 
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with a latency of 8-20 ms. Neurons firing with such latency were classified as receiving 
inputs from Aδ-fibres. Calculations of neuronal conduction velocities, were estimated 
by measuring the distance between the MMA stimulating site and the cervico-medullary 
recording site (25-30 mm). An additional 1 ms was included for the central synaptic 
delay (Schepelmann et al., 1999; Bartsch and Goadsby, 2003b).  
 
The baseline response probability was calculated from up to three trials. Sufficient time 
was allowed to elapse between each trial to allow the cell to recover. A minimum 
response probability of 30% was required for a cell to be considered responsive to 
trigeminovascular nociceptive stimulation and suitable for further study (Nagler et al., 
1973). Post-stimulus histograms following stimulation of the SSS were constructed in 
the same way over 50 electrical stimuli as previously described (Shepheard et al., 1999; 
Shields and Goadsby, 2005, 2006). The main body of the response was found to occur 
with a latency of 10-20 ms in both the TCC and the VPM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Post-stimulus histograms –calculation of response probability 
Post-stimulus histogram demonstrating the response of a representative second order 
neuron in the trigeminocervical complex, to electrical stimulation of the middle 
meningeal artery. The number of spikes per 1 ms bin was collected over 25 stimuli. The 
mean number of spikes per bin was then calculated. * stimulus artefact 
 
*
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2.11.4 Analysis of the neuronal responses to microiontophoretic ejection of glutamate 
receptor agonists 
 
Neuronal action potential firing in response to microiontophoretic ejection of glutamate 
agonists was analysed as cumulative rate histograms. The data was collected into 
successive one second bins. The ejection current of each agonist was titrated for each 
cell to produce a sustainable firing rate - comparable to the response elicited by 
stimulation of the receptive field. Response profiles of different receptors were taken 
into account and in experiments where more than one agonist was ejected, care was 
taken to produce similar firing activity during baseline periods, as activation of different 
receptors produces different profiles of response (Stone, 1985) (figure 33). 
 
 
 
 
 
 
Figure 33: Titration of glutamate receptor agonists’ responses 
A cumulative histogram composed of successive responses to L-glutamate (40 nA) and 
kainate (15 nA) is used as an example. The total spike count between cursors 1 and 2 
was 2020 and that was comparable to the total spike count between cursors 3 and 4 
(1903). These figures indicate that peak height cannot be used to reflect the total activity 
if the response profiles are appreciably different (Stone, 1985).  
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Each agonist was ejected for approximately 7 seconds. An interval period of 
approximately 40 seconds, at which holding current was applied before the subsequent 
ejection, was used when more than one agonist were ejected.  An interval period of 
approximately 30 seconds was used when only one agonist was ejected. Interval period 
was judged on the response profiles of the different agonists used such as enough 
recovery period was allowed and the slow decline responses of some receptors was not 
affecting the responses of the next test compound (Stone, 1985). At least five pulses of a 
glutamate agonist or five cycles of three different glutamate agonists ejected in a 
random order were recorded during baseline period. Five cycles were used as the firing 
rate could naturally vary between pulses – this was used to reduce the possibility of 
registering a spurious effect. The mean firing rate during each ejection period was 
calculated using the “Spike®” software package. The mean background firing rate – 
during the retention phase – was calculated and subtracted from the firing rate during 
the preceding ejection phase to calculate the net effect of each glutamate agonist (figure 
34). The AC/DC amplifier channel was used as a guide for the start and end point of 
each increase in firing rate (figure 34). This was done as the increase in firing rate in 
response to microiontophoretic ejection of glutamate agonists, is not limited to the 
ejection duration, as this among others depends on the drug diffusion from the end of 
the tip, the distance of the electrode from the cell and the receptor’s response profile, for 
example, kainate receptor activation produces a prolonged increase in firing rate (figure 
33).   
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Figure 34: Peri-stimulus histograms – calculation of glutamate agonists-evoked 
responses 
The mean firing rate of a thalamocortical neuron during each 7 seconds ejection of 
NMDA, Fluorowillardiine and Iodowillardiine was calculated by measuring the rate 
during the ejection phase (for example NMDA: between red cursors R1-R2; 
Fluorowillardiine: between green cursors G1-G2; Iodowillardiine: between blue cursors 
B1-B2) and subtracting the corresponding rate of the retention phase (for example 
Fluorowillardiine: between cursors R2-G1; Iodowillardiine between cursors G2-B1). 
The increase in cell firing was calculated separately for each agonist (for example 
NMDA: between red cursors; Fluorowillardiine: between green cursors; 
Iodowillardiine: between blue cursors). The mean firing rate of trigeminocervical 
neurons was calculated using the same approach. 
 
 
 
2.11.5 Selection criteria used to identify cells suitable for microiontophoretic study  
 
Both trigeminocervical and thalamocortical neurons were required to display the 
following criteria before they were selected for microiontophoretic study: 
 
• Electrical stimulation of the MMA or the SSS was the primary method for 
identifying suitable neurons. Neurons had to respond to electrical stimulation of 
the vessel with a response probability of at least 30% before further 
characterisation was undertaken. This minimum required level of response 
ensured that only neurons activated by a nociceptive trigeminovascular input 
were studied.  
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• Each cell was required to have a V1 ophthalmic cutaneous receptive field (TCC 
neurons) or a cranio-facial receptive field (VPM neurons). Modulation of the 
cutaneous inputs however was only studied in the TCC. Generally neurons in 
both the TCC and VPM activated by convergent viscerosomatic inputs from 
dural vascular structures rarely had receptive fields located on the body.  
 
• Once a suitable unit was identified on the basis of its response to dural electrical 
stimulation glutamate agonists were ejected. As glutamate receptors are 
predominantly located on the cell body of neurons, an increased firing rate in 
response to agonist ejection was taken as evidence that the electrode was 
recording from the soma of a neuron and not from an axon. Five repeated stable 
baselines had to be recorded for a cell to be considered for further examination. 
 
• Microiontophoretic ejection of an inhibitory drug had to be followed by 
recovery of both dural responses to electrical stimulation and glutamate agonist-
evoked activation, comparable to baseline recordings. This allowed neuron 
recovery to be monitored and ensured that the effect was not due to the cell 
drifting away from the electrode tip. 
 
2.11.6 Histological confirmation of recording sites 
 
The location of each recording site was verified by two methods. The first involved 
direct marking of the recording site by ejection of Pontamine Sky Blue. A 
microiontophoretic pump (BAB-350 Iontophoresis Pump, Kation Scientific, 
Minneapolis, USA) was used to eject Pontamine Sky Blue using a current of 3 μA for 
10 minutes. Alternatively the depth of each recording site was recorded from the 
microdrive and two reference points were then marked along the electrode tract dorsal 
and ventral to the recording sites. The recording sites were then reconstructed using 
these reference points. At the end of each experiment a 5 mm thick coronal section 
encompassing the thalamus and electrode tract (for recordings in the VPM) or an upper 
spinal cord section encompassing the C1 spinal cord level and electrode tract (for 
recordings in the TCC) were removed, and placed immediately in neutral buffered 10% 
formalin (Sigma-Aldrich) for 24 hours. This was slowly replaced by 30% sucrose 
solution (BDH Laboratory Supplies) over subsequent days. Once the tissue block had 
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fully equilibrated in 30% sucrose it was cut using a freezing microtome into 40 μm 
sections and placed on microscope slides. Sections were then examined (Axioplan 
microscope, Zeiss, Germany at x 25 magnification) to locate Pontamine spots. Those 
sections in which blue marks were found were stained with a combination of neutral red 
and crysel violet and photographed (AxioCam MRc5 microscope camera, Zeiss, 
Germany). Recording sites were then reconstructed, approximating their original 
positions into coronal planes for diagrammatic purposes. 
 
 
2.12 Statistical Analysis 
 
All statistical analysis was carried out using SPSS v 16 (SPSS, Chicago, USA). 
 
2.12.1 Electrophysiological studies 
 
The mean net firing rate was calculated for each of the successive cycles of glutamate 
agonists during each of the test conditions. Five pulses were analysed to avoid 
variations of the responses of a cell between individual pulses and the reliability of the 
measurements was tested using Cronbach’s alpha. The average of the three baselines 
obtained following stimulation of dural structures was used for further comparisons. A 
repeated measures ANOVA for both responses evoked by glutamate agonists and dural 
stimulation were computed with two factors: Drugs and Repeats, to determine intra- and 
inter- drug effects and interactions. Bonferroni corrections were applied and when the 
assumption of sphericity with regards to the factor of Repeats was violated, adjustments 
were made for the degrees of freedom and P values according to the Greenhouse-
Geisser correction. The results from all cells were analysed together and compared by a 
series of Student’s paired t-tests to examine the effect of each intervention in turn. An 
independent t test was used for group comparisons to compare the effects of antagonists 
over two different neuronal subpopulations. This approach was taken to make sure that 
any artefact caused by current ejection was not mistaken for a drug effect. Significance 
was assessed at the P < 0.05 level (Field, 2005). All data are expressed as the mean 
value and the standard error of the mean (SEM) for each treatment group. 
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2.12.2 Intravital microscopy 
 
The effects of electrical stimulation and CGRP administration on dural vessel diameter 
were calculated as a percentage increase from the pre-stimulation baseline diameters.  
The nature of the experimental set-up, where the magnification of the dural vessel 
visualised was different in each animal by virtue of selecting an appropriate target 
vessel, resulted in dural vessel diameter being measured in percentage change from 
baseline. The typical vessel diameter measured was 115 ± 7 μm. All data are expressed 
as mean ± SEM. Statistical analysis was performed using an ANOVA for repeated 
measures with Bonferroni post-hoc correction for multiple comparisons followed by 
Student’s paired t-test.  To compare the effect of Iodowillardiine only and 
Iodowillardiine and UBP 302 an independent samples t-test was used. Significance was 
assessed at the P <0.05 level (Field, 2005) and all data are expressed as the mean value 
and the standard error of the mean (SEM) for each treatment group.
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Chapter 3: Activation but not blockade of the iGluR5 kainate receptor 
attenuates neurogenic dural vasodilation in an animal model of 
trigeminovascular nociception 
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3.1 Introduction 
 
A key manifestation of migraine is activation, or the perception of activation, of 
trigeminal afferents mainly in the ophthalmic division of the trigeminal nerve, which 
innervate the pain-producing intracranial structures, such as the dura mater (Goadsby, 
2005b). Stimulation of the dura mater and blood vessels in humans is known to produce 
headache-like pain referred to the ophthalmic division of the trigeminal nerve (Penfield, 
1932, 1934; Penfield and McNaughton, 1940; Wolff, 1948; McNaughton and Feindel, 
1977). Migraine pathophysiology is believed to involve the release of neuropeptides 
from trigeminal afferents innervating pain producing intracranial structures (Edvinsson 
and Goadsby, 1994). Electrical stimulation of dura mater causes CGRP release from the 
pre-junctional nerve fibres innervating the dural blood vessels, resulting in reproducible 
vasodilation (Williamson et al., 1997c). Trigeminal nerve activation causes dural blood 
vessel dilation (Williamson et al., 1997b) and given that dural blood vessel distension is 
painful in humans (Ray and Wolff, 1940), the reaction of dural blood vessels is used as 
an indication of trigeminal nerve activation from a peripheral perspective and it enables 
us to model some aspect of the migraine attack. 
 
The development of intravital microscopy permitted the direct study of the peripheral 
branch of the trigeminovascular system by means of neurogenic dural vasodilation 
(NDV). NDV is substantially due to the release of CGRP following electrical 
stimulation of the dura from pre-junctional trigeminal nerve fibers innervating the dural 
blood vessels (Kurosawa et al., 1995; Williamson et al., 1997a; Akerman et al., 2002b, 
c). Upon release, CGRP binds to CGRP receptors on dural vessels and results in 
vasodilation (figure 35). Intravital microscopy uses a thinned closed cranial window 
combined with a video microscopy device that allows the visualisation and 
measurement of cranial (dural and pial) blood vessels in real time (Williamson et al., 
1997a, c; Petersen et al., 2004; Gozalov et al., 2005; Petersen et al., 2005b; Petersen et 
al., 2005a).   
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CGRP 
 
 
 
 
 
 
 
 
 
 
Figure 35: Summary of neurogenic dural vasodilation 
The diagram shows a schematic representation of a dural artery innervated by a 
trigeminal sensory nerve.  Electrical stimulation (ES) causes CGRP release from the 
pre-junctional activated trigeminal neurons.  CGRP activates CGRP receptors in the 
smooth muscle of the dural artery causing the vessel to dilate. 
 
 
 
 
 
The CGRP antagonist CGRP8-37 is able to inhibit completely NDV, whereas substance P 
is not implicated in the development of the reproducible neurogenic vasodilation as NK1 
receptor antagonists were unable to inhibit NDV (Williamson et al., 1997c), as well as 
demonstrating similarly poor results in clinical trials (Goldstein et al., 1997; Goldstein et 
al., 2001).   This further indicates the importance of CGRP in neurogenic vasodilation 
and the good utility of NDV in modelling partly the pharmacology of the 
trigeminovascular system. Why SP plays no role in migraine pathophysiology is not 
well understood. As CGRP and SP are colocalised mainly in C fibres arising from the 
trigeminal ganglion, someone will expect a contribution of both neuropeptides in the 
observed vasodilation. The importance of CGRP over SP might reflect a greater density 
of Aδ fibres innervation of the cerebral circulation or it could reflect preferential 
activation of Aδ over C fibres or it could reflect differential release of CGRP from C 
fibres pools (Edvinsson and Hargreaves, 2000). The measurement of dural vessel 
dilation due to electrical stimulation-evoked release of CGRP, which is present in 
trigeminal afferents innervating dural structures, including the MMA (Keller and 
Marfurt, 1991),  is an established method of characterising trigeminovascular activation. 
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Moreover, since CGRP receptor antagonists are clearly effective in acute migraine 
(Olesen et al., 2004b; Ho et al., 2008), the pharmacology of the control mechanisms for 
dural CGRP release are of direct relevance to the development of newer migraine 
therapies.  
 
The NDV model has proven ability to predict anti-migraine therapeutic potential as 
compounds with anti-migraine efficacy in the clinic, such as BIBN4096BS, topiramate, 
rizatriptan and sumatriptan were effective in inhibiting NDV (Williamson et al., 1997c; 
Williamson et al., 1997b; Williamson et al., 2001; Petersen et al., 2004; Akerman and 
Goadsby, 2005b; Recober and Russo, 2007). There are also a series of compounds 
which includes calcium channel blockers and cannabiods, that are able to inhibit NDV, 
as well as trigeminovascular activation in other models of migraine and thus represent 
potential new migraine therapeutics (Akerman et al., 2001; Akerman et al., 2003a; 
Akerman et al., 2004b; Shields et al., 2005; Akerman et al., 2007).   
 
CGRP and NO, are potent vasodilators and are able to cause an immediate headache and 
a delayed migraine in patients  (Iversen et al., 1989; Iversen and Olesen, 1994; Lassen et 
al., 2002; Afridi et al., 2004; Afridi et al., 2005b). Similarly when used in intravital 
microscopy by systemic administration, are able to cause reproducible dural blood 
vessel dilation. CGRP is acting on vascular CGRP receptors (Akerman et al., 2002b, c; 
Akerman et al., 2004a). Due to a direct action of exogenous CGRP on post-synaptic 
CGRP receptors on the smooth muscle of dural arteries drugs that can inhibit CGRP-
induce dilation demonstrate at least their partial action on the smooth muscles of blood 
vessels, whereas compounds that can inhibit NDV but not CGRP-induced dilation, have 
a direct action on the pre-junctional site of the trigeminal fibres innervating the dural 
vessels. Thus, intravital microscopy further helps to dissect the pharmacology of the 
trigeminovascular system.  
  
The presence of iGluR5 subunits in trigeminal ganglion neurons (Sahara et al., 1997) 
and at the pre-synaptic sites of primary afferents (Hwang et al., 2001; Lucifora et al., 
2006; Hegarty et al., 2007) indicates a possible role of kainate receptors in 
trigeminovascular physiology. Evidence from immunocytochemical studies also exists 
for peripheral transport of kainate receptor on sensory, both myelinated and 
unmyelinated axons (Carlton et al., 1995; Coggeshall and Carlton, 1998), suggesting its 
possible presence on the pre-junctional site of the trigeminal peripheral branch.  It has 
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been shown that activation of these receptors on peripheral axons leads to increased 
activity along the sensory root and thus to peripheral nociceptive transduction (Agrawal 
and Evans, 1986; Ault and Hildebrand, 1993).  
 
In the present study we investigated the possible involvement of pre-junctional iGluR5 
kainate receptors in a model employing NDV using the selective iGluR5 receptor 
agonist Iodowillardiine (Swanson et al., 1998) and the selective receptor antagonist UBP 
302 (More et al., 2004). As iGluR5 subunits are located on trigeminal nerve endings 
(Sahara et al., 1997), a demonstration of an effect would provide further evidence of a 
potential opportunity for treating migraine through this site.  
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3.2 Methods 
 
3.2.1 Animals 
 
Male Sprague-Dawley rats (280–370 g; n = 37) were anaesthetised with pentobarbitone 
(60 mgkg-1) and cannulated for measurement of blood pressure, experimental drug 
administration and maintenance of anaesthesia (15 mgkg-1hr-1). 
 
3.2.2 Drugs 
 
The effects of the specific iGluR5 antagonist UBP 302 (50 mgkg-1) and the specific 
iGluR5 agonist Iodowillardiine (5, 10 and 20 mgkg-1) were investigated on neurogenic 
and CGRP induced vasodilation. Both Iodowillardiine and UBP 302 were dissolved in 
saline (pH 8) and administrated intravenously. In control experiments equal volumes of 
vehicle only was administered (section 2.10).  
 
3.2.3 Experimental protocol 
 
Neurogenic dural vasodilation and CGRP- induced vasodilation 
 
A thinned closed cranial window was performed allowing the visualisation and 
measurement of the MMA in real time, using a video microscopy device. NDV was 
achieved by electrical stimulation of the cranial window as described in section 2.4.1.  
In brief, a bipolar stimulating electrode was placed on the thinned cranial window, close 
to the MMA. The surface of the cranial window was stimulated at 5 Hz, 1 ms for 10 s 
(Grass S88 Stimulator) with increasing voltage until maximal dilation was observed. 
Subsequent electrically induced responses in the same animal were then evoked using 
that voltage.  CGRP induced dilation was achieved via the administration of CGRP 
(Tocris Cookson Ltd., UK) 1 µgkg-1 intravenous bolus injection via the cannulated 
femoral vein.  This dose of CGRP has been shown repeatedly to produce maximal 
vessel dilation (Williamson et al., 1997c; Akerman et al., 2002c).  
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Effect of iGluR5 receptor agonist Iodowillardiine on Evoked Dural Vessel Dilation 
 
Two control responses to dural electrical stimulation were performed (interval time 
between stimulations: 15 minutes), and at least 10 minutes later, Iodowillardiine, at 
doses of 5, 10, and 20 (n = 6 for each dose) mgkg-1 was administered intravenously. 
Electrical stimulation was then repeated at 5, 15, 30, 45, 60 and 90 minutes after drug 
administration. For those doses, at which no full recovery was observed after 90 minutes 
of Iodowillardiine treatment, CGRP 1 µgkg-1 was administered intravenously at least 10 
minutes after the 90 minute response to dural electrical stimulation (figure 36). In the 
experiments where the antagonist UBP 302 was co-administrated with Iodowillardiine 
(n = 6), two control responses to dural electrical stimulation were performed, and at 
least 10 minutes later UBP 302 50 mgkg-1 was administrated intravenously, followed by 
intravenous administration of Iodolwillardiine 10 mgkg-1, 5 minutes later. Electrical 
stimulation was then repeated at 5, 15, 30, 45, 60 and 90 minutes after Iodowillardiine 
administration (figure 36). 
 
 
 
 
 
Figure 36: Electrical stimulation experimental protocol 
Two control responses to electrical stimulation (ES) were performed before 
administration of Iodowillardiine or UBP 302 or control. ES was repeated   at 5, 15, 30, 
45, 60 and 90 minutes. When Iodowillardiine was administrated, CGRP (1 mgkg-1) was 
given after the 90 minute, to test the vessel vitality. 
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Effect of the iGluR5 receptor antagonist UBP 302 on Evoked Dural Vessel Dilation 
 
Two control responses to dural electrical stimulation were performed, and at least 10 
minutes later, UBP 302, at a dose of 50 mgkg-1 (n = 5) was administered intravenously. 
Electrical stimulation was then repeated at 5, 15, 30, 45, 60 and 90 minutes after drug 
administration (figure 36). 
 
Effect of Iodowillardiine on CGRP-Evoked Dural Vessel Dilation 
 
Two control responses to CGRP (1 µgkg-1) induced dilation were performed, and at 
least 10 minutes later 10 mgkg-1 Iodowillardiine (n = 6) was administered intravenously 
and then the CGRP induced dilation was repeated at 5, 15, 30, 45, 60 and 90 minutes 
after the agonist treatment (figure 37). 
 
 
 
 
 
 
 
Figure 37: CGRP bolus experimental protocol 
Two control responses to CGRP (1 mgkg-1) dilation were performed before 
administration of Iodowillardiine (10 mgkg-1) and then followed for 60 minutes. 
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3.3 Results 
 
Baseline blood pressure and respiratory parameters were within normal limits for all 
animals. 
 
Visualised branches of the MMA through the closed cranial window with diameter 
ranging from 90 to 140 µm were studied. Electrical stimulation (50-150 µA) of the 
cranial window, produced transient control responses in the range of 50 to 180% 
increase in dural blood vessel diameter (n = 31), compared to baseline diameter at rest 
(figure 38). Each vasodilation was calculated as the maximum difference in vessel 
diameter following electrical stimulation compared to the diameter at rest. For each 
animal, the mean ± SEM of the control neurogenic dural vasodialations was set as 
maximum baseline dilation- normalised to 100%. Subsequent dilations were expressed 
as a percentage of the control response.    
  
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Neurogenic dural vasodilation 
Examples indicating the measurement of the MMA diameter before electrical 
stimulation (ES) of the dura mater, 30 seconds post ES which resulted in vessel dilation 
and during recovery period. The two levelled lines (white) define the vessel under study 
and its diameter is measured through the video dimensional analyser. 
 
 
 
 
baseline post-ES recovery 
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3.3.1 Effects of Iodowillardiine on neurogenic dural vasodilation  
 
The iGluR5 receptor agonist Iodowillardiine given intravenously at 5 mgkg-1 had no 
effect on the responses to electrical stimulation of the cranial window, but a significant 
attenuation was observed at 10 (F3,12 = 8.2; P < 0.005; figure 39; table 16) and 20   
mgkg-1 (F3,15 = 14.3; P < 0.001; figure 39; table 16). At both doses Iodowillardiine 
produced its maximal effect after 15 minutes and responses were not fully recovered 90 
minutes after drug administration. Iodowillardiine at 20 mgkg-1 inhibited neurogenic 
dural vasodilation by 50% (t5 = 5.2; P < 0.005; n = 6) and 90 minutes after treatment 
with Iodowillardiine NDV had not fully recovered to baseline. CGRP (1 µgkg-1) 
intravenous administration, at least 10 minutes after the 90 minute neurogenic-induced 
dilation, caused maximum dilation to baseline levels. The CGRP induced-dilation was 
significantly different (t5 = 4.2; P < 0.05) from the neurogenic dilation recorded at 90 
minutes after Iodowillardiine treatment, indicating that the vessel was still responding. 
Control vehicle injections demonstrated no significant effect (figure 39). 
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Figure 39: Effect of intravenous administration of Iodowillardiine (5, 10, and 20 
mgkg-1) on neurogenic vasodilation 
A. Following control responses to electrical stimulation, rats were injected with 
Iodowillardiine at 5, 10 or 20 mgkg-1 and electrical stimulation was repeated after 5, 15, 
30, 45, 60 and 90 min. Both 10 and 20 mgkg-1 doses of Iodowillardiine inhibited NDV. 
CGRP 1 µgkg-1 was given intravenously after the 90 min neurogenic induced dilation 
and the CGRP induced dilation was significantly different from the neurogenic dilation 
recorded 90 min after Iodowillardiine treatment. B, C. Example of neurogenic dural 
vasodilation tracing (Spike2 v5) prior any pharmacological treatment (B) and at 15 
minutes after 20 mgkg-Iodowillardiine injection (C). The initial reduction immediately 
after electrical stimulation (ES) of the dura is due to spasm reaction to ES of the MMA.  
*, P < 0.05 significance compared with the control response. #, P < 0.05 significance 
compared with the 90 minute response to electrical stimulation.  
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3.3.2 Effect of UBP 302 on neurogenic dural vasodilation 
 
The iGluR5 receptor antagonist UBP 302 given intravenously at 50 mgkg-1, elicited no 
change in NDV (F1,5 = 0.6; P = 0.5; n = 5; figure 40). UBP 302 administration did not 
alter the diameter of the vessels under observation at rest prior to electrical stimulation 
and at the dose of 50 mgkg-1 did not elicit any significant blood pressure changes. 
Control vehicle injections demonstrated no significant effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Effect of UBP 302 50 mgkg-1 on neurogenic vasodilation  
Following control responses to electrical stimulation, rats were intravenously injected 
with UBP 302 at 50 mgkg-1 (n = 5) and electrical stimulation was repeated after 5, 15, 
30, 45, 60 and 90 min. No significant effect was observed. 
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3.3.3 Effects of Iodowillardiine and UBP 302 on neurogenic dural vasodilation  
 
Iodowillardiine given alone at 10 mgkg-1 significantly inhibited NDV by 31% (n = 6; t5 
= 7.2; P < 0.001; figure 39, 41; table 16). Ninety minutes after Iodowillardiine 
treatment, full recovery was not observed after electrical stimulation and CGRP 1 µgkg-1 
was given intravenously to test vessel response. The iGluR5 receptor antagonist UBP 
302 (50 mgkg-1) given alone did not cause any significant changes in vessels response to 
electrical stimulation of the cranial window (F1,5 = 0.6; P = 0.5; n = 5; figure 40). 
However, pre-treatment with UBP 302 50 mgkg-1 5 minutes prior to Iodowillardiine 10 
mgkg-1 administration reversed the inhibition of NDV (F2,11 = 0.6; P = 0.6; n = 6; figure 
41) caused by Iodowillardiine when administered alone. Grouped comparisons of UBP 
302 when administered alone (figure 40) and UBP 302 given intravenously pre-
Iodowillardiine treatment showed no significant difference between the two 
experimental setups.  
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Figure 41: Effect of intravenous administration of Iodowillardiine 10 mgkg-1 on 
neurogenic dural vasodilation and the effect of pre-treatment with UBP 302 at 50 
mgkg-1 
After control responses to electrical stimulation, Iodowillardiine at 10 mgkg-1 was either 
injected or pre-treated with UBP 302 at 50 mgkg-1 5 minutes before Iodowillardiine and 
electrical stimulation was repeated at 5, 15, 30, 45, 60 and 90 minutes. Inhibition of 
NDV is seen in response to Iodowillardiine, which is not fully recovered after 90 min 
and CGRP injection at 1 µgkg-1 after the 90 min electrical stimulation produce 
maximum dilation. The inhibition in response to Iodowillardiine was reversed by the 
iGluR5 antagonist UBP 302. 
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3.3.4 Effects of Iodowillardiine on CGRP-induced dural vasodilation 
 
CGRP bolus injections were used to induce dural vasodilation in response to activation 
of CGRP receptors on the vessel walls. Systemic administration of CGRP at 1 µgkg-1 
was able to produce reproducible dural blood vessel dilation in the range of 75 to 155% 
(n = 6) and resulted in a transient decrease in blood pressure of 29 ± 4%, lasting 1-2 
minutes, compared to baseline levels at rest. For each animal, mean control responses 
were set as maximum dilation of 100% ± SEM. Intravenous administration of 
Iodowillardiine (10 mgkg-1) had no significant effect on vessel dilation in response to 
CGRP (n = 6; F2,11 = 2.8; P = 0.1; figure 42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Effects of intravenous Iodowillardiine (10 mgkg-1) on CGRP bolus 
induced vasodilation 
Following control responses to CGRP administration, rats were injected with 
Iodowillardiine at 10 mgkg-1 and CGRP injection was repeated after 5, 15, 30, 45, 60 
and 90 minutes. Overall, no significant effect of Iodowillardiine on CGRP induced 
vasodilation was observed.  
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Table 16: Effects of intravenous injection of Iodowillardiine 10 mgkg-1, 
Iodowillardiine 20 mgkg-1, UBP 302 50 mgkg-1, co-administration of 10 mgkg-1 
Iodowillardiine and 50 mgkg-1 UBP 302 and control vehicle on neurogenic dural 
vasodilation 
 
  
% Increase in dural vessel diameter 
 
 
Time 
point 
 
 
Iodowillardiine  
10 mgkg-1 
 
Iodowillardiine  
20 mgkg-1 
 
UBP 302  
50 mgkg-1
 
Iodowillardiin
e  
10 mgkg-1 &  
UBP 302  
50 mgkg-1 
 
 
Control 
vehicle 
 
Control 
response 
 
 
179 ± 7 
 
197 ± 25  
 
168 ± 7 
 
180 ± 14 
 
165 ± 12 
5 min 165 ± 8 178 ±24   
*(t5 = 2.7, n = 6) 
 
166 ± 7 184 ± 20 170 ± 12 
15 min 150 ± 5  
*(t5 = 7.2, n = 6) 
152 ± 17  
*(t5 = 5.2, n = 6) 
 
158 ± 3 181 ± 18 168 ± 11 
30 min 149 ± 6  
*(t5 = 9.9, n = 6) 
164 ± 17  
*(t5 = 3.1, n = 6) 
 
154 ± 5 186 ± 16 171 ±13 
45 min 151 ± 6 
*(t5 = 5.3, n = 6) 
167 ± 22  
*(t5 = 3.2, n = 6) 
 
157 ± 8 181 ± 16 170 ±10 
60 min 160 ± 4  183 ± 22  
*(t5 = 3.4, n = 6) 
 
158 ± 14 186 ± 16 164 ± 7 
90 min 165 ± 4  
*(t5 = 1.0, n = 6) 
 
181 ± 21 157 ± 13 189 ± 19 164 ± 11 
* P < 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 156
3.4 Conclusions 
 
The kainate iGluR5 selective receptor agonist Iodowillardiine was able to significantly 
attenuate NDV at doses of 10 and 20 mgkg-1 by a maximum of 50%, and this inhibition 
was blocked by pre-treatment with the selective iGluR5 receptor antagonist UBP 302. 
When the antagonist UBP 302 was administrated alone it caused no inhibition or further 
dilation of the blood vessels under investigation. These data indicate that activation of 
the iGluR5 carrying kainate receptors inhibits neurogenic vasodilation at the peripheral 
terminal of trigeminal nerve and its vasculature. Blockade of these receptors with the 
antagonist UBP 302 does not elicit any significant effects. Iodowillardiine failed to 
inhibit vasodilation induced by systemic administration of CGRP. As CGRP is likely 
acting directly on CGRP receptors on the smooth muscle of dural arteries to induce 
dural vasodilation (Williamson et al., 1997a, c), failure of Iodowillardiine to block this 
effect at concentrations that were able to inhibit significantly NDV, suggests that 
Iodowillardiine is acting at the pre-junctional site. The data are compatible with the 
existence of a pre-synaptic iGluR5 kainate receptor on trigeminovascular nerve 
terminals in the dura mater (figure 43). 
 
Although information about the presence of kainate receptors on trigeminal peripheral 
processes is not available from anatomical studies, data from this study favours the 
existence of iGluR5 kainate receptors at this site. iGluR5 receptors have been found in 
the trigeminal ganglia and on primary afferents in the spinal cord and caudal brainstem 
(Sahara et al., 1997; Hegarty et al., 2007). The trigeminal ganglion is bipolar, with its 
peripheral afferent fibres innervating the dural structures and centrally projecting to the 
TCC. The pharmacology of the peripheral and central projections of the trigeminal 
ganglion in general mirror each other; thus, work demonstrating the presence of kainate 
receptors on central primary afferents may also apply on the neuronal mechanisms 
involving the peripheral trigeminal afferents. In agreement with this, there is evidence of 
functional kainate receptors on peripheral sensory axons (Carlton et al., 1995; 
Coggeshall and Carlton, 1998; Kinkelin et al., 2000). 
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Figure 43: Overview of the effects of systemic administration of the iGluR5 kainate 
receptor agonist Iodowillardiine 
Selective activation of iGluR5 receptors was shown to result in inhibition of neurogenic 
dural vasodilation suggesting the existence of a pre-synaptic iGluR5 kainate receptor on 
trigeminovascular nerve terminals in the dura mater. ES; electrical stimulation 
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The blockade of NDV by Iodowillardiine, may involve either pre- or post-synaptic 
receptors, or both. Iodowillardiine at concentrations that were able to inhibit 
significantly NDV was unable to block dilation induced by exogenous CGRP. Due to a 
direct action of exogenous CGRP on post-synaptic CGRP receptors on the smooth 
muscle of dural arteries, it is likely that Iodowillardiine has no effect on dural vessels. 
There is no current anatomical evidence for the presence of kainate receptors on dural 
vessels, although the complete absence or expression of non-functional kainate receptors 
on cerebral vessels has been suggested (Faraci et al., 1994; Morley et al., 1998; St'astny 
et al., 2002). In addition, detection of kainate receptors on the heart and cardiac nerve 
terminals has been demonstrated but a functional role has not been shown (Gill et al., 
1998; Gill et al., 2007). Results from the present study, as shown with both the iGluR5 
kainate agonist and antagonist, support the absence of at least functional iGluR5 
carrying kainate receptors on dural vessels. 
 
Neurogenic dural vasodilation has been shown to be almost completely blocked by the 
CGRP antagonist CGRP8-37 and as such the observed dilation is due to the release of 
CGRP from the trigeminal peripheral pre-junctional site, acting on CGRP receptors on 
the vessels (Williamson et al., 1997a). The data presented in this study indicate a pre-
junctional effect for Iodowillardiine on the trigeminovascular system, probably from a 
reduction of CGRP release from peptidergic trigeminal afferents. As Iodowillardiine 
was able to reduce the degree of meningeal vasodilation by 50%, the new data suggest 
that iGluR5 activation does not completely block the presynaptic release of CGRP. The 
mechanism of Iodowillardiine activation of iGluR5 kainate receptors resulting in 
reduction of CGRP release is not known. It has been proposed that presynaptic spinal 
kainate receptors function as autoreceptors at primary afferent synapses in the dorsal 
horn (Agrawal and Evans, 1986) and Kerchner and colleagues (2001a) demonstrated 
that activation of presynaptic kainate receptors carrying the iGluR5 subunit, by specific 
agonists acting at a presynaptic locus, reduces glutamate release from primary afferent 
sensory synapses (Kerchner et al., 2001a). In our study it is possible that the selective 
iGluR5 receptor agonist Iodowillardiine inhibits transmitter release from the pre-
junctional site in a similar manner as with central primary afferents, and thus partially 
reduces CGRP release from the peripheral end of the trigeminal nerve. The absolute 
mechanism of regulation of neurotransmitter release by kainate receptors remains to be 
established (Kerchner et al., 2001a; Lerma, 2003). Previous studies on presynaptic 
kainate receptors in central brain synapses, indicate that strong activation of kainate 
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receptors leads to inhibition of glutamate release (Huettner, 2003; Lerma, 2003), 
possibly by inactivating calcium or sodium channels, or both (Kamiya and Ozawa, 
2000). As release of both glutamate and CGRP from trigeminal neurons is controlled by 
calcium channels (Xiao et al., 2008), it is likely that strong activation of kainate 
receptors, which could be achieved by systemic administration of selective agonists, 
inactivates calcium channels and reduces neurotransmitter release. Metabotropic 
mechanisms have also been suggested to play a role in central presynaptic kainate 
receptor mediated reductions neurotransmitter (Negrete-Diaz et al., 2006). In the 
hippocampus, biphasic effects of kainate receptors have been reported, showing that 
weak activation enhances neurotransmitter release, and both ionotropic and 
metabotropic mechanisms have been suggested (Kamiya, 2002; Lerma, 2003; 
Rodriguez-Moreno and Sihra, 2004). Such bidirectional effects however, have not been 
reported for pre-synaptic kainate receptors on sensory fibres. Inhibition of glutamate and 
neuropeptides release following activation of kainate receptors is in agreement with the 
proposed role of AMPA and NMDA glutamate receptors on sensory fibres (Lee et al., 
2002; Bardoni et al., 2004). The fact that blockade of the iGluR5 receptors with UBP 
302 did not cause any baseline dilation or neurogenic induced dilation changes, could 
suggest that kainate receptors at the pre-junctional site are not tonically activated, but 
when selectively activated can regulate dural vessel diameter. UBP 302 is not degraded 
in the blood, so when co-applied with Iodowillardiine it blocked the Iodowillardiine 
induced inhibition of NDV. The possibility of iGluR5 activation by endogenous 
glutamate release and subsequent regulation of glutamate and CGRP release at the 
peripheral trigeminal end cannot be excluded (deGroot et al., 2000; Huettner et al., 
2002).  
 
Since ganglionic sympathetic efferents in normal rats largely do not express kainate 
receptors (Carlton et al., 1998; Coggeshall and Carlton, 1999), it is unlikely that the 
kainate receptor agonist caused norepinephrine or vasoconstrictor peptide release in our 
experiments. The fact that NDV is not affected by either α1/α2-adrenoreceptor agonists 
and antagonists, as well as β-adrenergic antagonists further illustrates that the adrenergic 
system does not play a significant role in the pharmacology of neurogenic 
trigeminovascular responses in the dura mater (Akerman et al., 2001). Our data are 
consistent with the common feature of compounds that successfully inhibit NDV with a 
likely effect on Aδ trigeminal afferents to inhibit the release of CGRP.     
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The selectivity of the compounds used over kainate receptors has been demonstrated on 
native and recombinant kainate receptors. Iodowillardiine showed high selectivity on 
native iGluR5 dorsal root ganglia kainate receptors (EC50 140 nM) over hippocampal 
AMPA receptors (EC50 19 mM) (Wong et al., 1994) and is one of the most potent 
kainate receptor agonists defined to date. Iodowillardiine potently activates homomeric 
iGluR5 and heteromeric iGluR5/KA2 kainate receptors but shows no activity on  
homomeric iGluR6 or iGluR7 kainate receptors and only weak activity on heteromers of 
iGluR6 and 7 with KA2 (Jane et al., 1997; Swanson et al., 1998). UBP 302 
demonstrates similar affinity for homomeric and heteromeric iGluR5 kainate receptors, 
but very little affinity on iGluR6 kainate receptors (More et al., 2004). The 
demonstration that kainate receptors in trigeminal ganglia neurons are heteromeric 
iGluR5/KA2 assemblies (Sahara et al., 1997) further supports that the compounds used 
were selectively acting on iGluR5 carrying kainate receptors.   
 
Results from this study support a role of iGluR5 receptor agonists as a potential 
approach to the development of anti-migraine therapies consistent with previous work 
(Filla et al., 2002; Sang et al., 2004; Weiss et al., 2006), although suggesting other 
possible mechanisms of action, as the anti-nociceptive effects in these models in which 
kainate receptors were blocked, are more likely due to at least central actions of the 
compounds used. In a recent clinical study the highly selective kainate receptor 
antagonist LY466195 was effective in aborting migraine attacks (reported by Johnson, 
KW International Headache Research Symposium, Copenhagen 2007), as well as inhibit 
trigeminovascular activation in an animal model (Weiss et al., 2006). Consistent with 
our data LY466195 failed to inhibit NDV as well as CGRP and capsaicin-induced 
dilation (Chan et al., 2009), further suggesting that kainate receptor antagonists do not 
exhibit their anti-nociceptive effects via peripheral mechanisms. In this context anti-
nociceptive effects of iGluR5 activation have been previously reported, in which the 
iGluR5 specific agonist (RS)-2-Amino-3-(3-hydroxy-5-tert-butylisoxazol-4-
yl)propanoic acid increased the hind paw withdrawal latency to thermal and mechanical 
stimulation in rats (Wu et al., 2003).   
 
In vivo studies in which intravital microscopy techniques were used, showed that topical 
application on the cranial window of kainate or the iGluR5 specific agonist (RS)-2-
Amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid, could cause a small but 
significant dilation of the underlying dural vessels, an effect blocked by a nitric oxide 
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synthase inhibitor (Faraci et al., 1994) or by heme oxygenase (Robinson et al., 2002). 
Results from these studies suggest that kainate has no direct effect on dural blood 
vessels and that kainate-induced dilation on both dural and cerebral arterioles is due to 
the formation of nitric oxide or carbon monoxide from an extra-vascular source (Faraci 
et al., 1994; Robinson et al., 2002). In our studies both the iGluR5 receptor agonist and 
antagonist used at high doses by intravenous administration, had no effects on vessel 
dural tone at rest and their action was tested on neurogenic induced dilation, which 
involves low intensity brief electrical stimulation of the cranial window. These 
differences could be due to the different drugs used, as both UBP 302 and 
Iodowillardiine are highly selective for iGluR5 and derivatives from the same precursor, 
willardiine (Swanson et al., 1998; More et al., 2004), as well as due to the different 
technique that was applied. Furthermore, the absence of an effect on vessel tone by both 
willardiine derivatives used, is unlikely to be due to the anaesthetic as it is a well 
established regimen that has not been observed to alter blood vessel diameter or blood 
flow studies (Akerman et al., 2001; Akerman and Goadsby, 2005c; Holland et al., 
2005). Using the same anaesthesia and methods other compounds have been shown to 
affect vascular tone (Akerman et al., 2001; Akerman and Goadsby, 2005c), and this is 
usually as a consequence of blood pressure changes. These observations suggest that 
pentobarbital itself has no actions on vascular tone. 
 
Neurogenic dural vasodilation is an established model of trigeminal activation and has 
proved highly predictive of anti-migraine efficacy (Williamson et al., 1997c; 
Williamson et al., 1997b; Akerman and Goadsby, 2005b). As the method does not 
investigate the central component of the trigeminovascular system however, the efficacy 
of many anti-migraine compounds that act centrally may not be seen using this model. 
To our knowledge both the iGluR5 receptor agonist and antagonist used in our study 
have not been previously described in in vivo models and no data exists for blood-brain 
barrier penetration, although the existence of carboxylic groups on both compounds 
might suggest decreased lipophylicity of the molecules. The restricted blood brain 
barrier penetration of the agonist used, as suggested from its structure, makes it unlikely 
that the compound had any effects on central medullary nuclei that control 
cardiovascular reflexes. As NDV is based on local stimulation of peripheral trigeminal 
afferents and thus compounds that can inhibit the vasodilatory response have the 
potential to inhibit trigeminovascular nociceptive transmission at this site of action. This 
might explain the mode of action of iGluR5 receptor activation seen in the current study, 
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and this is believed to be the site of action of well characterized anti-migraine 
compounds that do not cross the blood-brain barrier (Williamson et al., 1997c). Since 
CGRP receptor antagonists are effective in acute migraine (Olesen et al., 2004b; Ho et 
al., 2008), the pharmacology of the control mechanisms for dural CGRP release by 
kainate receptors are of direct relevance to the development of newer migraine 
therapies. The intravital microscopy models, whilst helping to identify compounds that 
may be of therapeutic value in the clinic are also able to help us dissect the 
pharmacology of the trigeminovascular system, and therefore the mechanisms 
underlying migraine and the actions of therapeutic compounds. 
 
The role of kainate receptors on trigeminal afferents under normal physiological 
conditions is not known, although studies of kainate receptors on other peripheral 
sensory afferents suggest an action of these receptors in detecting normal sensory 
responses and upon their activation they participate in peripheral nociceptive 
transduction (Agrawal and Evans, 1986; Ault and Hildebrand, 1993). A similar 
mechanism might exist on trigeminal afferents. Although direct evidence from animal 
models of migraine showing increased glutamate release in the periphery following 
trigeminovascular activation do not exist, increased glutamate release is seen following 
stimulation of Aδ and C fibres from peripheral sensory neurons (deGroot et al., 2000). 
These results indicate that stimulation of Aδ and C fibres can result in peripheral release 
of glutamate, providing a major source of ligand for the glutamate receptors localised on 
peripheral primary afferents (deGroot et al., 2000). This might account for trigeminal 
afferents as well, as during migraine attacks it has been shown that glutamate and 
glutamine levels are elevated in the plasma and in the CSF (Ferrari et al., 1990; 
Martinez et al., 1993; Alam et al., 1998). Lam et al, (2009) showed that peripheral 
application of glutamate activates trigeminal nociceptive afferents innervating 
craniofascial structures and can induce peripheral sensitization, reflected by changes to 
the mechanical activation threshold. It is remained to be determined whether peripheral 
kainate receptors on trigeminal afferents could be activated by the increased levels of 
glutamate under such abnormal conditions.  
 
In conclusion, this study demonstrated that activation of the peripheral iGluR5 kainate 
receptors with the selective agonist Iodowillardiine is able to inhibit neurogenic dural 
vasodilation as monitored by intravital microscopy. This effect is likely to result from 
inhibition of pre-junctional release of CGRP from trigeminal neurons. From these data 
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kainate iGluR5 receptor agonists acting peripherally may be novel approaches to anti-
migraine therapy, although their central effects on this receptor class require further 
studies with appropriate methods and compounds. 
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Chapter 4: Pre- and post-synaptic modulation of nociceptive dural 
input to the trigeminocervical complex via the iGluR5 kainate receptor  
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4.1 Introduction 
 
Migraine pathophysiology involves activation, or the perception of activation of 
trigeminal afferents that innervate the meninges (Goadsby et al., 2002; Goadsby, 2007). 
The nociceptive inflow from the meninges to the spinal cord is relayed on second order 
neurons in the TCC, before ascending to higher brain areas.  Stimulation of dural vessels 
produces Fos immunoreactivity, as well as increased neuronal activity in the trigeminal 
nucleus caudalis and the dorsal horn at the C1 and C2 spinal cord levels. Further to the 
convergent inputs from dural structures including the MMA, second order trigeminal 
neurons also receive inputs from the ophthalmic dermatome of the cutaneous receptive 
field, and the cervical afferents innervating the neck  (Bartsch and Goadsby, 2002; 
Piovesan et al., 2003). This neural connectivity in the TCC plays a fundamental role in 
the perception of head pain, sensitivity to sensory information and allodynia of the facial 
skin seen during migraine attacks (Selby and Lance, 1960; Burstein et al., 2000; 
Goadsby et al., 2002). Thus an increased understanding of the mechanisms and the 
pharmacological profile of trigeminocervical second order neurons has major 
implications for the pathophysiology and treatment of migraine. 
 
Trigeminocervical nociceptive transmission  involves release of glutamate from primary 
afferents and there is substantial evidence that glutamate receptors are involved in 
trigeminovascular nociceptive processing (Vikelis and Mitsikostas, 2007). The presence 
of functional kainate receptors in DRG (Agrawal and Evans, 1986; Huettner, 1990), 
trigeminal ganglion (Sahara et al., 1997) and in both pre- and post-synaptic sites in 
superficial laminae of the spinal cord and caudal brainstem (Li et al., 1999; Hwang et 
al., 2001; Hegarty et al., 2007), indicate the importance of characterising their function 
in the TCC. Kainate receptors participate in post-synaptic sensory transmission in the 
spinal cord (Li et al., 1999) and regulate post-synaptic firing (Bortolotto et al., 1999) and 
pre-synaptic neurotransmitters’ release (Kerchner et al., 2002). Growing evidence has 
further illustrated activation and modulation of kainate receptors by nociceptive stimuli 
(Ruscheweyh and Sandkuhler, 2002; Wu et al., 2007). 
 
Competitive iGluR5-selective receptor antagonists were effective in reducing Fos 
expression in the TCC after stimulation of the trigeminal ganglion (Filla et al., 2002; 
Weiss et al., 2006), and along with the previous intravital study (chapter 3), the 
possibility of a central effect of kainate receptor antagonists acting directly on trigeminal 
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neurons in the TCC is raised. In the present study, we used electrophysiology in 
combination with microiontophoresis to investigate the potential in vivo effects of 
iGluR5 agents on second order neurons in the TCC, utilizing the willardiine-derived 
iGluR5 receptor antagonist UBP 302, in order to clarify to some degree the role of 
iGluR5 kainate receptors in trigeminovascular nociceptive processing (figure 44). The 
responses of neurons in the TCC were examined in relation to dural stimulation and 
nociceptive and non-nociceptive activation of the cutaneous facial receptive field.   
 
 
 
 
 
Figure 44: Electrophysiology of neurons in the trigeminocervical complex–
microiontophoresis 
Electrophysiological recordings were made from second order neurons in the 
trigeminocervical complex, which received convergent inputs from dural vessels and the 
ophthalmic dermatome of the facial skin. 
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4.2 Methods 
 
4.2.1 Animals 
 
Thirty six male Sprague-Dawley rats (300–370 g) were anesthetised with 60 mgkg-1 
pentobarbital intraperitoneally and then maintained with 10-20 mgkg-1h-1 α-chloralose 
made up with 2-hydroxy-β-cyclodextrin by intravenous injections. The surgical 
preparation was as described previously (section 2.3). Arterial blood gas parameters 
were measured regularly during the experiment and were within physiological limits.  
 
4.2.2 Drugs and microiontophoresis 
 
Seven-barrel carbon-fibre electrodes were used to deliver microiontophoretically freshly 
prepared solutions of glutamate receptor agents. For each electrode, the central barrel 
was filled with 200 mM NaCl for automated current balance. The test compounds used 
by microiontophoresis in this study were: the iGluR5 antagonist UBP 302, the 
unselective ionotropic glutamate receptors antagonist CNQX, saline control which 
represents the ejection of both Cl- and OH- ions, since the pH of the saline was adjusted 
by the addition of 0.01 M NaOH, the ionotropic glutamate agonists L-glutamate 
monosodium, Iodowillardiine, Fluorowillardiine, SYM 2081, NMDA. Pontamine sky 
blue dye was used for marking recording sites. All the iGluR tested compounds were 
chosen according to their pharmacological activity (table 17) and were ejected as anions 
and retained with small positive currents. Microiontophoretic barrels had resistances of 
9-100 MΩ.  
 
 
 
 
 
 
 
 
 
 
 168
Table 17: Characteristics of test compounds used by microiontophoresis  
SYM 2081, (2S,4R)-4-Methylglutamic acid; NMDA, N-methyl-D-aspartic acid; CNQX, -cyano-7-
nitroquinoxaline-2,3-dione; UBP 302, (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrim idine-
2,4-dione 
 
 
 
 
 
4.2.3 Experimental protocol 
 
Neurons were identified by their response to ophthalmic (V1) facial and corneal 
receptive field stimulation.  Once neurons were identified, they were tested for a stable 
response to electrical MMA stimulation and an increased firing rate to all 
microintophorised glutamate agonists, as described in section 2.11.5. Neurons were 
selected based on the above criteria.    Three baseline responses to MMA stimulation 
were collected 5 minutes apart. The glutamate agonists tested for each experiment were 
ejected in a random order and once five stable baseline cycles were recorded, then UBP 
302 or vehicle control was ejected at increasing currents (10, 20, 30, 40, 50 and 100 
 Polarity Ejection 
current (nA) 
pH Pharmacological activity 
 
 
L-glutamate 
 
(-) 25 - 65 8.0 
 
non-selective glutamate receptor 
agonist (Watkins and Jane, 2006) 
 
 
SYM 2081 
 
(-) 50 - 100 8.0 
selective iGluR5, iGluR6 kainate 
receptors ligand (Jones et al., 1997) 
 
 
Fluorowillardiine 
 
(-) 10 - 20 8.0 
selective iGluR1,2 and 4 AMPA 
receptor agonist (Jane et al., 1997) 
 
 
Iodowillardiine 
 
(-) 5 - 25 8.0 
selective iGluR5 kainate receptor 
agonist (Jane et al., 1997; Swanson 
et al., 1998) 
 
NMDA (-) 10 - 20 8.0 
selective NMDA receptor agonist 
(Watkins and Jane, 2006) 
 
 
 
CNQX 
 
 
(-) 20 8.0 
potent AMPA/kainate receptor 
antagonist (Watkins and Jane, 2006) 
and weak antagonist at the glycine 
modulatory site on NMDA receptors 
(Lester et al., 1989; Watkins and 
Jane, 2006) 
 
UBP 302 
 
(-) 
10, 20, 30, 
40, 50, 100 
 
8.0 
selective iGluR5 kainate receptor 
antagonist (More et al., 2004) 
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nA), each current applied during one individual cycle of agonists ejection. A post-
stimulus histogram was collected during each UBP 302 ejecting current and at the end 
of the 30 minutes recovery period. CNQX was applied at 20 nA over three cycles of 
glutamate agonists and a post-stimulus histogram was collected at the end of the third 
cycle. To assess the effects of the receptor antagonists on noxious and non-noxious 
stimulation of the cutaneous facial receptive field, light touch, noxious pinch and 
corneal brush were randomly applied during baseline cycles, during each UBP 302 (for 
all currents) or CNQX or vehicle control ejection and following the recovery period.  At 
the conclusion of the receptor antagonist or vehicle control ejection, receptor agonist 
cycles were continued for 30 minutes and the neuronal responses were observed.   
Upon termination of the experiment, the location of the recording site was established as 
described previously (section 2.11.6). 
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4.3 Results 
 
4.3.1 Localisation and neuronal characteristics 
 
A total of 61 units were studied from the TCC. Extracellular recordings were made from 
WDR neurons responding in a reversible excitatory manner to all glutamate agonists 
tested and to MMA electrical stimulation with latencies consistent with Aδ fibres (on 
average 8-12 ms). Overall cells were located at a depth of 489 ± 39 µm below the dorsal 
cervical spinal cord surface (figure 42). Cells tested for evoked responses to SYM 2081 
(iGluR5/6 subunit agonist; n = 35) but not to Iodowillardiine were found in laminae III-
IV. Cells tested for evoked responses to Iodowillardiine (iGluR5 agonist; n = 31) with or 
without evoked responses to SYM 2081 were found in superficial laminae (II-III).  
neuronal subpopulations did not elicit any differences in their response probability to 
MMA or receptive field stimulation (P ≥ 0.32). Thus, no further analysis was contacted 
to further investigate these subpopulations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45:  Localisation of recording sites within the trigeminocervical complex 
A. Reconstruction of recording sites within the C1 spinal cord level, plotted after 
Paxinos and Watson (1997), indicating recording sites identified histologically (solid 
circles) and by microdrive readings (open circles). A photomicrograph demonstrating a 
recording site marked by ejection of pontamine sky blue (arrow) is shown. B. An 
original trace showing a cluster of cells in the TCC, firing in response to stimulation of 
the MMA. * stimulus artefact 
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4.3.2 Effect of iGluR5 kainate receptor antagonist UBP 302 on trigeminocervical 
neurons 
 
The effects of UBP 302 at currents 10, 20, 30, 40, 50 and 100 nA were tested on a total 
of 27 WDR trigeminovascular neurons, and compared to the effects of saline at the same 
currents and duration (n = 15). The main body of the response to MMA stimulation was 
found to have a latency of 10-20 ms following the stimulus, representing Aδ fibres. 
 
Effect of UBP 302 on middle meningeal artery-evoked stimulation 
 
UBP 302 produced a differential response when microintophorised into the TCC. It 
significantly inhibited in a dose dependent manner evoked firing to MMA stimulation in 
15 out of 27 neurons (F3,35 = 13.70; P < 0.001; figure 46). The maximum recorded 
inhibition of 69% (t12 = 7.57; P < 0.001) was obtained at the highest ejection current of 
100 nA. In 12 of the 27 neurons tested evoked responses to MMA stimulation were 
significantly facilitated (F7,39 = 6.74; P < 0.001; figure 46). In some cases further to the 
facilitation observed from the Aδ fibres inputs, a decrease in the threshold to C fibre 
activation was also observed during application of UBP 302. The firing returned to 
baseline within 30 minutes in both groups (figure 46). Vehicle control ejection had no 
effect (n = 15; F4,50 = 0.46, P = 0.75). 
 
Based on the responses of the two groups of cells to UBP 302 ejection, these units were 
further analysed separately and will be referred to as the inhibitory group and 
facilitatory group.  
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Figure 46: Effect of microiontophoretically administered UBP 302 on middle 
meningeal artery evoked firing  
Ejection of UBP 302 produced two opposing responses. A. In 15 units ejection of UBP 
302 demonstrated a dose dependent inhibition of the cell firing, maximally at 100 nA 
(inhibitory group). C. In 12 neurons UBP 302 significantly potentiated cell firing 
(facilitated group). Control vehicle had no effect. B, D. Post-stimulus histograms from a 
representative cluster of neurons in the two groups, recorded before UBP 302 ejection, 
during ejection of UBP 302 at 100 nA, and 30 minutes after the cessation of ejection. * 
P < 0.05 
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Effect of UBP 302 on glutamate receptor agonist evoked activity 
 
For all agonists tested there was no difference across the mean firing of the five repeated 
epochs recorded during baseline (L-glutamate: n = 33, F3,83 = 1.90, P = 0.14; 
Fluorowillardiine: n = 25, F2,40 = 0.34, P = 0.68; SYM 2081: n = 33, F2,78 = 2.08, P = 
0.12; Iodowillardiine: n = 26, F3,78 = 0.24, P = 0.88; NMDA: n = 6, F4,20  = 1.68, P = 
0.20) and all responses were highly reliable (Cronbach’s α ≥ 0.95). 
 
The effect of UBP 302 on Fluorowillardiine evoked firing was tested in 17 units and 
UBP 302 failed to inhibit significantly neuronal firing across time (F4,54 = 1.99; P = 
0.12; figure 47). Saline control ejections produced no significant effects across the 
pulses of Fluorowillardiine (n = 8; F2,16 = 0.52, P = 0.63). Based on the MMA 
stimulation evoked responses recorded during UBP 302 application, as previously 
described, 12 of the units were clustered in the inhibitory group and 5 were clustered in 
the facilitatory group. Neurons in both groups exhibited similar responses to UBP 302 
ejection and there was no significant difference between these units (independent t test: 
inhibitory group vs facilitatory group; P ≥ 0.41; table 18). 
 
All neurons which displayed NMDA-evoked firing were grouped in the inhibitory 
group. UBP 302 (n = 6; F3,13 = 2.75, P = 0.09) or control (n = 6; F2,9 = 1.36  , P = 0.30) 
did not alter firing in response to NMDA.   
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Figure 47: Effects of microiontophoretically delivered UBP 302 on the firing rates 
of second order neurons to pulsed ejections of the agonists L-glutamate, 
Iodowillardiine, Fluorowillardiine, NMDA and SYM 2081 
A.  Example of the effects of UBP 302 on the firing rates to pulsed ejections of 
Fluorowillardiine, Iodowillardiine and NMDA. Cell firing in response to the ejected 
agonists returned to baseline levels within 30 min after UBP 302 microiontophoresis 
ceased. B-F. Comparison of the current response curves for UBP 302 and control (Cl- 
and OH-) on Iodowillardiine (B), SYM 2081 (C), L-glutamate (D), Fluorowillardiine (E) 
and NMDA (F) evoked responses. B-D. Cell firing in response to Iodowillardiine (n = 
19), SYM 2081 (n = 18) and L-glutamate (n = 18) was significantly inhibited by 
microiontophoretically administered UBP 302. E-F. Cell firing in response to 
Fluorowillardiine (n = 17) and NMDA (n = 6) was unaffected by microiontophoretically 
delivered UBP 302. Vehicle control had no significance on any agonist-evoked firing. * 
P < 0.05  
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Table 18: Effects of UBP 302 on the responses to Fluorowillardiine-evoked firing 
on the neurons of the inhibitory and facilitatory groups   
Comparison of the UBP 302 effects at different currents on neurons clustered in the 
inhibitory group and the facilitatory group. Neurons in both groups were not 
significantly sensitive to microiontophoretically administered UBP 302 and there was no 
difference between the two groups. Data are presented as the mean firing in percentage 
(± standard error of the mean) of baseline firing.  
 
 
 
 
UBP 302 reversibly and significantly inhibited trigeminal firing in response to 
microintophorised Iodowillardiine and demonstrated dose dependency (n = 19; F3,40 =  
16.22; P < 0.001; figure 47). The inhibition reached its maximum at the higher ejection 
current of 100 nA (figure 47). Overall in all 19 units tested, UBP 302 significantly 
decreased the firing rate at 20, 30, 40, 50 and 100 nA (P < 0.05 for 30 nA; P < 0.01 for 
20, 40 and 50 nA; P < 0.001 for 100 nA), while cell firing in response to control ejection 
of control produced no significant effects across the pulses of Iodowillardiine (n = 7; 
F1,2 = 1.0, P = 0.42). Iodowillardiine evoked firing returned to baseline 15-30 minutes 
after UBP 302 ejection ceased. Based on the responses of the MMA evoked activity to 
UBP 302, 9 units displayed inhibitory responses and 10 were clustered in the facilitatory 
group. Iodowillardiine evoked firing was inhibited by UBP 302 in both groups during 
UBP 302 ejection and there was no significance between the two groups (independent t 
test: inhibitory group vs facilitatory group; P ≥ 0.41; table 19).  
 UBP 302 doses 
 10 nA 20 nA 30 nA 40 nA 50 nA 100 nA 
 
Inhibitory group (n = 12) 
(paired t test vs baseline) 
 
91± 10%  
(t11  = 0.86;  
P = 0.41) 
 
78 ± 12% 
(t11  = 1.73;  
P = 0.11)  
 
92 ± 17% 
(t11  = 0.50;  
P = 0.63) 
 
74 ± 12%  
(t11  = 2.80;  
P = 0.02) 
 
79 ± 13% 
(t11  = 1.97;  
P = 0.07) 
 
71 ± 11% 
(t11  = 3.25;  
P = 0.01) 
 
Facilitatory group (n = 5) 
(paired t test vs baseline) 
113 ± 22% 
(t4  = 1.13;  
P = 0.32) 
82 ± 17%  
(t4  = 0.73; 
 P = 0.95) 
74 ± 6% 
(t3  = 4.41;  
P = 0.02) 
72 ± 18% 
(t3  = 0.52;  
P = 0.64) 
81 ± 17% 
(t3  = 0.91;  
P = 0.43) 
66 ± 20% 
(t3  = 0.77;  
P = 0.50) 
 
 
independent t test 
(inhibitory vs 
facilitatory) 
 
 
t(15) = 0.85; 
 P = 0.41 
 
t(15) = 0.25;  
P = 0.81 
 
t(14) = 0.44; 
 P = 0.67 
 
t(14) = 0.11; 
 P = 0.92 
 
t(14) = 0.001;  
P = 1.0 
 
t(14) = 0.33; 
 P = 0.97 
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Table 19: Effects of UBP 302 on the responses to Iodowillardiine evoked firing on 
the neurons of the inhibitory and facilitatory groups   
Comparison of the UBP 302 effects at different currents on neurons clustered in the 
inhibitory group and the facilitatory group. Neurons in both groups were significantly 
inhibited by microiontophoretically administered UBP 302 at all currents. Data are 
presented as the mean firing in percentage (± standard error of the mean) of baseline 
firing. 
 
 
 
 
SYM 2081 evoked firing was reversibly reduced by UBP 302 in a dose dependent 
manner (n = 18; F3,46 =  9.15; P < 0.001; figure 47) and in a related way as with 
Iodowillardiine evoked activity, especially at high currents (independent t test 
Iodowillardiine vs SYM 2081: P > 0.05). In all 18 units tested, UBP 302 significantly 
decreased the firing rate at 40, 50 and 100 nA (P < 0.05 for 40, 50 and 100 nA). Saline 
control ejection had no effects on SYM 2081 evoked firing (n = 15; F2,19 = 1.78; P = 
0.20). UBP 302 reduced firing in both inhibitory (n = 9) and facilitatory (n = 9) grouped 
cells with no significant difference between the two groups (table 20). 
 
 
 
 
 
 
 UBP 302 doses 
 10 nA 20 nA 30 nA 40 nA 50 nA 100 nA 
 
Inhibitory group (n = 9) 
(paired t test vs baseline) 
 
63  ± 9%  
(t8  = 3.05; 
 P < 0.05) 
 
49 ± 13% 
(t8  = 3.06;  
P < 0.05)  
 
46 ± 12% 
(t8  = 3.49;  
P < 0.01) 
 
40 ± 12%  
(t8  = 3.76;  
P < 0.01) 
 
52 ± 11% 
(t7  = 2.97;  
P < 0.05) 
 
24 ± 8% 
(t7  = 4.98; 
P < 0.01) 
 
Facilitatory group (n = 10) 
(paired t test vs baseline) 
86 ± 6% 
(t9  = 2.86;  
P < 0.05) 
73 ± 8%  
(t9  = 3.37;  
P < 0.01) 
65 ± 11%  
(t9  = 3.41;  
P < 0.01) 
59 ± 9% 
(t9  = 4.56;  
P < 0.01) 
52 ± 9% 
(t8  = 4.73;  
P < 0.01) 
30 ± 9% 
(t8  = 6.38;  
P < 0.001) 
 
independent t test 
(inhibitory vs facilitatory) 
t(11) = 0.05; 
 P = 0.96 
t(17) = 0.59; 
P = 0.57 
t(17) = 0.35; 
 P = 0.73 
t(13) = 0.52; 
 P = 0.61 
t(15) = 0.85; 
 P = 0.41 
t(15) = 0.59; 
 P = 0.57 
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Table 20: Effects of UBP 302 on the responses to SYM 2081-evoked firing on the 
neurons of the inhibitory and facilitatory groups   
Comparison of the UBP 302 effects at different currents on neurons clustered in the 
inhibitory group and the facilitatory group. Neurons in both groups were significantly 
inhibited by microiontophoretically administered UBP 302 at 40, 50 and 100 nA. Data 
are presented as the mean firing in percentage (± standard error of the mean) of baseline 
firing. 
 
 
 
 
 
 
 
L-glutamate evoked firing was significantly decreased by UBP 302 ejection (n = 18; 
F3,40 = 3.64; P < 0.05; figure 47). The antagonist was able to reduce significantly and 
reversibly the probability of neuronal firing in response to L-glutamate ejection when 
compared to control (P < 0.05 for 20 and 40 nA; P < 0.001 for 50 and 100 nA). UBP 
302 was able to reduce firing on both inhibitory and facilitatory grouped cells in a 
similar fashion (independent t test: inhibitory group vs facilitatory group: P > 0.05 for 
10, 30, 40, 50 and 100 nA; P < 0.05 for 20 nA; table 21). Compared to baselines, cells 
clustered in the inhibitory group were significantly inhibited by UBP 302 at all currents, 
whereas neurons clustered in the facilitatory group were significantly inhibited by UBP 
302 only at higher currents (table 21).  Microintophorised controls did not affect cell 
firing in response to L-glutamate ejection (n = 15; F3,35 = 2.01, P = 0.13). 
 
 
 
 
 
 UBP 302 doses 
 10 nA 20 nA 30 nA 40 nA 50 nA 100 nA 
 
Inhibitory group (n = 9) 
(paired t test vs baseline) 
 
100  ± 13%  
(t8  = 0.90; 
 P = 0.39) 
 
76 ± 19% 
(t8  = 1.08;  
P = 0.31)  
 
69 ± 26% 
(t8  = 1.17;  
P = 0.28) 
 
39 ± 10%  
(t8  = 2.94;  
P < 0.05) 
 
35 ± 8% 
(t8  = 3.28;  
P < 0.05) 
 
24 ± 7% 
(t8  = 3.92; 
P < 0.05) 
 
Facilitatory group (n = 9) 
(paired t test vs baseline) 
91 ± 12% 
(t8  = 0.65;  
P = 0.54) 
82 ± 11%  
(t8  = 1.45;  
P = 0.19) 
81 ± 9%  
(t8  = 1.52;  
P = 0.17) 
72 ± 9% 
(t8  = 3.03;  
P < 0.05) 
56 ± 10% 
(t8  = 4.76;  
P < 0.05) 
45 ± 12% 
(t8  = 4.90;  
P < 0.05) 
 
independent t test 
(inhibitory vs facilitatory) 
 
t(16) = 0.62; 
 P = 0.55 
t(16) = 0.84; 
 P = 0.42 
t(16) = 0.98; 
 P = 0.34 
t(16) = 2.44; 
 P < 0.05 
t(16) = 1.95; 
 P = 0.69 
t(16) = 1.80; 
 P = 0.91 
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Table 21: Effects of UBP 302 on the responses to L-glutamate-evoked firing in the 
inhibitory and facilitatory groups 
Comparison of the UBP 302 effects at 10, 20, 30, 40, 50 and 100 nA on neurons 
clustered in the inhibitory group and the facilitatory group. Neurons in the inhibitory 
group were significantly inhibited by microiontophoretically administered UBP 302 at a 
variety of currents. Neurons in the facilitatory group were significantly inhibited only at 
high currents compared to baseline; however there was no difference between the two 
groups. Data are presented as the mean firing in percentage (± standard error of the 
mean) of baseline firing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBP 302 doses 
 10 nA 20 nA 30 nA 40 nA 50 nA 100 nA 
 
Inhibitory group (n = 9) 
(paired t test vs baseline) 
 
65  ± 12%  
(t8  = 3.53; 
 P <0.05) 
 
69 ± 25% 
(t8  = 2.54;  
P < 0.05)  
 
59 ± 21% 
(t8  = 2.10;  
P = 0.07) 
 
58 ± 28%  
(t8  = 2.59;  
P < 0.05) 
 
37 ± 14% 
(t7  = 3.86;  
P < 0.05) 
4 
22 ± 10% 
(t7  = 4.95; 
P < 0.05) 
 
Facilitatory group (n = 9) 
(paired t test vs baseline) 
101 ± 18% 
(t8  = 0.32;  
P = 0.76) 
69 ± 16%  
(t8  = 1.42;  
P = 0.19) 
83 ± 26%  
(t8  = 1.75;  
P = 0.12) 
70 ± 23% 
(t8  = 2.20;  
P = 0.06) 
26 ± 6% 
(t8  = 5.46;  
P < 0.05) 
38 ± 17% 
(t8  = 3.81;  
P < 0.05) 
 
independent t test 
(inhibitory vs facilitatory) 
t(16) = 1.82; 
 P < 0.05 
t(10) = 2.29; 
 P = 0.15 
t(16) = 1.57; 
 P = 0.15 
t(16) = 1.71; 
 P = 0.11 
t(12) = 1.34; 
 P = 0.21 
t(10) = 2.12; 
 P = 0.06 
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Effect of UBP 302 on receptive fields 
 
The effects of UBP 302 on responses to innocuous (brush) and noxious (pinch and 
corneal brush) mechanical stimulation of the V1 facial cutaneous receptive field were 
tested in 26 WDR neurons (figure 48). Based on the responses of the MMA evoked 
activity to UBP 302 14 of the neurons recorded were clustered in the inhibitory group 
and 12 were clustered in the facilitatory group, and neurons were analysed separately 
based on their group. 
 
Microiontophoretic ejection of UBP 302 had no effect on firing rate in response to non-
noxious stimulation of the V1 ophthalmic cutaneous area (n = 26; F2,53 = 2.35, P = 0.10) 
and there was no difference between the inhibitory and facilitatory groups (P ≥ 0.07).  
 
UBP 302 significantly reduced in a dose-dependent manner evoked firing to both pinch 
and corneal brush stimulation in all neurons clustered in the inhibitory group (pinch: 
F3,30 = 11.09, P < 0.001; corneal: F3,31 = 10.16, P < 0.001), and noxious stimulation 
evoked firing returned to baseline within 30 minutes after the occlusion of UBP 302 
ejection. Evoked responses to noxious stimuli were unchanged by UBP 302 in the cells 
that exhibited facilitation of the MMA (pinch: F7,36 = 0.76, P = 0.53; corneal: F3,61 = 
1.03, P = 0.38). For both responses to pinch and corneal stimulation, there was a 
significant difference between the inhibitory and facilitatory groups (P < 0.05).  
 
Vehicle control ejection at the same currents and duration did not change the firing rate 
evoked by innocuous (F3,34 = 1.05; P = 0.39) and noxious (pinch: F7,37 = 0.62; P = 0.63; 
corneal: F2,24  = 1.16; P = 0.34) stimulation of receptive field. 
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Figure 48: Effects of microiontophoretically delivered UBP 302 on the firing rates 
of second order neurons in response to receptive field characterisation 
A. Cell firing in response to light brush was inhibited by UBP 302 at low currents in the 
inhibitory group. C, E Cell firing in response to pinch (C) and to corneal stimulation (E) 
were significantly inhibited by UBP 302 in the inhibitory group, but noxious evoked 
responses to both pinch and corneal stimulus was unchanged by UBP 302 in the 
facilitatory group. Control ejection at the same currents and duration did not change the 
firing rate evoked by innocuous and noxious stimulation of receptive field. Data 
represent the mean firing in percentage (± standard error of the mean) of baseline firing. 
* P < 0.05  
B, D, F.  Example of the effects of UBP 302 on the firing rates to light brush (B), pinch 
(D) and corneal brush (F) from a representative neuron clustered in the inhibitory group. 
Cell firing returned to baseline levels within 30 min after UBP 302 microiontophoresis 
stopped. Break lines indicate the period during which cell firing in response to 
stimulation of the middle meningeal artery and to ejected glutamate agonists was tested.  
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4.3.3 Effects of CNQX on trigeminocervical neurons 
 
To test if the facilitatory effects of UBP 302 were due to unselective binding of UBP 
302 to other iGluR subunits, the unselective iGluR antagonist CNQX was 
microintophorised on WDR neurons that displayed increased firing rate in response to 
random ejection of L-glutamate, NMDA and SYM 2081 and received inputs from the 
dura mater after electrical stimulation of the MMA. Due to the high potency of CNQX, 
the antagonist was microejected at a current of 20 nA over three repeated cycles of the 
agonists. The effects of CNQX were tested on a total of 10 neurons, and compared to the 
effects of saline at the same current and duration (n = 9). 
 
 
Effect of CNQX on middle meningeal artery-evoked stimulation 
 
Application of CNQX resulted in significant inhibition of MMA electrical stimulation to 
43 ± 13% compared to baseline levels (n = 10; t9 = 3.97; P < 0.005) and control (t16 = 
4.21; P < 0.005), and this effect was ubiquitous among all cells (figure 49). Control 
ejection at the same duration did not affect responses to MMA stimulation (n = 9; F2,16 = 
0.74, P = 0.49).  
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Figure 49: Effect of microiontophoretically administered CNQX on middle 
meningeal artery evoked firing 
A. Ejection of CNQX significantly inhibited cell firing in response to MMA stimulation, 
returning to baseline 30 minutes after CNQX ejection stopped. Vehicle control had no 
effect. B. Post-stimulus histograms from a representative neuron. The post stimulus 
histograms were recorded before CNQX ejection, during ejection of CNQX and 30 
minutes after ejection. * P < 0.05 
 
 
 
 
 
Effect of CNQX on glutamate agonists-evoked activity 
 
The baseline responses to glutamate receptor agonist application demonstrated good 
stability and there was no difference across the mean firing of the five repeated epochs 
(L-glutamate: n = 19, F3,46 = 1.62, P = 0.20; NMDA: n = 19, F4,72 = 0.53, P = 0.72; SYM 
2081: n = 19, F2,32 = 0.26, P = 0.75). Responses for all the glutamate agonists across 
time demonstrated significant reliability (Cronbach’s α ≥ 0.92). 
 
Cell firing in response to L-glutamate, SYM 2081 and NMDA was significantly reduced 
by CNQX and due to the increasing inhibition that CNQX produced during each cycle, 
each one of the three cycles was analysed individually (figure 50). CNQX inhibited L-
glutamate evoked responses to 16 ± 9% (t7 = 5.50, P < 0.005) and abolished SYM 2081 
evoked firing (t7 = 4.21, P < 0.005). NMDA evoked firing was significantly reduced to a 
lesser degree than to L-glutamate and SYM 2081 (F4,28 = 10.96, P < 0.001). Ejection of 
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Cl- and OH- ions at the same current as the CNQX, had no significant effect on 
glutamate receptor agonist evoked firing (n = 9; P ≥ 0.12). 
 
 
 
 
 
 
Figure 50: Effects of microiontophoretically delivered CNQX on the firing rates of 
second order neurons to pulsed ejections of the glutamate receptor agonists L-
glutamate, NMDA and SYM 2081 
 A.  Example of the effects of CNQX on the firing rates to pulsed ejections of the L-
glutamate, Iodowillardiine and SYM 2081. Cell firing in response to the ejected agonists 
returned to baseline levels within 30 min after CNQX microiontophoresis ceased. B-E. 
Effects of CNQX on cell firing in response to L-glutamate (B), SYM 2081 (C) and 
NMDA (D), separately for each cycle. CNQX strongly inhibited L-glutamate (n = 8) and 
SYM 2081(n = 8) evoked firing. NMDA-evoked firing (n = 8) was significantly reduced 
to a lesser degree compared to L-glutamate and SYM 2081. Ejection of control (n = 9) 
had no significant effects on glutamate agonists-evoked firing. * P < 0.05 
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Effect of CNQX on receptive fields 
 
CNQX significantly inhibited both non-noxious receptive fields to 24 ± 7% (t9 = 2.9; P 
< 0.05) and pinch (noxious) evoked firing to 40 ± 9% (t9 = 5.7; P < 0.005) and to a 
lesser degree noxious corneal mechanical stimulation 45 ± 17% (t4 = 2.72; P = 0.053; 
figure 51). No facilitation was observed on any of the neurons tested with CNQX. 
Ejection of control did not produce any inhibition (n = 9; P ≥ 0.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Effects of microiontophoretically delivered CNQX on the firing rates of 
second order neurons to receptive field characterisation 
 A-C. Comparison of the current-response charts for CNQX and saline on the cell firing 
in response to light brush (A), pinch (B) and corneal (C). CNQX significantly inhibited 
both non-noxious and noxious pinch receptive field and to a lesser degree noxious 
corneal mechanical stimulation. No inhibition was observed during ejection of control. * 
P < 0.05 
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4.4 Conclusions 
 
The current study provides evidence that kainate receptors in the TCC can regulate 
trigeminovascular transmission, probably pre- and post- synaptically, and this is the first 
study, to our knowledge, to suggest a pre-synaptic modulatory role for spinal kainate 
receptors at the level of individual neurons in vivo. By using specific agonists the study 
demonstrated the presence of post-synaptic kainate receptors in the TCC. Selective 
antagonism of iGluR5 receptors was shown to result in inhibition of trigeminovascular 
processing in some synaptic locations, which was also accompanied by inhibition of cell 
firing in response to noxious mechanical stimulation of the ophthalmic cutaneous 
receptive field (figure 52). In a further neuronal subpopulation, ejection of the selective 
receptor antagonist UBP 302 facilitated trigeminovascular processing, perhaps by 
differentially targeting iGluR5 receptors at pre-synaptic locations (figure 52). In contrast 
to the dual effects of UBP 302, application of CNQX resulted only in inhibition of 
nociceptive transmission in the TCC.  
 
 
 
 
 
 
Figure 52: Overview of the effects of microintophorised UBP 302 on second order 
trigeminovascular neurons 
Selective antagonism of iGluR5 receptors was shown to result in inhibition of 
trigeminovascular processing in some synaptic locations (A), and in facilitation of 
trigeminovascular processing in a different neuronal subpopulation (B). 
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By using selective receptor agonists and the selective iGluR5 receptor antagonist UBP 
302, the study has demonstrated the presence of post-synaptic kainate receptors in the 
TCC and particularly the presence of functional iGluR5 kainate receptors. Recent 
anatomical evidence, demonstrated the presence of different kainate subunit mRNA in 
cultured spinal neurons  (Dai et al., 2002) and the localisation of all subunits at both pre- 
and post- synaptic sites in the rat dorsal horn by confocal and electron microscopy (Lu 
et al., 2005). Further to the latest anatomical studies, our data are in agreement with 
electrophysiological evidence showing activation of spinal cord neurons by kainate (Li 
et al., 1999; Kerchner et al., 2001a). The present evidence of selective activation of 
iGluR5 receptors in dorsal horn neurons is in contrast to studies implying that kainate 
receptors in the spinal cord were predominantly insensitive to the iGluR5 agonist ATPA 
(Kerchner et al., 2001a). It is possible that prolonged activation of kainate receptors as 
described in Kerchner’s study (2001a), converts agonist actions into antagonist effects 
(Chittajallu et al., 1999). In our studies, we used the receptor agonist Iodowillardiine 
which has a higher selectivity over iGluR5 subunits than ATPA (Swanson et al., 1998) 
and for the microejection period used no desensitisation was observed. As shown in 
dorsal horn neurons from iGluR5 or iGluR6 knockout mice, the iGluR5 subunit is 
expressed in these neurons and probably forms heteromeric assemblies with the iGluR6 
subunit (Kerchner et al., 2002). Consistent with the anatomical evidence on the presence 
of kainate receptors, reconstruction of the recording sites in our studies provided 
evidence for the presence of iGluR5/6 subunits in superficial laminae of the TCC. In our 
studies, in experiments in which only SYM 2081 (iGluR5/6 agonist) was used as a 
kainate agonist- in addition to the NMDA and AMPA agonists or L-glutamate used, 
cells with evoked responses to SYM 2081 were mainly found in laminae III-V. In 
experiments in which Iodowillardiine was used as a kainate agonist (iGluR5 agonist), 
cells with evoked responses to Iodowillardiine were found in more superficial laminae. 
In consideration of the laminae localisation of the iGluR5-preferentially activated 
neurons, it is plausible that iGluR5 receptors could be found mostly in superficial 
laminae (inner lamina II and III). However the fact that cells activated by SYM 2081 
were found at a greater depth (laminae III-V) indicates that the kainate evoked responses 
from these neurons could at least partly count for iGluR5/6 kainate receptors and not 
exclusively for the iGluR5 subunit. However, the experimental methods do not allow for 
a quantitative analysis of the presence of different subunits. These subpopulations did 
not elicit any differences in their response probability to MMA or receptive field 
stimulation (P ≥ 0.32) and equally inhibitory and facilitatory responses were recorded 
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from these neurons. Thus, no further analysis was contacted to further investigate these 
subpopulations. 
 
The selectivity of UBP 302 for iGluR5 kainate receptors over AMPA and NMDA 
receptors was proven by its failure to block Fluorowillardiine-evoked firing in the same 
neurons where responses to kainate agonists’ were inhibited. Further to the blockade of 
kainate receptor evoked firing, UBP 302 was able to block partially L-glutamate evoked 
responses suggesting that kainate receptors carrying the iGluR5 subunit could possibly 
participate in the generation of post-synaptic currents (Lee et al., 1999; Li et al., 1999; 
Kerchner et al., 2001a). The inhibition of the noxious stimulation evoked firing is 
possibly produced by the post-synaptic inhibition of iGluR5 kainate receptors on these 
neurons.  Whole-cell currents in dorsal horn neurons are significantly reduced in iGluR6 
knockout mice, suggesting a prominent role for this subunit in the assembly of 
functional kainate receptors that also include the iGluR5 subunit (Kerchner et al., 2002). 
In the current study blockade of the iGluR5 kainate receptor in a subpopulation of 
neurons, reduced post-synaptic firing in response to trigeminovascular activation, 
suggesting an important contribution of the iGluR5 subunit in post-synaptic sensory 
neurotransmission on second order neurons, at least at the level of TCC.    
 
It has been shown that high intensity, low frequency stimulation of the dorsal root nerve, 
which is sufficient to activate Aδ and C fibres, activates post-synaptic kainate receptors 
on spinal dorsal horn neurons. In contrast, low intensity stimulation that activates only 
non-nociceptive primary fibres is insufficient (Li et al., 1999). This suggests that kainate 
receptors are post-synaptically placed, largely at synapses that receive inputs from 
nociceptive primary afferent fibres, although an opposing study showed no significant 
contribution of kainate receptors to C fibre-evoked excitatory post-synaptic currents 
(Dahlhaus et al., 2005). In our study, in the same subpopulation of neurons where 
trigeminovascular activation was inhibited by UBP 302, the iGluR5 selective antagonist 
preferentially inhibited noxious over non-noxious receptive field responses. This may 
further support the hypothesis that innocuous sensory transmission is not mediated by 
iGluR5 kainate receptors on WDR neurons in the TCC.  
 
Interestingly, the iGluR5 receptor selective antagonist in addition to the inhibition of 
trigeminovascular activation also facilitated trigeminovascular processing in a subset of 
neurons.  These facilitated responses were accompanied by reduction in responses to 
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selective kainate receptor agonists, while responses of the same neurons to 
Fluorowillardiine were unaffected. As the post-synaptic kainate evoked currents were 
inhibited by UBP 302, it is unlikely that the observed facilitation was due to non-
binding modality phenomena of the UBP 302. The post-synaptic inhibition of 
Iodowillardiine/SYM 2081-evoked firing further suggests that the observed facilitation 
was due to post-synaptic activation of other excitatory receptors, by pre-synaptically 
released excitatory neurotransmitters. The increased released of excitatory 
neurotransmitters has likely occurred during noxious stimulation, and thus UBP 302 
failed to inhibit noxious evoked firing in these neurons. The classical iGluR receptor 
antagonist CNQX produced only inhibition of cell responses to glutamate receptor 
agonists, receptive field mechanical stimulation and MMA electrical stimulation, so it is 
unlikely that the facilitatory effects of UBP 302 were due to unselective actions of the 
antagonist on other iGluR receptors.  
 
It has been shown that iGluR5 subunits are expressed in the trigeminal ganglion (Sahara 
et al., 1997) and iGluR5 subunits are pre-synaptically located on primary afferents in the 
dorsal spinal cord, as well as on GABAergic interneuronal terminals (Lu et al., 2005). 
Although multiple mechanisms by which kainate receptors modulate cerebral 
neurotransmission have also been described (Kullmann, 2001), it is believed that in the 
spinal cord pre-synaptic kainate receptors on primary afferents act as autoreceptors and 
occlude further glutamate release when activated (Kerchner et al., 2001a) (figure 19). 
When kainate heteroreceptors on GABAergic terminals are activated by glutamate 
spillover from neighbouring excitatory synapses they occlude GABA/glycine release via 
a complex mechanism which involves activation of GABAB autoreceptors (Kerchner et 
al., 2001b) (figure 19), and thus promote a possible pro-nociceptive mechanism in the 
spinal cord. Based on the in vitro observations by Kerchner and his colleagues (2002), 
the facilitation observed in a subpopulation of trigeminovascular neurons by antagonism 
of iGluR5 kainate receptor is more likely to be due to blockade of pre-synaptic kainate 
autoreceptors, resulting in enhanced glutamate release in response to electrical 
stimulation of the Aδ and C fibres surrounding the MMA. The released glutamate could 
then act on “non-kainate” GluRs, resulting in facilitated sensory transmission. Given 
that in these neurons post-synaptic kainate evoked firing was reduced by UBP 302, it is 
also likely that post-synaptic iGluR5 kainate receptors do not mediate sensory  
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Figure 53: Proposed mechanism of action of microintophorised UBP 302 on 
trigeminovascular activation 
A. During baseline electrical stimulations of the middle meningeal artery, activation of 
primary afferents innervating the adjacent dura causes glutamate release. Glutamate 
activates post-synaptic kainate receptors in addition to AMPA and NMDA receptors 
activation, promoting nociceptive transmission from second order neurons in the 
trigeminocervical complex. Pre-synaptic kainate receptors on primary afferents could be 
activated by glutamate and control glutamate release, whereas activation of kainate 
receptors on inhibitory interneurons is also possible. B. Local application of UBP 302 
by microiontophoresis can selectively block post-synaptic kainate receptors and inhibit 
nociceptive transmission, whereas blockade of pre-synaptic kainate receptors might not 
occur, or its effects are less important. C.  Local application of UBP 302 by 
microiontophoresis can selectively block post-synaptic kainate receptors. In addition 
blockade of pre-synaptic kainate receptors might inhibit the negative control feedback of 
glutamate release by kainate receptors. This results in increased glutamate release, 
which by acting on a bigger scale on AMPA and NMDA receptors facilitates 
nociceptive transmission. Further more it is also possible that post-synaptic iGluR5 
kainate receptors do not mediate sensory transmission in all second order neurons. 
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transmission in all second order neurons. With the current known action of kainate 
receptors on inhibitory interneurons, it is unlikely to explain the observed facilitation as 
a plausible action of UBP 302 on kainate heteroreceptors (figure 53).   
 
The role of kainate receptors in trigeminovascular processing has been relatively 
obscure due to the lack of selective antagonists. Although it has been shown that the so 
called non-NMDA receptors are involved in trigeminocervical activation (Mitsikostas et 
al., 1999; Storer and Goadsby, 1999), kainate receptors have only recently been linked 
with migraine headache (Filla et al., 2002; Weiss et al., 2006). Inhibition of neurons that 
modulate sensory input in the TCC is a plausible target for the development of anti-
migraine compounds. The inhibition of trigeminovascular neurons from both UBP 302 
and the classical AMPA/kainate antagonist CNQX are in agreement with the positive 
clinical results from the use of  the AMPA/kainate receptor antagonist LY293558 (Sang 
et al., 2004) and the iGluR5 selective antagonist LY466195 (oral presentation by 
Johnson KW, International Headache Research Seminar, Copenhagen, 25 March 2007). 
However, the facilitated trigeminovascular processing observed in some neurons raises 
the question of whether the TCC is the site of action of the clinically active kainate 
compounds. The presence of kainate receptors in other brain structures involved in 
migraine pathophysiology (Binns et al., 2003; Eyigor et al., 2005), raises the possibility 
that the clinical actions may be on other brain areas or might reflect the sum of 
responses in the TCC and/or of responses in other structures.   
 
Results from the current study provide evidence for the regulation of trigeminovascular 
transmission by both post- and pre- synaptic kainate receptors and indicate a modulatory 
role of kainate receptors in trigeminovascular nociceptive processing, at the level of 
TCC. Differential activation of kainate receptors defines novel roles of this receptor in 
pro- and anti- nociceptive mechanisms in the TCC. 
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Chapter 5: Modulation of nociceptive dural input to the 
ventroposteromedial thalamic nucleus via the iGluR5 kainate receptor 
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5.1 Introduction 
 
The ventroposteromedial thalamic nucleus (VPM) is the site of convergence of 
trigeminocervical nociceptive inputs in the thalamus (Ohye, 1990; Angus-Leppan et al., 
1995). Thalamic activation is known to occur in spontaneous attacks of migraine (Afridi 
and Goadsby, 2006) and trigeminovascular stimulation in animals excites neurons in the 
VPM (Davis and Dostrovsky, 1988a; Zagami and Lambert, 1990) as well as induces 
blood flow changes in the thalamic region (Lambert et al., 1988). The VPM has been 
shown to be a site of action of triptans (Shields and Goadsby, 2006) and β-blockers that 
are effective in migraine treatment (Shields and Goadsby, 2005).  
 
The preceding chapters examined the role of kainate receptors at a peripheral trigeminal 
site and in the TCC. At these sites, the results indicated a possible role of kainate 
receptors in anti- and pro- nociceptive mechanisms, although the complete detail of the 
role of iGluR5 receptors in migraine pathophysiology, specificly in the VPM, remains to 
be determined. Only limited studies have examined the role of kainate receptors in 
synaptic transmission in the thalamus and it has been demonstrated that iGluR5 kainate 
receptors are present in the thalamus at both pre- and post-synaptic locations (Ibrahim et 
al., 2000a).   In vitro electrophysiological evidence suggests that although kainate 
receptors are present post-synaptically and can produce small inward currents following 
bath application of kainate, they do not contribute to the development of post-synaptic 
currents when electrical stimulation of corticothalamic fibres is applied (Bolea et al., 
2001). However, the role of post-synaptic kainate receptors in the thalamus in in vivo 
conditions remains unknown, as well as their role in the transmission of nociceptive 
information to higher brain areas.  
 
Under physiological conditions of sensory stimulation of the whiskers in rats, pre-
synaptic kainate receptors on GABAergic terminals of the thalamic relay nucleus (TRN) 
seem to have a disinhibitory effect via a reduction of the recurrent GABAergic 
inhibition, and this suggests an important, novel role of kainate receptors in the 
physiology of extracting sensory information from background neuronal activation (Salt, 
2002; Binns et al., 2003). Whether a similar role for kainate receptors on serotonergic 
synapses in the VPM nucleus exists is however unknown. The VPM thalamic nucleus 
receives serotonergic inputs from the rostral raphe complex including the dorsal raphe 
nucleus (DRN) (Consolazione et al., 1984) and the nucleus raphe median (Consolazione 
 193
et al., 1984; Peschanski and Besson, 1984). The PAG has also been shown to have 
serotonergic inputs to the thalamus (Consolazione et al., 1984).  
 
In the present study, we used electrophysiology in combination with microiontophoresis 
to investigate the potential in vivo effects of iGluR5 agents on third order neurons in the 
VPM, activated in response to electrical stimulation of the SSS (figure 54). To test if 
GABAergic influences occur with kainate receptor blockade on neurons responding to 
trigeminovascular stimulation, we tested whether blockade of GABAA receptor-
mediated transmission would alter sensory responses during microiontophoretic 
application of a selective kainate receptor antagonist. The possible role of kainate 
receptors on serotonergic synapses in the VPM was also tested. In order to investigate if 
modulation of serotonergic receptors in the VPM can alter the inhibitory responses to 
kainate receptor antagonism, we co-ejected 5-HT1A/B/D receptor compounds with a 
selective kainate receptor antagonist.  
 
 
 
 
Figure 54: Electrophysiology of neurons in the ventroposteromedial thalamic 
nucleus – microiontophoresis 
Electrophysiological recordings were made from third order neurons in the 
ventroposteromedial (VPM) thalamus that received trigeminal convergent inputs from 
dural vessels. 
 194
5.2 Methods 
 
5.2.1 Animals 
 
Thirty-six male Sprague-Dawley rats (280–405 g) were anesthetised with 60 mgkg-1 
pentobarbital intraperitoneally and then maintained with a 25-35 mgkg-1h-1 infusion 
(section 2.2). The surgical preparation was as described in section 2.3.5. 
 
5.2.2 Drugs and microiontophoresis 
 
Micropipette barrels were filled with 200 mM NaCl for automated current balance, 
pontamine sky blue dye, UBP 302, Iodowillardiine, NMDA, Fluorowillardiine, 
Bicuculline methiodide, naratriptan hydrochloride, WAY100135, GR127935, NAS-181 
and NaCl at pH 8 which was used as control (Na+ for cations or Cl- and OH- for anions). 
All tested compounds were chosen according to their pharmacological activity (table 
22), and were ejected either as anions or cations as shown in table 22. 
Microiontophoretic barrels had resistances of 16-120 MΩ.  
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Table 22: Characteristics of test compounds used by microiontophoresis  
* Control: Cl- and OH-  
** Control: Na+  
NMDA, N-methyl-D-aspartic acid; UBP 302, (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrim 
idine-2,4-dione; Bicuculline methiodide, [R-(R*,S*)]-5-(6,8-Dihydro-8-oxofuro[3,4-e]-1,3-benzodioxol-
6-yl)-5,6,7,8-tetrahydro-6,6-dimethyl-1,3-dioxolo[4,5-g]isoquinolinium iodide; WAY100135, (S)-N-tert-
Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride; GR127935, N-[4-
Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methy-l-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-
4-carboxamide hydrochloride; NAS-181, (2R)-2-[[[3-(4-Morpholinylmethyl)-2H-1-benzopyran-8-
yl]oxy]methyl]morpholine dimethanesulfonate 
 
 
 
 
 
 
 Polarity Ejection 
current (nA) 
pH Pharmacological activity 
 
 
Fluorowillardiine 
 
(-) 5 - 25 8.0 
 
iGluR1, 2 and 4 AMPA 
receptor agonist (Jane et al., 
1997) 
 
 
Iodowillardiine 
 
(-) 5 - 25 8.0 
 
iGluR5 kainate receptor agonist 
(Jane et al., 1997; Swanson et 
al., 1998) 
 
NMDA (-) 10 - 50 8.0 
 
NMDA receptor agonist 
(Watkins and Jane, 2006) 
 
UBP 302* 
 
(-) 20, 40, 80  
 
8.0 
 
iGluR5 kainate receptor 
antagonist (More et al., 2004) 
 
Bicuculline 
methiodide** (+) 80 5.5 
 
GABAA receptor antagonist 
(Olsen et al., 1976) 
 
Naratriptan 
hydrochloride** (+) 60 5.5 
 
5-HT1B/D/F receptor agonist 
(Humphrey et al., 1990; Hoyer 
et al., 1994) 
 
WAY100135** (+) 60 5.5 
 
5-HT1A receptor antagonist 
(Cliffe et al., 1993; Fletcher et 
al., 1993) 
 
NAS-181** (+) 60 5.5 
 
5-HT1B receptor antagonist (rat 
specific)(Berg et al., 1998) 
 
GR127935** (+) 60 5.5 
 
5-HT1B/D/F receptor antagonist 
(Clitherow et al., 1994) 
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5.2.3 Experimental protocol 
 
Neurons were identified stereotaxically in the region of the VPM by their response to 
facial receptive field stimulation.  All neurons displayed a stable response to electrical 
stimulation of the SSS and an increased firing rate to microintophorised glutamate 
receptor agonist(s), as described in section 2.11.5. Three baseline responses to SSS 
stimulation (50 stimuli were displayed in post-stimulus histograms) were collected 5 
minutes apart. When more than one agonist was tested, the agonists tested for each 
experiment were ejected in a random order. Once five stable baseline cycles were 
recorded, UBP 302 or vehicle control were ejected at currents 20, 40 and 80 nA (each 
current applied in a random) over 5 cycles of Iodowillardiine, or at 80 nA over 3 cycles 
of Iodowillardiine/Fluorowillardiine/NMDA ejection. A post-stimulus histogram was 
collected at the maximum ejection current of UBP 302 and during recovery period (15 
minutes). To test the effect of the GABAA and 5-HT1 receptors compounds, each drug 
was co-ejected with Iodowillardiine, as was the control at the same current and duration. 
These compounds were co-ejected with UBP 302, upon establishment of an action of 
UBP 302 on cell firing, and their responses were compared to that of UBP 302 at 80 nA 
and control alone (figure 55). Post-stimulus histograms were recorded during each 
condition. Upon termination of the experiment, the tissue was fixed in order to identify 
the location of the recording site (section 2.11.6). 
 
 
 
 
 
 
 
 
 
Figure 55: Drug ejection protocol 
Diagram demonstrating schematically the protocol for drug ejection during 
microiontophoretic experiments in the VPM. Due to restrictions on the number of 
available barrels not all studies could be conducted on individual cells.  
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5.3 Results 
 
5.3.1 Localisation and neuronal characteristics 
 
A total of 74 cells were studied in the VPM (figure 51), and each displayed convergent 
trigeminal viscerosomatic inputs classified by cutaneous receptive fields as shown in 
table 23. Cells responded with an increased probability of firing to electrical SSS 
stimulation with an average latency of 12 ± 0.6 ms to the onset. To be included in the 
study, a probability of firing of greater than 30% was required. Only cell bodies were 
recorded, which were characterised by their biphasic action potential morphology and 
increased firing response to glutamate receptor agonist(s).  
 
Cells responding to nociceptive stimulation of the cutaneous receptive field (WDR and 
NS) displayed similar probability of firing in response to SSS stimulation and 
exogenous application of the kainate receptor agonist Iodowillardiine, with LTM cells 
(P ≥ 0.28), and thus responses from both subpopulations were considered homogenous 
and included in the same group for further analysis. Although neurons in both groups 
displayed a probability of firing to electrical SSS stimulation of greater than 30%, a 
slightly higher voltage of 27 ± 3 V was used to excite LTM neurons compared to 
nociceptive responding neurons (21 ± 2 V).   
 
 
 
                 Table 23: Receptive field characteristics  
Receptive field characteristics Number of cells 
 Low threshold mechanosensitive (LTM) 26 
 
 Nociceptive specific (NS) 1 
 
 Wide dynamic range (WDR) 11 
 
 Vibrissal  
(# of vibrissae activated/cell: median) 
 
36 (2) 
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Figure 56:  Localisation of recording sites within the ventroposteromedial 
thalamus 
A. Reconstruction of recording sites within the ventroposteromedial thalamus (VPM) 
projected onto a representative section from Paxinos and Watson (1997). Sites directly 
identified from the ejection of pontamine sky blue are marked with solid circles (●) and 
sites reconstructed from the microdrive recordings with open circles (○). B. A 
photomicrograph demonstrating a recording site marked by ejection of pontamine sky 
blue (arrow) is shown. C. An original trace showing a cluster of cells in the VPM firing 
in response to stimulation of the superior sagittal sinus. * stimulus artefact 
CA1, CA2, CA3, CA1-3 fields of Ammon’s horn; EP, Entopeduncular nucleus; Po, 
Posterior complex; PVP, Paraventricular nucleus; RE, Reunions nucleus; VM, 
Ventromedial nucleus; VPL, Ventroposterolateral nucleus; VPM, Ventroposteromedial 
nucleus; RT, reticular nucleus 
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5.3.2 Selectivity of UBP 302 over Iodowillardiine, Fluorowillardiine and NMDA evoked 
firing 
 
Although the selectivity of the antagonist UBP 302 for iGluR5 receptors over AMPA 
and NMDA evoked firing was previously shown in the TCC (section 4.3.2), we tested 
the effects of UBP 302 on firing in response to microiontophoretic ejection of 
Iodowillardiine, Fluorowillardiine and NMDA on five VPM neurons.  
 
For all three agonists tested there was no difference across the mean firing of the five 
repeated epochs recorded during baseline (Fluorowillardiine: F4,16 = 0.99, P = 0.44; 
Iodowillardiine: F2,7 = 0.74, P = 0.49; NMDA:, F4,16 = 1.23, P = 0.34) and all responses 
were reliable (Cronbach’s α ≥ 0.9). 
 
The effects of UBP 302 were tested under the highest current used in this study (80 nA) 
over 3 repeated cycles of agonist ejection. Ejection of UBP 302 significantly inhibited 
firing in response to Iodowillardiine in all five neurons tested (F2,8 = 25.03, P < 0.001; 
figure 52), but not to NMDA (F2,8 = 4.21, P = 0.60; figure 52) and Fluorowillardiine 
(F2,8 = 1.99, P = 0.20; figure 57).  
 
Upon verification of the selectivity of UBP 302 for the iGluR5 agonist evoked firing at 
the level of the VPM, further tests where conducted by using only the agonist 
Iodowillardiine, thus assuring the presence of iGluR5 carrying kainate receptors on all 
neurons tested.   
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Figure 57: Effects of microiontophoretically delivered UBP 302 on the firing rates 
of third order neurons to pulsed ejections of the glutamate receptor agonists 
Iodowillardiine, Fluorowillardiine and NMDA 
A.  Example of the effects of UBP 302 on the firing rates to pulsed ejections of 
Fluorowillardiine, Iodowillardiine and NMDA. Cell firing in response to the ejected 
agonists returned to baseline levels within 2-5 minutes after UBP 302 
microiontophoresis ceased. B. Comparison of the effect of UBP 302 (80 nA) on 
Iodowillardiine, Fluorowillardiine and NMDA evoked responses. Cell firing in response 
to Iodowillardiine (n = 5), but not in response to Fluorowillardiine (n  = 5) and NMDA (n 
= 5) was significantly inhibited by microiontophoretically administered UBP 302. * P < 
0.05  
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5.3.3 Dose effects of UBP 302 ejected at currents 20, 40 and 80 nA on Iodowillardiine 
evoked firing 
 
UBP 302 reversibly suppressed the post-synaptic response to Iodowillardiine (n = 26; 
F4,40 = 12.18; P < 0.001; figure 58). This inhibition was proportionate to the magnitude 
of the ejecting current and by inference dose dependent, though the sensitivity to UBP 
302 did vary between a small number of neurons. In the majority of neurons recovery 
was immediate upon termination of UBP 302 ejection, though in some neurons it varied 
between 2-5 minutes after UBP 302 microiontophoresis ceased. Ejection of control (Cl- 
and OH-) at the same currents and duration had no effect (F4,40 = 1.55; P = 0.23; figure 
58). 
 
 
 
 
 
 
 
 
 
Figure 58: Effects of microiontophoretically delivered UBP 302 at currents 20, 40 
and 80 nA on the firing rates of third order neurons to pulsed ejection of 
Iodowillardiine 
A.  Example of a representative neuron of the effects of UBP 302 at currents 20, 40 and 
80 nA, applied in a random order over 5 consequent epochs of Iodowillardiine evoked 
firing. B. Current response curves for UBP 302 and control (Cl- and OH-) on 
Iodowillardiine evoked firing. * P < 0.05  
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5.3.4 Effect of UBP 302 on superior sagittal sinus-evoked stimulation 
 
Ejection of UBP 302 significantly inhibited the response to SSS stimulation in 
comparison to the control (n = 26; t25 = 3.47, P < 0.005; figure 59) in all neurons tested 
in a reversible manner. The drug was ejected for 3-4 minutes. In all cells full recovery 
was recorded 10-15 minutes after UBP 302 microiontophoresis ceased, in contrast to the 
almost immediate recovery seen on post-synaptic firing to Iodowillardiine ejection. 
Ejection of control (Cl- and OH-) had no effect in comparison to baseline (t25 = 1.74, P = 
0.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Effect of microiontophoresis of UBP 302 on responses of 
thalamocortical neurons to superior sagittal sinus stimulation  
A-C. Example of post-stimulus histograms from a representative neuron, recorded 
during baseline conditions (A), during ejection of UBP 302 (B) and during ejection of 
control Cl and OH anions (C). D. Comparison of the SSS stimulation evoked firing 
under each condition.  * P < 0.05 
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5.3.5 Effect of UBP 302 during blockade of GABAergic transmission  
 
The inhibitory action of UBP 302 (80 nA) on the Iodowillardiine response could be 
antagonised by the ejection of the selective GABAA antagonist bicuculline (80 nA) 
(UBP 302 vs. UBP 302 & Bicuculline: n = 6; t5 = 4.34, P < 0.05; figure 60). 
Iontophoresis of bicuculline significantly increased cell firing in response to 
Iodowillardiine compared to baseline levels (t5 = 3.36, P < 0.05). However, this was not 
significant when compared to its control (t5 = 1.81, P = 0.13; figure 60), making it 
unlikely that the GABAergic antagonist had any direct effect on neuronal excitability. 
Control ejection (Na+) had no significant effect compared to baseline recordings (n = 6; 
t5 = 0.03, P = 0.98; figure 60). 
 
Similarly bicuculline could fully reverse the inhibitory action of UBP 302 on SSS 
stimulation response (UBP 302 vs. UBP 302 & bicuculline: t5 = 3.77, P < 0.05; figure 
56), whereas individual ejection of bicuculline or Na+ control had no effect (P ≥ 0.46; 
figure 61).  
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Figure 60: Effect of microiontophoresis of UBP 302 and bicuculline on responses of 
thalamocortical neurons to Iodowillardiine ejection 
A. Example of the response of a neuron to pulsed Iodowillardiine. Ejection of drugs and 
their controls are shown with the solid bars. Ejection of control (Na+) and bicuculline 
alone had no effect, while ejection of UBP 302 had a potent inhibitory effect that was 
reversed by the GABAA receptor antagonist bicuculline. B. Comparison of the 
Iodowillardiine evoked firing under each condition. * P < 0.05 compared to control, # P 
< 0.05 compared to UBP 302. 
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Figure 61: Effect of microiontophoresis of UBP 302 and bicuculline on responses of 
thalamocortical neurons to superior sagittal sinus stimulation 
A-E: Example of post-stimulus histograms generated from a representative 
thalamocortical neuron following electrical stimulation of the SSS during baseline (A), 
ejection of UBP 302 (B), co-ejection of UBP 302 with bicuculline (C), ejection of Na 
cations (D) and during ejection of bicuculline alone (E).  F. Comparison of the SSS 
stimulation evoked firing under each condition. * P < 0.05 compared to control, # P < 
0.05 compared to UBP 302. 
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5.3.6 Effect of UBP 302 during modulation of serotonergic transmission  
 
Effect of naratriptan (5-HT1B/1D/F  receptors agonist) 
 
Ejection of UBP 302 (80 nA) or naratriptan (60 nA) individually significantly reduced 
SSS stimulation responses to a similar extend (UBP 302 vs. control: n = 9; t8 = 5.24, P < 
0.001; naratriptan vs. control: t8 = 7.52, P < 0.001; figure 62A-B). Co-ejection of the 
two drugs inhibited SSS stimulation responses even further to 53% ± 5 (t8 = 12.44, P < 
0.001) and this was significantly bigger than the inhibition induced by UBP 302 alone, 
(UBP 302 vs. UBP 302 & naratriptan: t8 = 2.34, P < 0.05; figure 62A-B). 
 
Ejection of UBP 302 or naratriptan individually significantly reduced responses to 
Iodowillardiine (UBP 302 vs. control: n = 7; t6 = 6.73, P < 0.001; naratriptan vs control: 
n = 7; t6 = 8.57, P < 0.001). Similarly to responses to SSS stimulation, co-ejection of the 
two drugs further inhibited Iodowillardiine responses by 20% (n = 7; t6 = 12.97, P < 
0.001) and this response was significantly different than the inhibition induced by UBP 
302 alone (UBP 302 vs. UBP 302 & naratriptan: t6 = 3.00, P < 0.05; figure 62C-D).  
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Figure 62: Effect of co-microiontophoresis of UBP 302 and naratriptan on 
responses of thalamocortical neurons to superior sagittal sinus stimulation and to 
Iodowillardiine evoked firing 
A. Example of post-stimulus histograms generated from a representative thalamocortical 
neuron following electrical stimulation of the SSS during baseline, ejection of UBP 302 
and co-ejection of UBP 302 with naratriptan. B. Comparison of the SSS stimulation 
evoked firing under each condition. C. Example of the response of a neuron to pulsed 
Iodowillardiine. Ejection of drugs is shown with solid bars. Ejection of UBP 302 has a 
potent inhibitory effect that is further reduced with the 5-HT1B/1D agonist naratriptan. D. 
Comparison of the Iodowillardiine evoked firing under each condition. * P < 0.05 
compared to control, # P < 0.05 compared to UBP 302.   
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Effect of GR127935 (5-HT1B/1D receptors antagonist) 
 
Ejection of the 5-HT1B/1D receptor antagonist GR127935 (60 nA) alone increased 
neuronal firing in response to Iodowillardiine to 33% but this was not significant 
compared to control Na+ (n = 13; t12 = 1.33, P = 0.21). Co-ejection of UBP 302 with 
GR127935 failed to reverse the inhibition induced by UBP 302 on post-synaptic firing 
in response to Iodowillardiine pulses (UBP 302 vs. control: n = 13, t12 = 6.12, P < 0.001; 
UBP 302 vs. UBP 302 & GR127935: n = 13; t12 = 1.29, P = 0.22; figure 63).  
 
In contrast, at the same duration and current GR127935 could significantly antagonise 
the inhibitory action of naratriptan on Iodowillardiine evoked firing (n = 5; naratriptan 
vs. control: t4 = 4.82, P < 0.05; naratriptan vs. naratriptan & GR127935: t4 = 6.26, P < 
0.05; figure 64).  
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Figure 63: Effect of microiontophoresis of UBP 302 and GR127935 on responses of 
thalamocortical neurons to Iodowillardiine ejection 
A. Example of the response of a neuron to pulsed Iodowillardiine. Ejection of drugs and 
their controls are shown with the solid bars. Ejection of neither Na cations nor Cl and 
OH anions or GR127935 alone had any effect. Ejection of UBP 302 had a potent 
inhibitory effect that was not reversed by the 5-HT1B/D receptor antagonist GR127935. 
B. Comparison of the Iodowillardiine evoked firing under each condition. * P < 0.05 
compared to control 
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Figure 64: Effect of co-application of UBP 302 with GR127935 and of naratriptan 
with GR127935 on responses of thalamocortical neurons to Iodowillardiine ejection  
A. Example of the response of a neuron to pulsed Iodowillardiine. Ejection of drugs is 
shown with the solid bars. Ejection of UBP 302 (80 nA) or naratriptan (60 nA) alone 
inhibited post-synaptic firing, which was further inhibited when the two drugs were co-
ejected. Administration of GR127935 (60 nA) failed to reverse the potent inhibitory 
effect of UBP 302 while was able to reverse the inhibitory actions of naratriptan. B. 
Comparison of the Iodowillardiine evoked firing under each condition. * P < 0.05 
compared to control, # P < 0.05 compared to naratriptan   
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Additionally, co-ejection of UBP 302 with GR127935 did not change the inhibitory 
actions of UBP 302 on firing in response to SSS stimulation responses (UBP 302 vs. 
control Cl- and OH-: n = 13, t12 = 9.09, P < 0.001; UBP 302 vs. UBP 302 & GR127935: 
t12 = 1.97, P = 0.07; figure 65). Ejection of the 5-HT1B/1D receptor antagonist GR127935 
(60 nA) alone significantly increased neuronal firing in response to superior sagittal 
sinus stimulation compared to its control Na+ (n = 13; t12 = 2.25, P < 0.05). 
 
 
  
Figure 65: Effect of microiontophoresis of UBP 302 and GR127935 on responses of 
thalamocortical neurons to superior sagittal sinus stimulation 
A-E. Example of post-stimulus histograms generated from a representative 
thalamocortical neuron following electrical stimulation of the SSS, during baseline 
conditions (A), ejection of UBP 302 (B), co-ejection of UBP 302 with GR127935 (C), 
and during ejection of control Na cations (D) and GR127935 alone (E). There was a 
reproducible inhibition of thalamic responses to SSS stimulation during iontophoresis of 
UBP 302 which was not reversed by co-administration of UBP 302 with the 5-HT1B/1D 
receptor antagonist. F. Comparison of the SSS stimulation evoked firing under each 
condition. * P < 0.05 compared to control 
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Effects of WAY100135 (5-HT1A receptor antagonist) 
 
Ejection of WAY100135 alone neither affected neuronal firing in response to 
Iodowillardiine (n = 9; t8 = 1.13, P = 0.29; figure 66) nor to SSS stimulation (t8 = 0.01, P 
= 0.99; figure 67) compared to control. Ejection of Na+ control did not affect neuronal 
firing compared to baseline (Iodowillardiine evoked firing: t8 = 0.73, P = 0.49; SSS 
stimulation evoked firing: t8 = 1.37, P = 0.21).  
 
Co-ejection of UBP 302 with WAY100135 did not alter the inhibition induced by UBP 
302 on post-synaptic firing in response to Iodowillardiine (UBP 302 vs. control: t8 = 
3.21, P < 0.05; UBP 302 vs. UBP 302 & WAY100135: t8 = 1.28, P = 0.24; figure 66).  
 
Additionally, co-ejection of UBP 302 with WAY100135 did not change the UBP 302 
induced inhibition on firing in response to SSS stimulation responses (UBP 302 vs. 
control: t8 = 4.86, P < 0.005; UBP 302 vs. UBP 302 & WAY100135: t8 = 0.95, P = 
0.37; figure 67).  
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Figure 66: Effect of microiontophoresis of UBP 302 and WAY100135 on responses 
of thalamocortical neurons to Iodowillardiine ejection 
A. Example of the response of a neuron to pulsed Iodowillardiine. Ejection of drugs and 
their controls are shown with solid bars. Ejection of neither Na+ cations nor Cl- and OH- 
ions or WAY100135 alone had any effect. Ejection of UBP 302 had a potent inhibitory 
effect that was not reversed by the 5-HT1A receptor antagonist WAY100135.  B. 
Comparison of the Iodowillardiine evoked firing under each condition. * P < 0.05 
compared to control 
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Figure 67: Effect of microiontophoresis of UBP 302 and WAY100135 on responses 
of thalamocortical neurons to superior sagittal sinus stimulation 
A-E. Example of post-stimulus histograms generated from a representative 
thalamocortical neuron following electrical stimulation of the SSS, during baseline 
conditions (A), ejection of UBP 302 (B), co-ejection of UBP 302 with WAY100135 
(C), and during ejection of control (D) and WAY100135 alone (E). There was a 
reproducible inhibition of thalamic responses to SSS stimulation during iontophoresis of 
UBP 302 which was not reversed by co-administration of UBP 302 with the 5-HT1A 
receptor antagonist. F. Comparison of the SSS stimulation evoked firing under each 
condition. * P < 0.05 compared to control 
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Effects of NAS-181 (rat 5-HT1B  receptor antagonist) 
 
Ejection of NAS-181 alone increased neuronal firing in response to Iodowillardiine by 
18% but this was not significant compared to control ions ejection (n = 10; t9 = 1.99, P = 
0.08). Co-ejection of UBP 302 with NAS-181 significantly reversed the inhibition 
induced by UBP 302 when ejected alone on Iodowillardiine evoked firing (UBP 302 vs. 
control: t9 = 14.43, P < 0.001; UBP 302 vs. UBP 302 & NAS-181: t9 = 6.37, P < 0.001; 
figure 68). 
 
Similarly, co-ejection of UBP 302 with NAS-181 significantly reversed the inhibition 
induced by UBP 302 when ejected alone on cell firing in response to SSS electrical 
stimulation (UBP 302 vs. control: t9 = 5.91, P < 0.001; UBP 302 vs. UBP 302 & NAS-
181: t9 = 6.26, P < 0.001; figure 69). Ejection of either NAS-181 alone or Na+ had any 
effect on neuronal firing in response to SSS stimulation (P ≥ 0.41). 
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Figure 68: Effect of microiontophoresis of UBP 302 and NAS-181 on responses of 
thalamocortical neurons to Iodowillardiine ejection 
A. Example of the response of a neuron to pulsed Iodowillardiine. Ejection of drugs and 
their controls are shown with the solid bars. Ejection of neither Na+ cations nor Cl- and 
OH- ions or NAS-181 alone had any effect. Ejection of UBP 302 had a potent inhibitory 
effect that was significantly reversed by the 5-HT1B receptor antagonist NAS-181. 
Comparison of the Iodowillardiine evoked firing under each condition. * P < 0.05 
compared to control, # P < 0.05 compared to UBP 302 
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Figure 69: Effect of microiontophoresis of UBP 302 and NAS-181 on responses of 
thalamocortical neurons to superior sagittal sinus stimulation 
A-E. Example of post-stimulus histograms generated from a representative 
thalamocortical neuron following electrical stimulation of the SSS, during baseline 
conditions (A), ejection of UBP 302 (B), co-ejection of UBP 302 with NAS-181 (C), 
and during ejection of control (D) and NAS-181 alone (E). There was a reproducible 
inhibition of thalamic responses to SSS stimulation during iontophoresis of UBP 302 
which was significantly reversed by co-administration of UBP 302 with the 5-HT1B 
receptor antagonist NAS-181. F. Comparison of the SSS stimulation evoked firing under 
each condition. * P < 0.05 compared to control, # P < 0.05 compared to UBP 302 
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5. 4 Conclusions 
 
This study demonstrates that glutamatergic neurotransmission selectively through 
iGluR5 carrying kainate receptors at the level of VPM can potently modulate 
trigeminovascular nociception. This modulation can be through post-synaptic iGluR5 
kainate receptors on third order neurons, since the selective iGluR5 receptor antagonist 
used, further to its inhibitory actions on trigeminovascular activation, could also 
antagonise post-synaptic firing in response to kainate receptors’ activation. Also 
evidence from this study suggests an interaction between iGluR5 receptor, GABAergic 
and serotonergic transmission at the level of VPM (figure 70).  
 
 
 
 
Figure 70: Overview of the effects of microintophorised UBP 302 on third order 
trigeminovascular neurons 
Selective antagonism of iGluR5 receptors was shown to result in inhibition of 
trigeminovascular processing and this effect was reversed by 5-HT1B (A) and GABAA 
(B) receptors antagonists. 
RT, reticular nucleus; SSC, somatosensory cortex; VPM, ventroposteromedial thalamic 
nucleus 
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The thalamus is a potentially exciting target for migraine research as nearly all afferent 
sensory information to the cerebral cortex is relayed through it. The thalamus receives 
large modulatory inputs from brainstem monoaminergic centres (Peschanski and 
Besson, 1984; Westlund et al., 1990; Simpson et al., 1997) and these areas have been 
implicated by brain imaging and other studies to be pivotal in migraine pathophysiology 
(Goadsby et al., 2002; Goadsby, 2007). From a translational neurosciences perspective 
VPM has proved a site of action of triptans, β-blockers and of valproate and has 
correlated with the efficacy of anti-migraine therapies in clinical practice (Shields et al., 
2003; Shields and Goadsby, 2005, 2006). The current study further supports that the 
VPM nucleus is a potential site of action of new kainate anti-migraine antagonists. 
 
Neurons identified in this study were mostly found along the shell region of the VPM. 
This is in agreement with previous studies in the VPM demonstrating that the neurons 
activated in response to trigeminovascular activation are located along the shell region 
of VPM with the posterior complex and the ventroposterolateral thalamus (Perl and 
Whitlock, 1961; Honda et al., 1983; Vahle-Hinz and Gottschaldt, 1983; Yokota et al., 
1985; Shields and Goadsby, 2005, 2006). All neurons identified in this study, were 
selectively activated by the iGluR5 receptors agonist Iodowillardiine, indicating the 
presence of functional kainate receptors in the VPM in agreement with 
electrophysiological and anatomical studies (Ibrahim et al., 2000a; Ibrahim et al., 2000b; 
Binns et al., 2003).  
 
Local ejection by microiontophoresis of the iGluR5 antagonist UBP 302 inhibited both 
cell firing in response to trigeminovascular activation and in response to an exogenously 
applied kainate receptor agonist. Since post-synaptic firing was inhibited, this suggests 
that blockade of post-synaptic kainate receptors can at least partly account for the 
observed reduction of trigeminovascular nociception. Using microiontophoresis and 
similar probes for kainate receptors, Binns and colleagues (2003) demonstrated that 
post-synaptic kainate receptors were present on neurons responding to whisker 
stimulation and be activated by selective receptor agonists. However, they could not be 
inhibited by the kainate receptor antagonist LY382884 and thus concluded that post-
synaptic kainate receptors do not participate in sensory modulation. It is possible that the 
antagonist used in the current study is more selective for kainate receptors and 
furthermore the currents used to eject Iodowillardiine (maximum 25 nA) were sufficient 
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to avoid high drug concentrations delivered to very small areas so that even when 
selective agonists are used, inappropriate receptors can be activated.  
 
In the same set of experiments Binns et al. (2003) showed that application of the kainate 
receptor antagonist LY382884 could inhibit sensory responses, without blocking post-
synaptic firing, and thus concluded that under in vivo physiological conditions activation 
of pre-synaptic kainate receptors on GABAergic terminals arising from the thalamic 
relay nucleus occurs during sensory stimulation. It has been suggested that blockade of 
these pre-synaptic kainate receptors results in an enhancement of the GABAergic 
inhibition evoked during sensory stimulation (Salt, 2002; Binns et al., 2003). Recurrent 
GABAergic inhibition is known to occur during sensory activation (Houser et al., 1980; 
Ross et al., 1993; Lee et al., 1994a, b); it is not clear though whether recurrent 
GABAergic inhibition also occurs during trigeminovascular activation. The modulatory 
action of GABA on sensory transmission in the thalamus is well documented (Salt, 
1989; Spreafico et al., 1993; Lee et al., 1994a, b; Hartings and Simons, 2000; Shields et 
al., 2003). In the experiments reported here application of the GABAA antagonist alone 
caused a non-significant increase of firing in response to SSS stimulation and this is in 
agreement with a previous microiontophoretic study of GABA receptors in the VPM 
(Shields et al., 2003). A significant effect of bicuculline could have been observed if a 
higher ejection current was used. Due to limitations of the technique however (higher 
current resulted in barrel blockage), this was not possible and remains unclear whether 
recurrent GABAergic inhibition also occurs during trigeminovascular activation. The 
inhibitory effects of UBP 302 were antagonised by bicuculline in a similar fashion 
shown by Binns et al. (2003) and this may additionally suggest that blockade of pre-
synaptic kainate receptors on GABAergic terminals might occur and result in an 
enhancement of the GABAergic inhibition. Furthermore, it is unlikely that UBP 302 
achieved its effects by a direct agonistic interaction with GABA receptors, since the 
direct application of a GABA receptor agonist would be expected to inhibit all 
glutamate agonists evoked firing and not selectively firing in response to kainate 
receptors activation (Kaneko and Hicks, 1990; Shields et al., 2003; Storer et al., 2004b).  
 
This study further investigated any possible pharmacological mechanisms by which 
UBP 302 exerted this effect through actions that involve serotonergic modulation. As 
triptans have agonist activity at multiple 5-HT1 receptor subtypes (Shields and Goadsby, 
2006), antagonists of 5-HT1A, 5-HT1B/1D and 5-HT1B receptors were co-ejected with 
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UBP 302. Antagonism of UBP 302 with a selective 5-HT1B antagonist reversed the 
inhibitory actions of UBP 302 in a similar fashion as bicuculline. This might suggest the 
possible presence of pre-synaptic kainate receptors on serotonergic terminals in the 
VPM and further indicate a possible role of these receptors in modulating serotonergic 
release in the sensory thalamus, in a similar fashion as on GABAergic terminals. Such a 
role for kainate pre-synaptic kainate receptors has been shown in other brain structures 
(Ohta et al., 1994). Again, it is unlikely that UBP 302 achieved its effects by a direct 
agonistic interaction with 5-HT receptors, since application of a serotonin receptor 
agonist would be expected to modify all evoked post-synaptic responses to ejected 
glutamate receptor agonists and not selectively firing in response to kainate receptors 
activation (Prieto-Gomez et al., 1989; Shields and Goadsby, 2006). In support with this 
is the fact that co-ejection of UBP 302 with naratriptan was able to further inhibit cell 
firing, suggesting that the two compounds were acting on separate neuronal receptors.  
 
Whether serotonergic transmission at the level of the VPM is modulated through kainate 
receptors under normal conditions is not known. In a microdialysis study it was shown 
that activation of kainate but not AMPA receptors on DRN and median raphe nucleus 
neurons can modulate extracellular serotonin levels (Tao et al., 1997) and additionally 
modulate serotonin release in the amygdale and PAG (Viana et al., 1997). That might 
suggest that kainate receptors on serotonergic terminals arising from the DRN could 
have an analogous modulatory role in the thalamus as shown on other central 
serotonergic terminals (Ohta et al., 1994), but this cannot directly concluded from our 
studies. A future study might involve serotonergic inhibition of the thalamus through 
stimulation of the DRN (Prieto-Gomez et al., 1989), and combined local ejection of 
selective kainate agents in the thalamus. The fact that the 5-HT1B antagonist could 
reverse the inhibitory action of the kainate receptor antagonist on post-synaptic firing in 
response to kainate receptors activation, might additionally suggest a post-synaptic 
modulatory interactions between kainate and 5-HT1B receptors. However, no further 
evidence exists for such post-synaptic receptor interactions in the thalamus and 
elsewhere in the brain. 
 
Why the effects of UBP 302 were reversed only by the 5-HT1B receptors antagonist and 
not by the 5-HT1B/1D receptor antagonist which, as shown here and elsewhere (Shields 
and Goadsby, 2006) can reverse the effects of naratriptan, is not known. This might 
suggest that triptans at the level of VPM mainly act through 5-HT1B receptors and may 
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reflect that in the rat brain 5-HT1B receptors outnumber 5-HT1D receptors (Bruinvels et 
al., 1993; Bruinvels et al., 1994; Varnas et al., 2001; Varnas et al., 2005). These effects 
may have also arisen through a combination of factors. Firstly, the 5-HT1B antagonist 
NAS-181 is twice as potent than the 5-HT1B/1D antagonist GR127935 (NAS-181: Ki for 
r5-HT1B receptors ~ 47 nM; GR127935: Ki for r5-HT1B receptors ~ 100 nM). 
Additionally as a technical limitation of the iontophoretic technique, we may not have 
been able to eject enough of the GR127935 compound to have an effect in the same way 
NAS-181 had an effect (though with the same current and duration GR127935 was able 
to reverse the effects of naratriptan), and thus it is not possible to know the 
concentration of any drug that each cell is exposed to.  
   
In conclusion, we propose that the VPM nucleus is likely involved in the transmission of 
painful sensory information to the cortex in conditions in which the trigeminovascular 
nociceptive system is active. Glutamatergic neurotransmission through kainate receptors 
in the VPM nucleus may potently modulate trigeminovascular nociception and this 
pharmacological action may explain some part of the efficacy of the kainate receptor 
antagonist LY466195 in migraine.  
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Chapter 6: Effects of LY466195 and topiramate on trigeminovascular 
nociception– potential actions in the treatment of migraine via kainate 
receptors 
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6.1 Introduction  
 
The previous studies of trigeminovascular nociception reported in this thesis (chapter 4 
and 6) examined the effects of a kainate receptor antagonist following acute 
administration, directly on neurons firing in response to trigeminovascular stimulation. 
The antagonist UBP 302 used in the previous studies is one of the most potent iGluR5 
kainate receptor antagonists described to date (More et al., 2004). However there is a 
lack of evidence on its lipophylicity and its ability to cross the blood-brain-barrier and to 
our knowledge the antagonist has not been previously described in an in vivo model. 
Although chemical analysis of the molecule was not conducted the existence of a 
carboxylic group on the compound might suggest decreased lipophylicity of the 
molecule. In order to examine the systemic effects of proposed antagonists for kainate 
receptors we utilised the iGluR5 kainate antagonist LY466195 and the anti-convulsant 
topiramate. 
 
LY466195 has been described as the one of the most potent kainate receptor antagonists 
to date (Weiss et al., 2006). In animals it has been shown to be effective in reducing Fos 
expression and PPE following stimulation of the trigeminal ganglion (Weiss et al., 
2006). Important clinical correlates also exist with a double-blinded randomized study, 
at which LY466195 was significantly efficacious in relieving head pain in 50% of 
migraine patients (Johnson, KW, International Headache Research Seminar, 
Copenhagen, 25 March 2007). 
 
Moreover topiramate is a clinically effective migraine preventive (Bussone et al., 2006) 
and has been effective in animal models of trigeminovascular activation relevant to 
migraine (Storer and Goadsby, 2004; Akerman and Goadsby, 2005a, b). Topiramate is a 
widely used anti-convulsant (Perucca, 1997; Rosenfeld, 1997). It’s mechanisms of 
action are as yet poorly understood and a variety of sites have been proposed, including 
certain voltage-activated Na+ and Ca2+ channels, GABAA receptors, and AMPA/kainate 
glutamate receptors (Shank et al., 1994; Dodgson et al., 2000; Silberstein and Tfelt-
Hansen, 2006). It seems that the common mechanism of action on these different 
receptors is allosteric modulation of the channels through protein phosphorylation 
mainly by protein kinases A and C (Silberstein and Tfelt-Hansen, 2006). Recently it has 
been suggested that the site of action of topiramate in anti-epileptic treatment is the 
iGluR5 subunit of the kainate receptor (Gryder and Rogawski, 2003; Dudek and 
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Bramley, 2004), since it has been shown that topiramate can inhibit iGluR5-mediated 
currents in the amygdala and also inhibit kainate-induced clonic seizures but not AMPA 
or NMDA induced seizures (Gryder and Rogawski, 2003; Kaminski et al., 2004). 
 
In the present study, we used electrophysiology in combination with microiontophoresis 
to investigate the potential in vivo effects of LY466195 on second order neurons in the 
TCC as well as on third order neurons in the VPM. In addition LY466195 was given 
intravenously and recordings were made from the VPM and TCC. Due to experimental 
limitations, topiramate was only given intravenously and recordings were made from 
third order neurons in the VPM (figure 71).   
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Figure 71: Electrophysiology of neurons in the ventroposteromedial thalamic 
nucleus and in the trigeminocervical complex 
Electrophysiological recordings were made from second order neurons in the 
trigeminocervical complex (TCC) and from third order neurons in the 
ventroposteromedial thalamus (VPM). LY466195 was administered by 
microiontophoresis at both areas (A and B). In addition LY466195 was administered 
intravenously and recordings were made from neurons that received convergent inputs 
from dural vessels in both the VPM and the TCC (C). Topiramate was administered 
intravenously and recordings were made from neurons that received convergent inputs 
from dural vessels in the VPM (C). 
TG; trigeminal ganglion 
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6.2 Methods 
 
6.2.1 Animals 
 
Sixty-four male Sprague-Dawley rats (280–380 g) were anesthetized with 60 mgkg-1 
pentobarbital intraperitoneally and then maintained with 25-35 mgkg-1h-1 infusion of 
pentobarbital (section 2.2). Surgical procedures, stimulation of the dural vessels and 
recordings were as described in sections 2.3.4-5 and 2.4.2-3. 
 
6.2.2 Drugs  
 
Microiontophoretic application 
 
Micropipette barrels were filled with 200 mM NaCl for automated current balance, 
pontamine sky blue, Iodowillardiine, NMDA, Fluorowillardiine, LY466195 and dH2O 
at pH 8 which was used as control (OH ions were ejected as control). In some 
experiments in the TCC serine was also included in one of the barrels, and it was used as 
a ligand of the glycine site of NMDA receptors in the presence of LY466195. As 
LY466195 displayed some activity on NMDA receptors (Weiss et al., 2006), serine was 
used in order to study any possible effects of the antagonist on the glycine site of 
NMDA receptors. All tested compounds were chosen according to their 
pharmacological activity (table 24), and were all ejected as anions as shown in table 24. 
Microiontophoretic barrels had resistances of 25-65 MΩ.  
 
Intravenous application 
 
Intravenous injections of LY466195 and topiramate were given as described in section 
2.9.2. The doses selected for each drug were based on previous in vivo applications of 
these compounds in rats (table 25).  
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Table 24: Characteristics of test compounds used by microiontophoresis 
NMDA, N–methyl–D–aspartic acid; LY466195, (3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoro-1-
pyrrolidinyl]-methyl]de cahydro-3-isoquinolinecarboxylic acid 
 
 
 
 
 
 
Table 25: Characteristics of test compounds administered intravenously  
LY466195, (3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl]-methyl]de cahydro-3 
isoquinolinecarboxylic acid 
 
 
 
 Polarity Ejection 
current (nA) 
pH Pharmacological activity 
 
 
Fluorowillardiine 
 
(-) 5 - 25 8.0 
 
iGluR1,2 and 4 AMPA receptor 
agonist (Jane et al., 1997) 
 
 
Iodowillardiine 
 
(-) 5 - 25 8.0 
 
iGluR5 kainate receptor agonist 
(Jane et al., 1997; Swanson et 
al., 1998) 
 
NMDA (-) 10 - 50 8.0 
 
NMDA receptor agonist 
(Watkins and Jane, 2006) 
 
 
D-Serine 
 
(-) 80  8.0 
 
Ligand of the glycine site  of 
NMDA receptor (Mothet et al., 
2000) 
 
 
LY466195 
 
(-) 5, 10, 20  
 
8.0 
 
iGluR5 kainate receptor 
antagonist (Weiss et al., 2006) 
 
 
Drug 
 
 
Area of 
recording 
 
 
Doses 
 
 
Reference 
 
VPM 10, 50, 100  µgkg-1  
LY466195 
 
 TCC 50, 100, 200  µgkg
-
1 
 
 
(Weiss et al., 2006) 
 
 
 
Topiramate 
 
VPM 30  mgkg-1 
 
(Akerman and Goadsby, 
2005a, b) 
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6.2.3 Experimental protocol 
 
Recordings in VPM and TCC– microiontophoresis of LY466195 
 
Neurons were identified as previously described (section 2.11.5) in VPM and TCC. All 
neurons displayed baseline responses to dural vessel stimulation and five stable baseline 
cycles of glutamate receptor agonist were recorded. When more than one agonist was 
tested, the agonists tested for each experiment were ejected in a random order. 
LY466195 or vehicle control was ejected at currents of 5, 10 and 20 nA each current 
applied during 5 cycles of glutamate receptor agonists. A post-stimulus histogram was 
collected at the maximum ejecting current of LY466195 (20 nA) and during recovery 
period. The effects of LY466195 on second order neurons in the TCC were also tested 
fielding relation to nociceptive and non-nociceptive activation of the cutaneous facial 
receptive field.  
 
To test any possible effects of LY466195 on NMDA receptor’s glycine site, serine 
(NMDA receptor’s glycine site ligand) was co-ejected with NMDA on second order 
neurons in the TCC responding to stimulation of the MMA. Serine was then co-ejected 
with LY466195 (20 nA), and their effects on NMDA-evoked firing were compared to 
that of serine and control when ejected alone. Post-stimulus histograms were recorded 
during each condition. Upon termination of the experiment, the tissue was fixed in order 
to identify the location of the recording site (section 2.11.6). 
 
Recordings in VPM and TCC– intravenous administration of LY466195 and topiramate 
 
Once a neuron with convergent inputs from the dura mater and facial receptive field was 
identified responses were tested using the following protocol. (1) Three baseline 
collections of dural stimulation (2) intravenous administration of LY466195 (at doses as 
shown in table 25) or topiramate (30 mgkg-1 for VPM recordings) or control vehicle 
intervention (3) Dural stimulation collections at 5, 10, 15, 20, 30, 40, 50, 60, 70, 80 and 
90 minutes. 
 
The effects of 100 µgkg-1 of LY466195 or control vehicle were also assessed on the 
post-synaptic firing in response to microintophorised Iodowillardiine, NMDA and 
Fluorowillardiine in four neurons with convergent inputs from the dura mater and facial 
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receptive field in the VPM. Responses were tested using the following protocol: (1) 
baseline collections of epochs representing firing in response to microintophorised 
Iodowillardiine, NMDA and Fluorowillardiine for at least 30 minutes (2) intravenous 
administration of LY466195 (100 µgkg-1) or control vehicle intervention (3) collections 
of epochs representing firing in response to microintophorised Iodowillardiine, NMDA 
and Fluorowillardiine for 90 minutes. 
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6.3 Results 
 
6.3.1 Effects of LY466195 on neuronal firing in the ventroposteromedial thalamic 
nucleus 
 
A total of 36 cells were studied in the VPM (figure 72), and each displayed convergent 
trigeminal viscerosomatic inputs classified by cutaneous receptive fields as shown in 
table 26. Cells responded with an increased probability of firing to electrical SSS 
stimulation with an average latency of 11 ± 2 ms to the onset. To be included in the 
study, a probability of firing of greater than 30% was required. Only cell bodies were 
recorded, which were characterized by their biphasic action potential morphology and 
increased firing response to glutamate receptor agonist(s).  
 
 
 
                 Table 26: Receptive field characteristics  
Receptive field characteristics Number of cells 
 Low threshold mechanosensitive (LTM) 13 
 
 Nociceptive specific (NS) 0 
 
 Wide dynamic range (WDR) 6 
 
 Vibrissal  
(# of vibrissae activated/cell: median) 
 
17 (2) 
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Figure 72:  Localisation of recording sites within the ventroposteromedial 
thalamus 
Reconstruction of recording sites within the ventroposteromedial thalamus (VPM) 
projected onto a representative section from Paxinos and Watson (1997) atlas. Sites 
directly identified from the ejection of pontamine sky blue are marked with solid circles 
(●) and sites reconstructed from the microdrive recordings with open circles (○). 
CA1, CA2, CA3, CA1-3 fields of Ammon’s horn; EP, Entopeduncular nucleus; Po, 
Posterior complex; PVP, Paraventricular nucleus; RE, Reunions nucleus; VM, 
Ventromedial nucleus; VPL, Ventroposterolateral nucleus; VPM, Ventroposteromedial 
nucleus 
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Effects of microiontophoretic application of LY466195 on post-synaptic firing evoked by 
glutamate agonists 
 
LY466195 was applied by microiontophoresis on cells firing in response to the agonists 
NMDA, Fluorowillardiine and Iodowillardiine (n = 9). For all three agonists tested there 
was no difference across the mean firing of the five repeated epochs recorded during 
baseline (Fluorowillardiine: F1,9 = 1.45, P = 0.26; Iodowillardiine: F1,10 = 1.46, P = 0.26; 
NMDA: F1,9  = 1.42, P = 0.27) and all responses were reliable (Cronbach’s α ≥ 0.86). 
 
LY466195 potently inhibited responses to Iodowillardiine (F1,11 = 5.57, P < 0.05) and 
NMDA (F2,20 = 33.29, P < 0.001) evoked-firing in a dose response manner (figure 73). 
Although a small effect of LY466195 was seen on Fluorowillardiine evoked firing this 
was not significant (F1,8 = 3.25, P = 0.11; figure 73). Cell firing in response to the 
ejected agonists returned to baseline levels with Iodowillardiine-evoked firing 
displaying an almost immediate recovery upon LY466195 microiontophoretic cessation, 
whereas recovery of cell firing in response to NMDA ejection was recorded within 2-5 
minutes after LY466195 microiontophoretic cessation. 
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Figure 73: Effects of microiontophoretically delivered LY466195 on the firing rates 
of third order neurons to pulsed ejections of the receptor agonists Iodowillardiine, 
Fluorowillardiine and NMDA  
A.  Example of the effects of LY466195 and control (OH-) on the firing rates to pulsed 
ejections of Fluorowillardiine, Iodowillardiine and NMDA. Cell firing in response to the 
ejected agonists returned to baseline levels immediately or within 2–5 minutes after 
LY466195 microiontophoresis ceased. B–C. Comparison of the effect of LY466195 and 
control OH- on Iodowillardiine (B), NMDA (C) and Fluorowillardiine (D) evoked 
responses. Cell firing in response to Iodowillardiine and NMDA, but not in response to 
Fluorowillardiine was significantly inhibited by microiontophoretically administered 
LY466195. * P < 0.05  
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Effects of microiontophoretic application of LY466195 on responses to dural 
stimulation 
 
Ejection of LY466195 significantly inhibited the response to SSS stimulation in 
comparison to control (n = 9; t8 = 6.64, P < 0.001; figure 74) in a reversible manner. The 
drug was ejected for 3-4 minutes at 20 nA. In all cells full recovery was recorded 5-10 
minutes after LY466195 microiontophoresis ceased. Ejection of control ions (OH-) had 
no effect in comparison to baseline (t8 = 1.14, P = 0.29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 74: Effect of microiontophoresis of LY466195 on responses of 
thalamocortical neurons to superior sagittal sinus stimulation 
A-C. Example of post-stimulus histograms from a representative neuron, recorded 
during baseline conditions (A), during ejection of LY466195 (B) and during ejection of 
control OH- (C). D. Comparison of the SSS stimulation evoked firing under each 
condition.  * P < 0.05 
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Effects of intravenous administration of LY466195 on responses to dural stimulation 
 
LY466195 administrated intravenously significantly inhibited thalamocortical activity in 
response to SSS stimulation at 50 (n = 6; F3,14 = 4.28, P < 0.05) and 100 µgkg-1 (n = 6; 
F3,11 = 8.66, P < 0.005) but not at 10 µgkg-1 (n = 5; F2,8 = 0.57, P = 0.59; figure 75). 
LY466195 at 100 µgkg-1 significantly decreased responses at 5 minutes and maximally 
at 20 minutes by 52% (t10 = 4.6, P < 0.005) returning to baseline levels after 90 minutes. 
At the dose of 50 µgkg-1 LY466195 displayed a significant effect on firing at 15 minutes 
(t7 = 4.08, P < 0.05) by maximum of 22% and responses returned to baseline levels 
within 90 minutes.  Intravenous administration of vehicle control had no effect on firing 
in response to SSS stimulation (n = 6; F3,15 = 0.77, P = 0.53).  
 
In all animals neither intravenous administration of LY466195 or saline control 
demonstrated any significant changes on blood pressure (table 27).  
 
 
 
 
 
Table 27: Blood pressure effects of LY466195   
LY466195 (µgkg-1)  
100 50 10 
Control 
 Pre- Post- Pre- Post- Pre- Post- Pre- Post- 
Blood pressure 
± SEM 
(mmHg) 
123 ± 13 111 ± 10 103 ± 9 100 ± 10 113 ± 15 111 ± 9 98 ± 16 96 ± 15 
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Figure 75: Effect of intravenously administrated LY466195 on responses of 
thalamocortical neurons to superior sagittal sinus stimulation  
LY466195 inhibited firing to dural electrical stimulation at 50 and 100 µgkg-1, but not at 
10 µgkg-1. * P < 0.05  
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Effects of intravenous administration of LY466195 on post-synaptic firing evoked by 
glutamate agonists 
 
 
LY466195 administrated intravenously at a dose of 100 µgkg-1 (n = 4) significantly and 
reversibly inhibited firing in response to microiontophoretic administration of 
Iodowillardiine (F2,7 = 27.33, P < 0.005) and NMDA (F1,6  = 10.72, P < 0.05) but not to 
Fluorowillardiine (F1,6 = 4.3, P = 0.08; figure 76). LY466195 decreased responses 10 
minutes following administration and overall there was no significant difference 
between its effects on Iodowillardiine and NMDA-evoked firing (independent t test 
NMDA vs. Iodowillardiine; P ≥ 0.56). Intravenous administration of vehicle control had 
no effect on firing in response to any of the three agonists tested (n = 4; P ≥ 0.30).  
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Figure 76: Effect of intravenously administrated LY466195 on post-synaptic firing 
of thalamocortical neurons to the glutamate receptor agonists NMDA, 
Fluorowillardiine and Iodowillardiine  
LY466195 (100 µgkg-1) inhibited firing to microiontophoretic application of 
Iodowillardiine (A) and NMDA (B) but not to Fluorowillardiine (C). * P < 0.05  
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6.3.2 Effects of LY466195 on neuronal firing in the trigeminocervical complex 
 
A total of 37 wide dynamic range (WDR) units were studied from the TCC (figure 77) 
and each displayed convergent trigeminal viscerosomatic inputs of the ophthalmic 
dermatome. Extracellular recordings were made from neurons responding in a reversible 
excitatory manner to all glutamate agonists tested and to MMA electrical stimulation 
with latencies consistent with Aδ fibres (on average 9-12 ms).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 77:  Localisation of recording sites within the trigeminocervical complex 
A. Reconstruction of recording sites within the C1 spinal cord level, plotted after 
Paxinos and Watson (1997) indicating recording sites identified histologically (solid 
circles represent pontamine sky blue spots) and by microdrive readings (open circles). 
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Effects of microiontophoretic application of LY466195 on post-synaptic firing evoked by 
glutamate agonists 
 
LY466195 was applied by microiontophoresis on cells firing in response to the agonists 
NMDA, Fluorowillardiine and Iodowillardiine (n = 8). For all three agonists tested there 
was no difference across the mean firing of the five repeated epochs recorded during 
baseline (Fluorowillardiine: F2,12 = 0.99, P = 0.39; Iodowillardiine: F2,13 = 0.43, P = 
0.64; NMDA: F2,16  = 2.41, P = 0.12) and all responses were reliable (Cronbach’s α ≥ 
0.94). 
 
As in the VPM, LY466195 potently inhibited responses to Iodowillardiine (F4,28 = 
26.41, P < 0.001) and NMDA (F2,11 = 12.56, P < 0.005) evoked-firing in a dose 
response manner (figure 78). A less potent effect of LY466195 was also seen on 
Fluorowillardiine-evoked firing (F2,13  = 4.46, P < 0.05; figure 78) and this was 
significant compared to control at the highest current (t11 = 2.78, P < 0.05). Cell firing in 
response to the ejected agonists returned to baseline levels with Iodowillardiine-evoked 
firing displaying an almost immediate recovery upon LY466195 microiontophoretic 
cessation, whereas recovery of cell firing in response to NMDA ejection was recorded 
within 2-5 minutes after LY466195 microiontophoretic cessation. 
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Figure 78: Effects of microiontophoretically delivered LY466195 on the firing rates 
of second order neurons to pulsed ejections of the glutamate receptor agonists 
Iodowillardiine, Fluorowillardiine and NMDA 
A.  Example of the effects of LY466195 on the firing rates to pulsed ejections of 
Fluorowillardiine, Iodowillardiine and NMDA. Cell firing in response to the ejected 
agonists returned to baseline levels immediately or within 3-5 minutes after LY466195 
microiontophoresis ceased. B–C. Comparison of the effect of LY466195 and control 
OH- on Iodowillardiine (B), NMDA (C) and Fluorowillardiine (D) evoked responses. 
Cell firing in response to Iodowillardiine, NMDA and to Fluorowillardiine was 
significantly inhibited by microiontophoretically administered LY466195. * P < 0.05  
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Effects of microiontophoretic application of LY466195 on responses to dural 
stimulation 
 
Ejection of LY466195 significantly inhibited the response to MMA stimulation in 
comparison to control OH- (n = 8; t7 = 4.51, P < 0.005; figure 79) in all neurons tested in 
a reversible manner. The drug was ejected for 4 minutes at 20 nA. In all cells full 
recovery was recorded 5-10 minutes after LY466195 microiontophoresis ceased. 
Ejection of control ions (OH-) had no effect in comparison to baseline (t7 = 1.65, P = 
0.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79: Effect of microiontophoresis of LY466195 on responses of 
trigeminocervical neurons to middle meningeal artery stimulation 
A-C. Example of post-stimulus histograms from a representative neuron, recorded 
during baseline conditions (A), during ejection of LY466195 (B) and during ejection of 
control OH- (C). D. Comparison of the MMA stimulation evoked firing under each 
condition.  * P < 0.05 
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Effects of microiontophoretic application of LY466195 and serine on NMDA-evoked  
post-synaptic firing  
 
As in both the VPM and TCC studies LY466195 demonstrated a significant action on 
NMDA receptors we aimed to investigate whether this effect was due to actions of 
LY466195 on the glycine/serine binding site of the NMDA receptor. Serine is an 
endogenous  co-agonist of glutamate at the NMDA receptor, increasing the affinity of 
the receptor for the endogenous agonist glutamate. LY466195 (20 nA) was co-ejected 
with NMDA on second order neurons in the TCC responding to stimulation of the 
MMA, under continuous presence of serine (80 nA). Post-stimulus histograms were 
recorded during each condition. 
 
Ejection of serine alone neither significantly affected neuronal firing in response to 
NMDA ejection (n = 6; t5 = -1.94, P = 0.11; figure 80) nor to MMA stimulation (t5 = 
0.13, P = 0.91; figure 80) compared to control (OH-). Co-ejection of serine with 
LY466195 failed to reverse the inhibitory actions of LY466195 on NMDA evoked post-
synaptic firing (LY466195 & serine vs. control: t5 = 4.71, P < 0.05; figure 80). 
Additionally, co-ejection of LY466195 with serine did not change the LY466195 
induced inhibition on firing in response to MMA stimulation (LY466195 & serine vs. 
control: t5  = 27.26, P < 0.001; figure 80).  
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Figure 80: Effect of microiontophoresis of LY466195 and serine on responses of 
trigeminocervical neurons  
A. Example of the response of a neuron to pulsed NMDA. Ejection of serine, LY466195 
and control (OH-) are shown with the solid bars. Ejection of LY466195 had a potent 
inhibitory effect that was not reversed by pre-treatment with serine. B. Comparison of 
the NMDA evoked firing under each condition. C. Post-stimulus histograms generated 
from a representative trigeminocervical neuron following electrical stimulation of the 
MMA. Microiontophoresis of serine or OH- control at the same current had no effect on 
neuronal firing. Co-ejection of LY466195 with serine failed to block the inhibitory 
actions of LY466195. D. Comparison of the MMA stimulation evoked firing under each 
condition. * P < 0.05 compared to control 
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Effects of microiontophoretic application of LY466195 on receptive field stimulation 
 
The effects of LY466195 on responses to innocuous (brush) and noxious (pinch and 
corneal brush) mechanical stimulation of the V1 facial cutaneous receptive field were 
tested in five WDR neurons (figure 81).  
 
LY466195 significantly reduced in a dose-dependent manner evoked firing to both 
pinch and corneal brush stimulation to a maximum of 65% and 85% respectively, as 
well as to innocuous mechanical stimulation of the ophthalmic dermatome by a 
maximum of 40%, in all neurons tested (brush: F1,6 = 8.75, P < 0.05; pinch: F1,6  = 0.81, 
P < 0.05; corneal: F1,7 = 7.99, P < 0.05). Firing returned to baseline within 15 minutes 
after the occlusion of LY466195 ejection.  
 
Vehicle control ejection at the same currents and duration did not change the firing rate 
evoked by innocuous (F2,5 = 0.04; P = 0.90) and noxious (pinch: F1,5 = 0.04; P = 0.87; 
corneal: F2,6  = 0.80; P = 0.46) stimulation of the receptive field. 
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Figure 81: Effects of microiontophoretically delivered LY466195 on the firing rates 
of second order neurons in response to receptive field characterisation 
Microiontophoretic application of LY466195 at currents 5, 10 and 20 nA significantly 
inhibited firing to both innocuous (brush: A) and nocuous (corneal: B; pinch: C) 
stimulation of the ophthalmic dermatome. Ejection of vehicle control had no effect on 
cell firing. * P < 0.05  
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Effects of intravenous LY466195 on middle meningeal artery-stimulation evoked activity 
 
LY466195 administered intravenously significantly inhibited trigeminocervical activity 
in response to MMA stimulation at a dose of 100 µgkg-1 (n = 7; F2,10 = 4.22, P < 0.05; 
figure 82)  by a maximum of 33% (t12 = 4.48, P < 0.05; table 28). LY466195 at 200 
µgkg-1 significantly decreased responses (n = 5; F3,11 = 5.28, P < 0.05) at similar levels 
as the 100 µgkg-1 dose by a maximum of 32% (t6 = 4.20, P < 0.05; figure 82) and there 
was no significant difference between the effects induced by the two doses (P ≥ 0.40). 
Cell firing returned to baseline levels within 90 minutes. Neither LY466195 at the dose 
of 50 µgkg-1 (n = 5; F2,7 = 2.70, P = 0.13) nor saline control (n = 7; F2,7  = 2.25, P = 0.18) 
displayed a significant effect on cell firing in response to MMA stimulation. In all 
animals neither intravenous administration of LY466195 nor of saline control 
demonstrated any significant changes on blood pressure (table 29).  
 
 
 
 
Table 28: Percentage of maximum inhibition of cell firing by different LY466195 
doses in response to dural stimulation 
LY466195 (µgkg-1) 
10 50 100 200 
 
TCC VPM TCC VPM TCC VPM TCC VPM 
% inhibition – 5 7 22 33 52 32 – 
  P = 0.6 P = 0.1 P < 0.05 P < 0.05 P < 0.05 P < 0.05 P < 0.05 
 
 
 
Table 29: Blood pressure effects of LY466195   
LY466195 (µgkg-1)  
200 100 50 
Control 
 Pre- Post- Pre- Post- Pre- Post- Pre- Post- 
Blood pressure 
± SEM 
(mmHg) 
98 ± 17 88 ± 11 108 ± 11 101 ± 10 93 ± 17 91 ± 18 118 ± 17 118 ± 18 
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Figure 82: Effect of intravenously administrated LY466195 on responses of 
trigeminocervical neurons to middle meningeal artery stimulation 
LY466195 inhibited firing to dural electrical stimulation at 200 and 100 µgkg-1, but not 
at 50 µgkg-1. * P < 0.05  
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6.3.3 Effects of intravenous administration of topiramate on responses to dural 
stimulation in the ventroposteromedial thalamic nucleus 
 
A total of 14 cells were studied in the VPM (figure 83), and each displayed convergent 
trigeminal viscerosomatic inputs classified by cutaneous receptive fields as shown in 
table 30. Cells responded with an increased probability of firing to electrical stimulation 
of the SSS with an average latency of 12 ± 2 ms to the onset. Recordings were made 
with microiontophoretic electrodes and all cells studied displayed increased firing in 
response to Iodowillardiine. Only cell bodies were recorded, which were characterised 
by their biphasic action and the increased firing in response to Iodowillardiine. 
Topiramate was not tested by microiontophoresis as difficulties in its solubility caused a 
high degree of barrel blockade.  
 
 
 
 
                 Table 30: Receptive field characteristics  
Receptive field characteristics Number of cells 
 Low threshold mechanosensitive (LTM) 4 
 
 Nociceptive specific (NS) 0 
 
 Wide dynamic range (WDR) 3 
 
 Vibrissal  
(# of vibrissae activated/cell: median) 
 
7 (3) 
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Figure 83:  Localisation of recording sites within the ventroposteromedial 
thalamus 
Reconstruction of recording sites within the ventroposteromedial thalamus projected 
onto representative sections from the Paxinos and Watson (1997) atlas. Sites directly 
identified from the ejection of pontamine sky blue are marked with solid circles (●) and 
sites reconstructed from the microdrive recordings with open circles (○). 
CA1, CA2, CA3, CA1-3 fields of Ammon’s horn; EP, Entopeduncular nucleus; Po, 
Posterior complex; PVP, Paraventricular nucleus; RE, Reunions nucleus; VM, 
Ventromedial nucleus; VPL, Ventroposterolateral nucleus; VPM, Ventroposteromedial 
nucleus; 3V, Third ventricle; RT, reticular nucleus 
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Topiramate administrated intravenously at 30 mgkg-1 significantly inhibited 
trigeminovascular activity in VPM in response to SSS stimulation (n = 8; F2,16 = 5.11, P 
< 0.05; figure 84)  at a maximum of 28% (t9 = 4.51, P < 0.005). Ninety minutes 
following intravenous administration of topiramate, no full recovery of cell firing in 
response to SSS stimulation was seen. Intravenous administration of dH2O given as 
vehicle control had no effect on firing in response to SSS stimulation (n = 6; F2,9 = 0.43, 
P = 0.69; figure 84). In all animals neither intravenous administration of topiramate nor 
of saline control demonstrated any significant changes on blood pressure (table 31).  
 
 
 
Table 31: Blood pressure effects of topiramate 30 mgkg-1   
 Topiramate (30 mgkg-1) Control 
 Pre- Post- Pre- Post- 
Blood pressure 
(mmHg) 
115 ± 16 110 ± 18 115 ± 16 113 ± 14 
 
 
 
 
 
 
Figure 84: Effect of intravenously administered topiramate on responses of 
thalamocortical neurons to superior sagittal sinus stimulation 
Topiramate at 30 mgkg-1 inhibited cell firing to dural electrical stimulation. Firing did 
not recovered 90 minutes following administration of topiramate. * P < 0.05  
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6.4 Conclusions 
 
The study demonstrated that the LY466195 compound either administrated 
intravenously or locally on neurons by microiontophoresis can potently inhibit 
trigeminovascular stimulation, both at the level of TCC and VPM. Furthermore the 
results obtained from recordings in both the TCC and the VPM following intravenous 
administration of LY466195 confirm an important role of VPM as a potential target of 
anti-migraine treatments. The microiontophoretic experiments conducted for this study 
demonstrated that although the compound has a potent action on iGluR5 receptor 
activation, it also potently inhibits NMDA-evoked firing. Intravenous administration of 
topiramate was able to inhibit firing of thalamocortical neurons in response to SSS 
stimulation; however due to the difficulties seen in using this compound with 
microiontophoresis further experiments will be needed in order to identify its site of 
action, as well as to have a better understanding of any interactions of this compound 
with glutamate receptors.  
 
Microiontophoretic application of LY466195 demonstrated a potent action of this 
antagonist on iGluR5 kainate receptor-evoked firing, and this is in accordance with its 
characterisation as described by Weiss and colleagues (2006). However we also 
observed a significant action on NMDA receptors. Based on in vitro binding data and 
electrophysiological studies on native iGluR5 receptors on DRG and on native NMDA 
receptors on hippocampal neurons, LY466195 was shown to be 55-fold selective for the 
iGluR5 receptor over NMDA receptor  and this antagonist activity of LY466195 was 
competitive (Weiss et al., 2006).  The compound given at 100 mgkg-1 orally was shown 
to have no ataxia related to NMDA antagonist-like behavioural effects in an automated 
activity monitoring system in rats (Weiss et al., 2006). A major limitation of 
microiontophoresis is that we cannot completely control the concentration of the drug 
ejected (Stone, 1985) and thus it is possible that we ejected enough of the drug to act 
unselectively on NMDA receptors. However, the NMDA effects of LY466195 were 
observed at very small currents (5 nA) and at this current the inhibitory action of 
LY466195 was more potent on NMDA-evoked firing rather than on selective iGluR5 
kainate receptors-evoked firing. It is worth mentioning that with this technique the 
antagonist UBP 302 demonstrated high selectivity for iGluR5 kainate receptors over 
NMDA and AMPA receptors as shown in chapters 4 and 5.  
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The kainate receptor subunits share common structural features, although they share less 
than 20% homology with the NMDA receptors at the amino acid level (Huettner, 2003), 
and as with most kainate receptor antagonists described to date, it is more common to 
have some action on AMPA receptors than on NMDA receptors (Ruscheweyh and 
Sandkuhler, 2002; Dolman et al., 2005). We aimed to further investigate whether the 
LY466195 compound has any actions on the glycine/serine binding site of the NMDA 
receptors as seen with the antagonist CNQX (used in studies described in chapter 4) 
which has an antagonistic action on the glycine/serine site of the NMDA receptor 
(Lester et al., 1989). Serine, which is derivered from glycine, is a co-agonist of 
glutamate at the NMDA receptor, increasing the affinity of the receptor for the 
endogenous agonist glutamate (Mothet et al., 2000; Shleper et al., 2005). Hence 
antagonism of this ligand binding site will also antagonise NMDA receptor function. 
Ejection of LY466195 in the presence of serine, failed to prevent the inhibitory actions 
of LY466195 on NMDA evoked firing. As LY466195 antagonist activity is competitive 
(Weiss et al., 2006), the excess presence of serine ejected by microiontophoresis could 
have competed with the actions of LY466195, if the later was acting on the 
glycine/serine site.  The results and the competitive nature of LY466195 could also 
suggest that LY466195 acts on the glutamate binding site.  
 
An NMDA receptor action of LY466195 was also seen in the VPM when LY466195 
was given intravenously, (100 µgkg-1); however these results should be treated carefully 
due to the small number of units tested. It was proved difficult to find cells with stable 
responses to all three agonists used for at least 30 min, in order to establish reliable 
baseline responses before administrating the antagonist. More experiments to better 
investigate this should be planned in the future. Perhaps a more ideal model to test the 
proposed NMDA action of the compound at the doses which was effective in reducing 
trigeminovascular activation is the CSD model. Since we know that NMDA receptor but 
not AMPA/kainate receptors are involved in the development of CSD (Lauritzen and 
Hansen, 1992), and thus the results could indicate whether systemic administration of 
the drug results in an action on NMDA receptor sites.   
 
Nevertheless LY466195 is a potent antagonist of trigeminovascular activation and its 
action on iGluR5 evoked firing further points to an important role of kainate receptors 
carrying the iGluR5 subunit in the trigeminovascular ascending pathway. 
Microiontophoresis of LY466195 was also able to inhibit both noxious and innocuous 
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sensory responses of the ophthalmic dermatome, with noxious responses being more 
sensitive to LY466195 when ejected at low currents. 
 
 Intravenous administration of LY466195 has further shown that it displays its 
maximum effect (~ 30% of inhibition) on trigeminocervical neurons at a dose of 100 
µgkg-1 and administration of a higher dose no longer potentiates the inhibitory actions of 
the compound. Responses of corticothalamic neurons at the same dose were further 
inhibited to ~ 50% indicating that at the level of the VPM a sum effect of LY466195 
was recorded, likely showing the effects of LY466195 both on second as well as on 
third order neurons, although an action of LY466195 in other areas is also possible. This 
further suggests that the VPM nucleus can be a potential target for new anti-migraine 
treatments. 
 
Topiramate has been suggested to display its anti-epileptic effects via multiple 
mechanisms: inhibition of voltage-sensitive Na+ channels, increased GABA-induced 
chloride influx (Gordey et al., 2000) and  blockade of glutamate-related excitatory 
neurotransmission. Specifically, topiramate inhibited the excitatory responses of 
hippocampal neurons elicited by selective activation of the iGluR5 kainate receptor 
subtype which are very important on the development of seizures (Rogawski et al., 
2003; Dudek and Bramley, 2004). In our experiments we failed to characterise the 
possible action of topiramate on ionotropic glutamate receptors with microiontophoresis, 
due to technical limitations. Intravenous administration of topiramate demonstrated 
inhibition of trigeminocervical firing in response to dural stimulation in cats (Storer and 
Goadsby, 2004). Similarly our experiments provided evidence for a significant 
inhibition of thalamocortical firing in response to dural stimulation. However, whether 
this reflects an action of the compound in the VPM or its action in the TCC as 
transmitted in the VPM cannot be dissected out with the systemic administration of the 
compound. In addition due to the different species used in the two studies, it is more 
difficult to conclude on the actual site of action of topiramate in the CNS. Systemic 
administration of drugs does not allow the possible localisation of their effects. This is 
particularly a problem in thalamic studies, as the drugs may have actions at more distal 
sites, such as the terminals of primary trigeminal nerves or in the TCC. In future 
experiments the site of action of topiramate could be shown by combining 
microinjection of topiramate in the TCC and recordings from third order neurons in the 
VPM. Failure to record full recovery of cell firing in response to dural stimulation 90 
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minutes following intravenous administration of topiramate, might reflect a prolonged 
activity of topiramate as the compound’s half life has been shown to be 21 hours 
(Silberstein and Tfelt-Hansen, 2006). 
 
It is clear that inhibition of trigeminovascular neurons activated by a nociceptive 
stimulus has been predictive of acute anti-migraine activity (De Vries et al., 1999) and a 
positive effect of the kainate acting compounds tested further suggests a possible role of 
kainate receptors in migraine pathophysiology. 
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Chapter 7: General discussion  
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The studies reported in this thesis aimed to investigate the potential role of kainate 
receptors carrying the iGluR5 subunit in areas known to be involved in migraine 
pathophysiology, and further to explore whether compounds with putative kainate 
receptor mechanism attenuate trigeminovascular transmission and thus be useful in 
migraine treatment. By using animal models that have been predictive of acute anti-
migraine activity we showed that iGluR5 kainate receptors are present on key structures 
of the “trigeminovascular ascending pathway” and may modulate, through different 
mechanisms at each locus, nociceptive trigeminovascular responses (figure 85).   
 
 
 
 
 
Figure 85: Overview of the role of iGluR5 kainate receptors in the 
“trigeminovascular ascending pathway” 
TG; trigeminal ganglion, TCC; trigeminocervical complex 
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7.1 Role of iGluR5 kainate receptors in the “trigeminovascular ascending 
pathway” 
 
The current thesis has demonstrated that iGluR5 kainate receptors are present at the pre-
junctional site of the trigeminal afferents. Under normal physiological conditions it is 
possible that these are silent receptors as their blockade did not show any tonic action. 
The role of these receptors on trigeminal afferents under normal physiological 
conditions is not known, although studies of kainate receptors on other peripheral 
sensory afferents suggest an action of these receptors in detecting normal sensory 
responses and upon their activation they participate in peripheral nociceptive 
transduction (Agrawal and Evans, 1986; Ault and Hildebrand, 1993). A similar 
mechanism might exist on trigeminal afferents. During migraine attacks it has been 
shown that glutamate and glutamine levels are elevated in the plasma and in the CSF 
(Ferrari et al., 1990; Martinez et al., 1993; Alam et al., 1998). It is thus likely that 
peripheral kainate receptors on trigeminal afferents could be activated by the increased 
levels of glutamate under such abnormal conditions. As shown in the current thesis, 
activation of these receptors could decrease durovascular afferent activation. This could 
suggest the presence of a pre-junctional mechanism which acts as a peripheral protective 
barrier against nociceptive trigeminovascular activation. A failure of this mechanism 
will result in a decreased threshold for the induction of the nociceptive neurogenic 
vasodilation. 
 
In the spinal cord and caudal brainstem kainate receptors are present at both pre- and 
post-synaptic locations (Petralia et al., 1994; Lucifora et al., 2006; Hegarty et al., 2007). 
Results from our studies show that kainate receptors at the post-synaptic site in the TCC 
participate in nociceptive transduction; although in some trigeminocervical synapses 
their post-synaptic inhibition did not alter trigeminovascular activation. On the other 
hand, at the pre-synaptic site on primary trigeminal afferents it is likely that kainate 
receptors control glutamate release – as seen in the spinal cord (Kerchner et al., 2001a), 
acting as a protective mechanism against excess glutamate release as a result of 
excessive trigeminovascular activation. Such a mechanism is in agreement with the 
proposed action of kainate receptors at the pre-junctional site, since activation of these 
receptors results in decreased neurotransmitter release. Failure of this proposed 
trigeminocervical pre-synaptic kainate receptor-mediated protective mechanism, will 
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result in a persistent neuronal hyperexcitability (figure 53) and possibly lead to central 
sensitization as seen in migraine attacks (Burstein et al., 2000; Burstein, 2001).  
 
In the VPM kainate receptors are present on thalamocortical synapses which relay 
trigeminovascular sensory responses. Their role in the thalamus is still not well 
understood due to the limited studies conducted to date on the pharmacology of kainate 
receptors in this structure. Blockade of kainate receptors, with the aid of selective 
antagonists, probably at the post-synaptic site, is able to inhibit cell firing in response to 
trigeminovascular stimulation, without predominantly affecting NMDA and AMPA 
mediated transmission. This indicates that kainate receptors participate in relaying 
ascending trigeminovascular sensory information to the cortex. Inhibition of 
trigeminovascular nociception at the level of VPM offers a last line of defence for 
controlling nociceptive inputs to the somatosensory cortex. Results from these studies 
suggest that the VPM nucleus is a potential site of action for new kainate receptor 
antagonists in migraine. VPM neurons may be a target for preventive treatments; 
certainly they are inhibited by β-adrenoceptor blockers, such as propranolol (Shields and 
Goadsby, 2005) and GABAergic modulators, such as valproate (Shields et al., 2003). 
Remarkably they may also be a target for triptans, 5-HT1B/1D receptor agonists, (Shields 
and Goadsby, 2006), further suggesting that this structure can be a potential target for 
the development of new anti-migraine therapies. Human imaging studies have 
confirmed activation of thalamus contralateral to pain in acute migraine (Bahra et al., 
2001; Afridi et al., 2005a), and the development of more selective kainate receptor 
antagonists in the future, will enable further investigation of this thalamic activation.  
 
Further to the possible post-synaptic role of kainate receptors in the VPM, it is likely 
that iGluR5 receptors are present on serotonergic terminals, in addition to their presence 
on GABAergic terminals arising from the thalamic reticular nucleus (Salt, 2002; Binns 
et al., 2003). The kainate receptor mediated inhibition seen in chapter 5 can be 
modulated by 5-HT1B receptor interactions. Although microiontophoretic application of 
selective compounds was able to reveal such interactions at the neuronal level, this 
technique does not provide any further tools for the investigation of the actual 
mechanism of such interactions. On GABAergic terminals it has been suggested that 
activation of kainate receptors decreases GABA release (Binns et al., 2003). A 
widespread finding for kainate receptors, is that they can play a significant role in 
neuromodulation through effects on presynaptic release of neurotransmitters (Chittajallu 
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et al., 1999; Lauri et al., 2001; Clarke and Collingridge, 2004). It is hence likely, that 
this mechanism may account for the kainate receptors on serotonergic terminals in the 
VPM, arising mostly from the DRN (Consolazione et al., 1984; Prieto-Gomez et al., 
1989; Tao et al., 1997). Thus inhibition of the mechanism controlling serotonin release 
via kainate receptors will result in increased levels of released serotonin which could 
additionally contribute to the inhibition of thalamocortical firing in response to SSS 
stimulation, by acting primarily on 5-HT1B receptors. Such a mechanism further suggests 
a significant role of kainate receptors in modulating neurotransmitter release that will in 
turn modulate trigeminovascular nociceptive transmission.  
 
Interestingly, the proposed sites of action of kainate acting compounds follow a similar 
pattern to the proposed action of triptans. Triptans have been shown to act at the 
presynaptic site of peripheral trigeminal afferents, at pre- and postsynaptic loci in the 
TCC and in the VPM (Goadsby et al., 2002; Shields and Goadsby, 2006).  These 
structures offer a potential target for novel anti-migraine medications, and the 
modulation of nociceptive transmission by kainate receptors along this pathway makes 
kainate receptors good candidates for the development of novel migraine therapeutics. 
More interestingly, the lack of a vascular function of kainate receptors-in contrast to 
triptans, and of a peripheral action for kainate antagonists makes a central site of action 
even more attractive and represents a novel, neuronal, non-vascular, and non-
serotonergic approach to the treatment of migraine.  
 
 
 
7.2 Targeting kainate receptors  
 
Several neurotransmitters, neuropeptides and receptor families have been implicated in 
migraine pathophysiology over the years, including serotonin, GABA, dopamine, 
glutamate, and families of ion channels including voltage- and ligand-gated channels 
(Williamson et al., 1997c; Mascia et al., 1998; Storer and Goadsby, 1999; Mitsikostas 
and Sanchez del Rio, 2001; Storer et al., 2004a; Storer et al., 2004b; Holland et al., 
2005; Akerman et al., 2007). The failure of triptans to relieve headache in all migraine 
patients, their increased side effects- including concerns on cardiovascular components, 
as well as the better understanding of migraine pathophysiology as a brain disorder, 
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point to the need for the development of new anti-migraine therapeutics that will have a 
specific action on the trigeminal nerve or on brain areas involved in migraine 
pathophysiology (Goadsby et al., 2002; Goadsby, 2005a, 2007).    
 
Glutamate is thought to be the major excitatory neurotransmitter for nociceptive 
information in the nociceptive ascending pathway (Hill and Salt, 1982; Salt and Hill, 
1982; Broman and Ottersen, 1992; Salt and Turner, 1998; Vikelis and Mitsikostas, 
2007) and thus targeting glutamate receptors is a potential mechanism for the 
development of anti-migraine therapeutics. Kainate receptors belong to the ionotropic 
glutamate receptor family and are believed to mediate fast-synaptic transmission 
although they appear to have a more distinct distribution than AMPA and NMDA 
receptors. AMPA receptors mediate fast, rapidly desensitizing excitation at most 
synapses, and are responsible for the initial reaction to glutamate in the synapse. AMPA 
receptors are usually co-expressed with NMDA, which are responsible for the long term 
potentiation of excitatory transmission, a mechanism particularly important for the 
development of memory (Watkins and Jane, 2006). As glutamate is the major excitatory 
neurotransmitter in the CNS, targeting the widely distributed AMPA and NMDA 
receptors causes numerous side effects such as memory impairment, psychotomimetic 
effects, ataxia, sedation, respiratory depression and motor dysfunctions (Koek et al., 
1988; O'Neill et al., 1998).  
 
The serious side effects seen with AMPA and NMDA blockers, as well as progress in 
the pharmacological characterisation of kainate receptor, led during the last decade, to 
the study of kainate receptors in animal models of nociception. It has been demonstrated 
that several kainate receptor antagonists have analgesic activity in a variety of animal 
models of pain, without showing considerable side effects (O'Neill et al., 1998).  The 
distinct presence of kainate receptors at synapses where higher control of excitability is 
required, such as in the dorsal horn, the hippocampus and the cortex, as well as their 
involvement in pathological conditions, like pain disorders and epilepsy, suggest a role 
for these receptors in controlling fast synaptic transmission. This is achieved by 
regulating neurotransmitter release from pre-synaptic terminals and by mediating post-
synaptic transmission. Thus, with the aid of selective kainate agents, synaptic 
transmission through kainate receptors can be targeted without particularly blocking fast 
glutamatergic transmission through NMDA and AMPA receptors.  
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Migraineurs have elevated levels of glutamate (Martinez et al., 1993; Peres et al., 2004) 
and glutamine (Rothrock et al., 1995) in the cerebrospinal fluid compared to controls, 
suggesting an excess of neuroexcitatory amino acids in the CNS. A correlation between 
the glutamate levels and the mean headache scores has been reported (Peres et al., 
2004), suggesting a persistent neuronal hyperexcitability that becomes heightened 
during an attack in migraineurs. In support of this hypothesis, is the finding that 
migraineurs exhibit cutaneous allodynia during an attack, and thus exhibit signs of the 
development of central sensitization (Burstein et al., 2000). Evidence from animals 
support that increased glutamate levels parallel changes in sensory thresholds of facial 
receptive fields as recorded from secondary neurons in the TCC (Oshinsky and Luo, 
2006), thus further supporting the involvement of glutamate in the development of 
cutaneous allodynia and central sensitization, as seen in migraineurs. The increased 
glutamate release during central sensitization indicates a prominent role for glutamate 
receptors on second and third order neurons. The fact that kainate receptor antagonists 
are better effective in persistent but not in acute pain and iGluR5 knockout mice develop 
an analgesic phenotype to chronic pain but not to acute pain models (Wu et al., 2007), 
indicate a role of kainate receptors in states of excess glutamatergic transmission in the 
nociceptive pathways. Thus kainate receptors could have a prominent role in the 
development of central sensitization, which is responsible for the prolongation of the 
migraine attack (Dodick and Silberstein, 2006). As triptans could be less effective in the 
majority of patients if taken following the development of allodynia (Burstein et al., 
2004), novel kainate receptor antagonists could be more efficient in aborting central 
sensitization of the trigeminovascular pathway and proved advantageous for patients 
who no longer respond to triptans.   
 
The particular study of the iGluR5 kainate receptors in this thesis, as well as in the 
variety of studies of the kainate receptors, was chosen due to the deficit of antagonists 
acting on other kainate subunits, as well as due to the lack of subunit-specific antibodies. 
To our knowledge the only kainate non-iGluR5 antagonist described to date is the 
molecule 5-nitro-6,7,8,9-tetrahydrobenzo[g]indole-2,3-dione-3-oxime (NS-102) which 
was initially proposed as a selective iGluR6 kainate receptor antagonist (Verdoorn et al., 
1994). However, functional assays have yielded contradictory results regarding its 
specificity for kainate over AMPA receptors. Additional problems with the solubility of 
this molecule have further limited the study of iGluR6 kainate receptors (Lerma et al., 
2001). Molecules with combined iGluR5/iGluR6 activity also exist, such as SYM-2081; 
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their use however as seen in chapter 4 cannot provide direct evidence on the 
characterisation of iGluR6 carrying receptors. Although with the currently available 
pharmacological tools we have been able to demonstrate a possible role of iGluR5 
subunit in migraine pathophysiology, a role for other kainate subunits might also exists. 
In agreement with this idea, is the existence of a specific iGluR6 kainate receptor gating 
mechanism that requires external Na+ to be operative (Paternain et al., 2003). Given that 
at least one form of familial hemiplegic migraine is associated with an abnormality in 
sodium channels (van den Maagdenberg et al., 2007), it behooves us to consider 
advances in understanding the characteristics of kainate receptors, and their relationship 
to sodium and other ion channels. 
 
A major hindrance in understanding kainate receptors has been the lack of specific 
agonists and antagonists. The separation between AMPA and kainate receptors has only 
been vaguely explored with few exceptions coming from the new willardiine derivatives 
and of a new series of decahydroxyisoquinoline carboxylates, which again favour the 
selectivity of iGluR5 carrying kainate receptors (Jane et al., 1997; Lerma et al., 2001; 
Mayer, 2005). Although a clear pharmacological boundary has been traced between 
NMDA and the other ionotropic glutamate receptor subfamilies (Watkins and Jane, 
2006), as seen in chapter 6 this is not absolutely true, as even antagonists described as 
highly selective agents for iGluR5 kainate receptors can display a significant action on 
NMDA receptors.  
 
 
7.3 Limitations and possible developments of the experimental procedures 
 
Several potential limitations need to be considered in the interpretation of these data. As 
noted above, electrical stimulation of the dura mater and of dural structures leads in 
intracranial nociception in humans (Penfield, 1932, 1934; Penfield and McNaughton, 
1940; Ray and Wolff, 1940; Wolff, 1948; Wirth and Van Buren, 1971). Experimental 
and clinical data suggest an activation of the trigeminal innervation of the cranial 
circulation with involvement of vasoactive neuropeptides such as CGRP (Goadsby et 
al., 1990; Edvinsson and Goadsby, 1995; Goadsby and Edvinsson, 1998) to explain the 
peripheral pain mechanisms of the migraine attack.  Based on these observations, 
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electrical stimulation was applied in the animal models used in this thesis, as this is the 
most consistent method of eliciting intracranial pain (Penfield, 1932, 1934; Penfield and 
McNaughton, 1940; Ray and Wolff, 1940; Wolff, 1948; Wirth and Van Buren, 1971). 
Migraine is a complex disorder involving, further to the pain component, sensory and 
motor disturbances and it is thus quite difficult to actually model migraine. It is 
therefore important to note that the animal models used are not an exact model for 
migraine, and are limited in that they provide data on neuronal firing or trigeminal 
neuronal activation via blood vessel dilation, responsive to trigeminovascular 
nociceptive stimulation. However, these models are a reasonable surrogate for 
modelling the intracranial nociception and trigeminovascular activation as seen in 
migraine attacks. In agreement with this view is that each method utilised in this study 
has demonstrated a close correlation to the clinical efficacy of acute anti-migraine 
treatments (Storer and Goadsby, 1997; Williamson et al., 1997a, c; Williamson et al., 
2001; Storer et al., 2004a; Storer and Goadsby, 2004; Akerman and Goadsby, 2005b; 
Shields and Goadsby, 2005, 2006).  
 
Stimulation of dural vessels could have additionally caused cortical activation and this is 
particularly a problem in VPM recordings, as corticothalamic neurons modulate 
thalamocortical activity directly through glutaminergic synaptic neurotransmission and 
indirectly by activation of GABAergic RN neurons. All efforts were concentrated on 
minimising current spread from the SSS to the somatosensory cortex. A balance had to 
be achieved between using a voltage of sufficient magnitude to activate 
trigeminovascular afferents, and not interfering with corticothalamic neurotransmission. 
 
Microiontophoresis has been used extensively to study the pharmacological modulation 
of trigeminovascular neurotransmission by iGluR5 kainate receptors in the TCC and 
VPM. There is a strong correlation between an inhibitory action of drugs in this model 
and clinical efficacy in treating migraine (Storer and Goadsby, 1997; Storer et al., 
2004a; Shields and Goadsby, 2005, 2006). Despite the general limitations associated 
with this technique, which have been discussed in section 2.8 the anatomical precision 
of drug delivery made it particularly suitable for studying trigeminocervical and 
thalamocortical pharmacology of kainate receptors in relation to sensory activation. 
Microiontophoretic ejection is suitable for examining the acute effects of drug 
administration on neuronal activity. This however can be a limitation when interpreting 
the effects of prophylactic agents as topiramate, which their effect might not be 
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observed if the agent displays an indirect-modulating mechanism of action. 
Microiontophoresis cannot mimic the complex changes that occur in the CNS following 
chronic administration. This does not invalidate the results of these studies, but it does 
high-light a limitation of the technique. Nevertheless, the small amount of drugs ejected 
locally on synapses was in favour of the study of kainate receptors with respect to their 
physiological property of rapid desensitisation (Jones et al., 1997), which is extensively 
seen during bath application of kainate agonists on brain slices and cell cultures 
(Huettner, 1990; Partin et al., 1993; Jones et al., 1997).  
 
Kainate receptors can clearly modulate synaptic neurotransmission and their 
involvement in trigeminovascular nociception in the thalamus and the caudal brainstem 
can be extremely complex. It is therefore unlikely to be able to control and study all the 
possible modulatory inputs that may exist on a neuron with microiontophoresis due to 
the limited number of barrels that can be used, and the complex networks that occur in 
these synapses. Thus, although different mechanisms of action of kainate receptors have 
been suggested, other mechanisms could also be present (Kullmann, 2001; Lerma, 
2003). Perhaps the modulation of the kainate receptor mediated inhibition by 5-HT1B 
receptor interactions, as seen in chapter 5, reflects an example of the complex 
mechanisms that might exist in these synapses. These experiments are limited in their 
scope, concentrating on specific questions on the function and pharmacology of kainate 
receptors with possible therapeutic effects. It should be noted that they were not 
intended to become an exhaustive examination of kainate mediated modulation of non-
glutamate neurotransmitters in the trigeminovascular sensory processing, and only a 
limited number of serotonergic and GABAergic receptors were studied in the VPM.  
Rather the studies provide a direction for further exploration of kainate receptor 
mediated effects on the trigeminovascular system. 
 
The lack of intrinsic interneurons in the rodent VPM allows for a relatively simple 
interpretation of the results. Though this unique physiology of the rodent VB does not 
allow us to correlate completely results with the possible effect that the drugs could have 
in the human thalamus. Since kainate receptors modulate GABAergic 
neurotransmission, their presence on intrinsic interneurons might further modulate the 
responses of thalamocortical synapses to trigeminovascular activation. However, as 
previously mentioned ejected drugs in rat thalamus can act only at one of two sites: 
either the pre-synaptic terminals of neurons projecting on third order neurons or the cell 
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bodies of third order neurons. When the modulation of glutamate receptor agonist-
driven firing was studied, the effect was localised more specifically to the post-synaptic 
membrane. Furthermore, as the rodent serotonergic system is fundamentally different to 
that of humans, it is unknown if the possible effects of the kainate antagonist on 
serotonergic transmission seen in the VPM (chapter 5) is relevant in humans. 
 
Despite the limitations mentioned above, dissecting out the involvement of kainate 
receptors in the modulation of nociceptive transmission is a realistic target.  If a 
dysfunction of sensory processing is capable of generating all of these migrainous 
symptoms, understanding the pharmacologic modulation of nociceptive 
neurotransmission may offer new insights into the pathogenesis of migraine. 
 
 
 
7.4 Conclusions 
 
The pre-clinical observations from this study further contribute to the advancement of 
our knowledge in the involvement of kainate receptors in the trigeminovascular system 
and may provide increased understanding of migraine mechanisms, as well as deliver 
new effective therapies. Glutamate is implicated in trigeminovascular activation, central 
sensitization and CSD. The pre-clinical and clinical observations argue for a strong link 
between migraine and the glutamatergic system, and kainate receptors represent a 
promising target for a valuable therapeutic approach to the migraine treatment. 
According to this study, the presence of functional kainate receptors illustrates the 
tactical localisation of these receptors in key structures for the migraine ascending 
pathway. Results from the current study provide evidence for the regulation of 
trigeminovascular transmission by both post-synaptic and pre-synaptic kainate receptors 
and indicate a modulatory role of kainate receptors in trigeminovascular nociceptive 
processing, at the peripheral level of trigeminal ganglia and at the levels of TCC and 
VPM. The use of microiontophoresis to study the involvement of the central kainate 
receptors offers a means of studying the effects of drugs on individual or small numbers 
of cells in vivo. The anatomical precision of delivery makes it ideally suited for studying 
the pharmacology of kainate receptors in trigeminovascular neurotransmission in the 
TCC and the thalamus. The results reported in this thesis not only illustrate the complex 
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neuromodulatory nature of kainate receptors in trigeminovascular nociception, but also 
further illustrate the complexity of migraine pathophysiology. This study suggests that 
differential targeting of kainate receptors will provide new impetus in migraine 
therapeutics and represents a novel, neuronal, non-vascular, and non-serotonergic 
approach to the treatment of migraine. 
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Appendix 
 
 
Table A1. Table of all chemicals used in experiments  
 
NAME CHEMICAL NAME (IUPAC) KNOWN BIOLOGICAL ACTIVITY 
Bicuculline [R-(R*,S*)]-5-(6,8-Dihydro-8-
oxofuro[3,4-e]-1,3-benzodi oxol-6-yl)-
5,6,7,8-tetrahydro-6,6-dimethyl-1,3-
dioxolo[ 4,5-g]isoquinolinium iodide 
GABAA receptor antagonist 
CGRP Calcitonin Gene-Related Peptide Calcitonin Gene-Related Peptide (amino 
acid)- neuromodulator 
CNQX 6-Cyano-7-nitroquinoxaline-2,3-dione AMPA/kainate antagonist   
D-Serine - Glycine agonist at the NMDA receptor 
Fluorowillardiine (S)-(-)-a-Amino-5-fluoro-3,4-dihydro-
2,4-dioxo-1(2H)pyr idinepropanoic 
acid 
AMPA receptor agonist   
GR127935 N-[4-Methoxy-3-(4-methyl-1-
piperazinyl)phenyl]-2'-methy l-4'-(5-
methyl-1,2,4-oxadiazol-3-yl)-1,1'-
biphenyl-4-ca rboxamide 
hydrochloride 
selective 5-HT1B/1D  receptor antagonist 
Iodowillarddine S)-(-)-5-Iodowillardiine iGluR5-subunit containing kainate 
receptor agonist 
L-Glutamate (S)-1-Aminopropane-1,3-dicarboxylic 
acid 
glutamate receptor agonist 
LY466195 [(3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-
4,4-difluoro-1-pyrrolidinyl]-
methyl]decahydro-3-
isoquinolinecarboxylic acid)] 
competitive GLUK5-selective kainate 
receptor antagonist 
NAS-181 (2R)-2-[[[3-(4-Morpholinylmethyl)-
2H-1-benzopyran-8-yl] 
oxy]methyl]morpholine 
dimethanesulfonate 
antagonist at the rat 5-HT1B receptor 
NMDA N-Methyl-D-aspartic acid NMDA receptor agonist 
SYM-2081 (2S,4R)-4-Methylglutamic acid kainate receptor modulator 
Topiramate ,3:4,5-Bis-O-(1-methylethylidene)-
beta-D-fructopyranose sulfamate 
anticonvulsant; knot well understood 
biological action; suggestions include: 
sodium channel blocker; GABAergic 
channels activator; kainate and AMPA 
receptors blocker 
UBP 302 (S)-1-(2-Amino-2-carboxyethyl)-3-(2-
carboxybenzyl)pyrim idine-2,4-dione 
competitive iGluR5-subunit containing 
kainate receptor antagonist 
WAY-100135 (S)-N-tert-Butyl-3-(4-(2-
methoxyphenyl)-piperazin-1-yl) -2-
phenylpropanamide dihydrochloride 
5-HT1A receptor antagonist 
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